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ABSTRACT 
 
 
 Retinoblastoma (Rb) is the most common intraocular malignancy in children 
comprising 4% of all pediatric tumors. Early intervention increases survival rates up to 
95% in developed countries; being survival rates associated to socio-economic status. 
Despite the high survival rates in developed countries, preservation of the eye and vision 
are continuing challenges in the management of Rb. Vitreous seeds constitute the greatest 
challenge in treatment of Rb. The unique location of these seeds within the vitreous 
makes them difficult to treat. Viable seeds showed reduced proliferative capacity and 
metabolism. making the majority refractory to current chemotherapeutics. This prompted 
the development of new delivery routes for chemotherapeutics, such as intra-ophthalmic 
artery, intravitreal, and subconjunctival administration. Still ocular salvage rates have not 
exceeded 70% in over two decades. Novel, safer therapies are required but there is a 
fundamental lack of knowledge about the biology of the tumor for the development of 
targeted therapies; the vitreous, as it surrounds the seeds; and the interactions between the 
vitreous and the seeds.  
 
 Despite the current understanding of how cancer is a multifaceted disease full of 
complex cellular and protein interactions (commonly referred to as the tumor 
microenvironment, TME), the immunology of the vitreous microenvironment and the 
role it plays in the sustainment of seeds in Rb disease is poorly understood. In this study, 
we begin investigating Rb tumor cells and how they alter the TME by examination of 
matrix metalloproteinases, a family of enzymes involved in degradation of the 
extracellular matrix and tissue remodeling heavily implicated in tumor migration and 
survival. We identified two gelatinases, MMP-2 and MMP-9, to be expressed in Rb cell 
lines and demonstrated by pharmacological inhibition and genetic knockdown, a role for 
these gelatinases in Rb cell migration, invasion, and survival. Additionally, we 
demonstrated how secretion of VEGF, involved in angiogenesis, and TGF, involved in 
metastasis, were altered by MMP-2 and MMP-9 pharmacological inhibition.  
 
 As MMPs are pivotal for the tumor and extracellular matrix interactions within 
the TME leading to tissue invasion, we then transitioned to the vitreous, investigating the 
vitreous as a TME and how it sustains Rb. Multiple proteins are found within the soluble 
phase of the vitreous that are associated with ocular pathological processes, including 
diabetes retinopathy and proliferative vitreoretinopathy. Therefore, we compared the 
presence of a small cohort of proteins associated to ocular pathologies, to healthy vitreous 
and to Rb patients’ vitreous samples, identifying high expression of Platelet-Derived 
Growth Factor Receptor  (PDGFR) and its ligand PDGFBB in the Rb samples. 
Additional studies of ex vivo healthy human vitreous, murine Rb xenografts, and patient-
derived Rb xenograft tissues, measured high activity of the PDGF-PDGFR signaling 
pathway in diseased, but not healthy tissue. We focused the next part of this work on the 
role PDGFR plays in vitreous seeds.  To investigate this pathway in depth we used 
established Rb cell lines, namely Y79-the metastatic and aggressive model, and Weri-1 
Rb, the non-metastatic model. Our work demonstrated PDGFR was overexpressed in 
Y79 cells, the metastatic model of Rb, in vitro. To provide mechanistic insight, we 
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utilized the tyrosine kinase inhibitor imatinib mesylate (IM), and demonstrated PDGF-
PDGFR signaling pathway regulates Rb cell proliferation, invasion, and survival. We 
found increased PDGF-PDGFR signaling resulted in higher activity of the p53-
inactivator, MDM2, as well as the pro-inflammatory NFB pathway, both of which are 
involved in tumor survival. As there is a lack of models for vitreous seeding, we utilized 
magnetic nanoparticles to generate the first in vitro vitreous seed model and demonstrated 
similar features between an ex vivo seed and one of our in vitro magnet-generated 3D 
tumor spheroids, validating our system. Using this novel technology, we recapitulated our 
in vitro 2D work and demonstrated  that inhibition of the PDGF-PDGFR signaling 
pathway results in decreased spheroid size. PDGFRB gene knockdown by siRNA 
confirmed the results with the pharmacological agent showing these results were PDGF-
PDGFR signaling-specific. 
 
 Next, we tested the effects of IM, as a potential Rb therapy, in retinal endothelial 
cells h(RECs) as retinal endothelial cell-associated toxicities are one of the challenges 
with conventional chemotherapies in Rb. We measured the capacity of hREC to 
proliferate and for tube formation in the presence of the therapy. Our results 
demonstrated neither proliferation nor tube formation of hRECs changed when exposed 
to IM. Upon further examination, we demonstrated the absence of PDGFRB mRNA 
expression in hRECs. Taken together these results illustrate the potential use of anti-
PDGFR therapy as a targeted therapy in Rb. 
 
 The last section of the study investigated the expression and function of members 
of the ATP-binding cassette (ABC) transporters as well as the multifunctional 
glycoprotein CD44 in Rb, as one of the properties of vitreous seeds is their resistance to 
chemotherapy. We discovered heterogeneous expression of multiple ABC transporters in 
vitro using Y79 Rb cell line and ex vivo using Rb vitreous samples. In addition to 
expression, the transporters efflux activity was determined. CD44 mRNA, whose protein 
is considered a promoter of chemoresistance, was highly expressed in naïve vitreous from 
Rb patients. These results illustrate that chemoresistance is not induced by treatment and 
is, instead, an innate feature of vitreous seeds. Flow cytometry analyses established (1) a 
high correlation between active, or phosphorylated PDGFR (p-PDGFR) and CD44; 
and (2) inhibition of p-PDGFR resulted in decreased CD44, as well. 
 
 Collectively, this study demonstrated the Rb TME plays a crucial role in Rb 
tumor properties. MMP-2 and MMP-9 are highly expressed in Rb and allow degradation 
of the ECM in tissue, increasing migration and invasion of Rb. Additional work focused 
on vitreous seeds and identified increasing signaling activity of the PDGF-
PDGFR signaling pathway in multiple Rb models, including in vitro cell lines, ex vivo 
Rb patient vitreous samples and tissue, as well as in a murine xenograft system. Next, we 
identified this pathway as a potential target, as pharmacological and genomic inhibition 
of the PDGF-PDGFR signaling pathway by IM and PDGFRB siRNA resulted in 
decreased proliferation, invasion, resistance, and survival. These cellular functions appear 
to be mediated by the downstream targets MDM2 and NFB. Our initial studies 
demonstrated a lack of drug-associated toxicity on hRECs with IM. This work is a further 
step in our quest for targeting vitreous seeding.   
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CHAPTER 1.    INTRODUCTION AND BACKGROUND 
 
 
Retinoblastoma (Rb) is the most common intraocular malignancy in children1. To 
date, few studies have attempted to examine how the tumor interacts with its 
surroundings, called the tumor microenvironment (TME). This dissertation seeks to 
reveal how these crucial interactions promote tumor survival and, thereby, allow 
introduction of targeted therapies for clinical use. 
 
 
History of Retinoblastoma Disease 
  
Retinoblastoma was first described in a case report by anatomist Pieter Pauw (also 
referred to as Petrus Pawius) in 1597 as a “an enormous tumor out of the left eye, until 
the untouched eyeball with all muscles protruded out, and had grown into such a mass 
that the protuberance had acquired the size of two fists”2. Two centuries later, in 1809, 
James Waldrop characterized these intraocular masses (known today as retinoblastoma) 
as fungus haematodes and recommended removal of the afflicted eye3. The tumor was 
first characterized as a glioma of the retina in 1864 by the German physician-scientist, 
Rudolf Virchow4. However, pathologist Simon Flexner and the Austrian ophthalmologist 
Hugo Wintersteiner noticed the formation of rosettes and described the tumor as 
neuroepithelioma4. Finally, in the 1920s, ophthalmic pathologist Frederick Herman 
Verhoeff noted the primitiveness of the tumor and the similarity to that of 
undifferentiated retinae, thus coining the term ‘retinoblastoma’5. In the 1960s, as 
treatment options began to advance, a classification system was needed to better 
understand outcomes and therapeutic effectiveness. Drs. Algernon Reese and Robert 
Ellsworth classified tumors based on rates of both ocular and vision salvage to radiation 
called the Reese-Ellsworth classification6,7. With chemotherapy slowly replacing 
radiation, a new classification system was developed in 2003 based on responses to 
chemotherapy, named the International Classification of Retinoblastoma8,9. Today, more 
is known about genetics of retinoblastoma and, by further understanding of this small 
subset of tumors, great leaps have been made in the fields of both genetics and oncology. 
 
 
Genetics of Retinoblastoma Disease 
 
 
Primary genetic alterations 
 
In 1971, physician-scientist Alfred Knudson postulated that multiple mutations 
were necessary for tumorigenesis and the hereditary basis for which cancer could arise10. 
This hypothesis is known as the “two hit hypothesis”. Using Rb as a model for his 
hypothesis, Knudson compared incidences, ages at time of diagnosis, number of eyes 
afflicted, and familial history of the disease. The results demonstrated first, patients with 
both eyes affected (bilateral disease) were younger and had a genetic predisposition to Rb 
while those patients with one affected (unilateral disease) were older and did not have a 
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family history of Rb10. Knudson concluded when comparing the two outcomes, that Rb 
required two mutations for tumorigenesis. The bilateral (or hereditary) form of the 
disease was caused by one germline mutation and a second, later mutation that occurred 
in somatic cells; meanwhile, patients with unilateral (non-hereditary) form of Rb required 
two mutations in somatic cells, thus the discrepancy in ages of diagnosis. Ultimately, this 
work proved crucial in the understanding of tumorigenesis and the origins of cancer.  
 
 Within the next decade, researchers had begun attempting to identify and locate 
the gene involved in Rb development. In 1984, the RB1 gene was first identified on 
chromosome 13q14.2 and was then subsequently cloned – the first time a tumor 
suppressor had been cloned11,12. The RB1 gene encodes the sequence for the 
retinoblastoma protein (pRb), a member of the pocket protein family found to be 
involved in a number of cellular events most notably in cell cycle progression13. pRb was 
initially thought to exist in two forms: (1) hypophosphorylated and (2) hyper-
phosphorylated, Mechanistically, depending on the level of phosphorylation pRb could 
bind the cell cycle and DNA synthesis E2F transcription factors (hypophosphorylated) or 
it could not (hyperphosphorylated)14,15. Yet, subsequent work has invalidated this 
hypothesis as pRb can exist in (at least) three states: (1) non-phosphorylated, (2) 
monophosphorylated, and (3) hyperphosphorylated, each with different respective 
function(s)16: 1) non-phosphorylated pRb has been associated with cellular arrest, or 
senescence, and exit of the cell cycle17; 2) monophosphorylated pRb has been readily 
detected in early G1 phase of cell cycle and prevents withdrawal from the cell cycle16; 
finally, 3) hyperphosphorylated pRb still lacks the ability to bind to E2F and, therefore, 
promotes cell cycle progression. Then, in the absence of pRb (such as mutations within 
the RB1 gene), E2F transcription factors are unbound and free to induce DNA synthesis 
and cell division.  This cell division may occur at a rapid rate, resulting in tumor 
formation, as tumors are the result of uncontrolled proliferation. RB1 and the protein 
which it encodes, have become increasingly detected in a number of malignancies, 
including lung, breast, and brain cancers18-20. More than 95% of Rb cases harbor 
mutations or promote methylation of RB1. However, 1-2% of Rb cases present with wild 
type RB1 (RB1+/+)21 and these tumors possess amplification of the proto-oncogene 
MYCN22.  
 
 
Secondary genetic alterations 
 
 While alterations in RB1 are necessary for Rb formation, work has shown that 
RB1 loss is insufficient to drive Rb tumorigenesis. When RB1 is lost (RB1+/- orRB1-/-), a 
benign tumor, called ‘retinoma’, develops23. One prevailing reason for this benign tumor 
formation is that unlike many other malignancies, Rb tumors harbor wild type p53. If 
RB1 is inactivated, tumor cells are able to withdraw from the cell cycle and undergo 
programmed cell death, or apoptosis24. Previous work by Dyer and colleagues, identified 
amplification of two inactivators of p53, mouse double minute homolog 2 (MDM2) and 
murine double minute X (MDMX, sometimes referenced as MDM4) in Rb and found 
upon amplification of either gene, p53-mediated cell death is inhibited and Rb tumors are 
formed24. Genetic analyses of fetal retinae, retinomas, and retinoblastomas have 
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illustrated other genes in which secondary mutations synergize with RB1 mutations to 
cause Rb tumor development including: KIF14, DEK, E2F3, and CDH11,  as well as 
mutations causing loss of expression of  key tumor suppressor proteins p16INK4a and p130 
that result in Rb when combined with an RB1 mutation23. Conflicting studies exist about 
the direct roles these genes may play in Rb tumorigenesis25. A number of studies have 
illustrated when comparing Rb to other malignancies, the genome of Rb is quite 
stable26,27. For instance, when conducting genetic analyses in a large cohort of samples, 
199 genes were identified that were unique to single tumors, demonstrating the vast 
heterogeneity of Rb tumors26. Further analyses have begun to investigate the epigenome 
of Rb and discovered while the Rb genome may be quite stable, the epigenome is 
anything but, finding a number of genes deregulated epigenetically27. 
 
 
Pathophysiology of Retinoblastoma 
 
 
Incidence 
 
 Rb is the most common intraocular cancer in children, but still is considered a 
rare pediatric malignancy with approximately 8,000 new cases presented every year 
worldwide28. The annual tumor incidence is approximately 1 in 16,000 – 18,000 live 
births and shows higher incidence in less industrialized nations28. Annually, there are 
between 200 – 300 new cases of Rb diagnosed in the United States5. China and India, the 
most populous countries in the world, see approximately 1,000 new cases every year29. 
Clinically, Rb is seen almost exclusively in children < 5 years old30. When examining 
incidence of unilateral (one eye) vs. bilateral (both eyes), approximately 60-70% of Rb 
patients will present with unilateral disease while 30 – 40% of patients will present with 
bilateral disease30,31. Normally, the two main symptoms of Rb are leukocoria, a reflection 
of light by a white mass, and crossing of the eyes, or strabismus28. The average age at 
time of diagnosis are 24 months for patients  with unilateral disease and 13 months for 
those with bilateral disease30. Patient statistics have not illustrated predisposition in Rb 
development among any specific race or gender4.  
 
 Socioeconomic factors play an important role in Rb diagnosis, care, and, 
ultimately, survival. When comparing worldwide incidence of Rb, the United States, 
Europe, and Australia harbor relatively low percentages of those afflicted with Rb (~ 
11% of cases), most patients that are affected with the disease are in middle-income 
countries (~69%) or low-income countries (~20%)28. The two main factors associated 
with survival of Rb are presence of physicians and human development index, a metric 
that considers multiple factors including education, life expectancy, and wealth32. 
Patients in countries with less-developed, poorer infrastructure typically have longer lag 
times that delay onset of diagnosis and provide a worse prognosis for survival33. 
Unfortunately, metastasis and survivability align with income disparities across the globe. 
Rates of metastasis and survivability in low-income countries are 32% and 40%, 
respectively. Meanwhile, middle-income countries experienced rates of approximately 
10% and 78%32. In developed countries, such as the United States, Rb is the most 
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survivable pediatric malignancy3. Given these discrepancies, there has been a large 
outreach to support global health initiatives in treating retinoblastoma. 
 
 
Primary tumor subtypes 
 
 Currently, there are five main growth patterns identified within Rb: endophytic, 
exophytic, mixed (both endophytic and exophytic), necrotic, and diffuse infiltrating.  
 
 Endophytic.  The endophytic growth pattern of Rb is one whereby the tumor 
begins growing into the vitreous cavity. These tumors are often vascularized but small 
pockets of tumor cells, called vitreous seeds, that break off from the primary tumor 
inhabit the vitreous cavity5.   
 
 Exophytic.  Exophytic Rb tumors typically grow away from the vitreous cavity 
and into the retina. These tumors can invade the choroid, the vasculature of the eye and 
normally present as retinal detachments. Similar to vitreous seeds, small pockets of free 
floating tumors can survive in the subretinal space (subretinal seeds)34.  
 
 Mixed.  Tumors with growth patterns termed mixed are, as the name implies, a 
mixture of both endophytic and exophytic growth patterns.  
 
 Necrotic.  Necrotic Rb growth pattern consists of high levels of necrotic tissue (> 
90% necrosis). This necrosis is not limited to tumor cells and may include nearby 
surrounding tissue (i.e. retina)35.   
 
 Diffuse infiltrating.  The rarest of the Rb growth patterns (comprising just 2% of 
classified tumors), diffuse infiltrating tumors invade both the retina and vitreous cavity 
without any large, primary mass. These tumors exhibit unique growth patterns and can 
form small pockets of tumors in the anterior chamber in a rare occurrence called anterior 
chamber seeding36.   
 
 
Metastatic retinoblastoma 
 
 Without medical attention and treatment, Rb will invade surrounding tissue and 
can metastasize via a number of different anatomical pathways. The most prevalent route 
of metastasis is through the optic nerve fiber bundles into orbital portion of the optic 
nerve and then into the brain or  into circulation of subarachnoid fluid that results in 
metastatic sites into distant parts of the brain, spinal cord and opposite optic nerve 37. 
Secondly, Rb may spread through the choroid in a process called haematogenous 
dissemination. Haematogenous dissemination of Rb leads to invasion of the orbital 
bones, lungs, brain, and surrounding bone as well as access to lymphatics37. Similarly, Rb 
tumors can disseminate through lymphatics into regional lymph nodes37-39. As is the case 
with all cancers, metastasis carries a poorer prognosis for survival40. 
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Treatment of Retinoblastoma 
 
Proper management and treatment of Rb is an ongoing topic. Options for 
treatment are often dependent on tumor size, location, and patient outcome. The goals 
when treating Rb are as follows: 1) save the child’s life, 2) salvage the globe, and 3) 
preserve vision. The first goal of saving lives is well met in developed countries (less so 
in developing countries). However, both globe salvage and vision preservation are still 
clinically challenging. The following section will seek to discuss the current methods of 
management and treatment options in Rb.  
 
 
Cryotherapy and thermotherapy 
 
 Cryotherapy and thermotherapy have both been used within the clinic and have 
shown some success. Cryotherapy works by freezing (-80ºC) tumor tissue, leading to ice 
crystal formation within the cell membrane, and cell lysis. However, cryotherapy is most 
commonly applied to small, anterior tumors in three, rapid freeze-thaw cycles41. 
 
 While cryotherapy involves freezing of the tumor, thermotherapy is the opposite 
in that the tumor is heated. Commonly, thermotherapy utilizes either an argon laser 
(532nm) or diode transpupillary / transscleral laser (810nm) with each laser possessing 
different utility. The argon laser is utilized to target and heat the tumor-supporting blood 
supply to temperatures above 60ºC for photocoagulation42. The diode laser is used to heat 
tissue at temperatures between 45ºC and 60ºC (below photocoagulation temperatures) 
and is capable of inducing tumor clearance43,44. Both cryotherapy and thermotherapy can 
be utilized for smaller tumors with minimal complications. 
 
 
Radiation 
 
 One of the most successful forms of treatment for Rb is the use of radiation to 
target the tumor. The advent of radiotherapy in Rb came at a time when removal of the 
affected eye (or eyes) was seen as the only therapeutic option45. Nearly 50 years ago, 
external beam radiotherapy (EBRT) became the standard treatment for Rb and patients 
with advanced intraocular disease had higher rates of ocular salvage instead of 
undergoing enucleation46. Yet, there has been a dramatic decrease in the use of EBRT in 
Rb as it exposes the pediatric population to significantly higher risk of secondary 
malignancies throughout their lives as has been extensively documented over the past 40 
years47-50. Despite this knowledge, EBRT remains a therapeutic option for patients with 
bilateral, advanced intraocular disease in the hopes of sparing at least one eye.  
 
 The  introduction of newer treatment modalities have allowed for safer, targeted 
radiotherapies including that of proton beam therapy that shows strong tumor control 
without the complications associated with EBRT51. Another therapy, called episcleral 
plaque brachytherapy (or simply brachytherapy) involves the placement of radioactive 
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plaques on to the sclera52. These plaques are typically loaded with radioactive Iodine-125 
(125I) sewn to the sclera directly over the tumor, minimizing damage to the surrounding 
tissue. Other isotopes may be used, such as Ruthenium-106 (106R). 
 
 
Chemotherapy 
 
 The current standard of care in managing and treating Rb is the use of 
chemotherapy. Often, patients presenting with bilateral Rb are given a chemotherapeutic 
regimen to help cytoreduce (or chemoreduce) tumor burden within the eye. Despite this, 
a single chemotherapeutic agent cannot be used to salvage all eyes53.  Combination 
chemotherapy increases the chance to eliminate tumor cells undergoing different stages 
of cell cycle due to their differences in mechanisms of action. Rb patients will often be 
treated with a combination of chemotherapies, most notably the combination of 
carboplatin, vincristine, and etoposide (see below). Other chemotherapeutic agents, such 
as cyclophosphamide (induces DNA crosslinking) and doxorubicin (similar mechanism 
as etoposide), may also be used54,55. The three most commonly used agents all possess 
different mechanisms of action:  
 
 Carboplatin. Carboplatin is a platinum-based alkylating agent that, upon uptake, 
acts on nucleophilic molecules and induces damage in DNA that ultimately result in 
apoptosis56.  
 
 Vincristine. In a similar manner, vincristine works by binding tubulin, a key 
molecule involved in microtubule polymerization in cell cycle57.  
 
 Etoposide. Etoposide is an effective chemotherapy aimed at inhibiting 
topoisomerase II, which plays a role in DNA ligation. By addition of etoposide, DNA 
ligation does not occur and there is an increase in DNA strand breaks that leads to cell 
death58.  
 
 Melphalan. Melphalan is a nitrogen mustard alkylating agent, similar to 
carboplatin with DNA damage being an end result of melphalan exposure59.   
 
 Thiotepa. Thiotepa, another alkylating agent, works similarly to both carboplatin 
and melphalan and induces DNA damage.  
 
 Topotecan. Topotecan is a topoisomerase I inhibitor that induces large numbers 
of both single strand and double strand breaks in DNA that lead to apoptosis. 
 
 
Chemotherapy delivery routes 
 
 There are multiple modes of delivery for chemotherapy. Method(s) of 
administration are decided based on individual case presentation of unilateral or bilateral, 
tumor size, location(s) of tumor, patient age, family history, and potential outcomes. The 
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most common method of chemotherapy delivery is intravenously (IVC). Normally, IVC 
administration of carboplatin, vincristine, and etoposide are used as a first-line therapy 
for treatment of Rb and are capable of salvaging eyes afflicted with advanced intraocular 
disease60. IVC chemotherapy has proven quite safe for the pediatric population and 
places patients at a much lower risk for development of secondary malignancies when 
compared to EBRT61. However, many chemotherapeutics have reduced penetration 
through the blood-retinal barrier (BRB) and may not reach cytotoxic levels55. Therefore, 
newer, more focal modes of delivery have been investigated.    
 
 One of these newer techniques is intra-arterial chemotherapy (IAC). In this 
method of delivery, chemotherapy is administered through the ophthalmic artery to 
achieve higher, more tumoricidal concentrations. Most commonly, melphalan is 
administered through IAC. Reports have claimed IAC is vastly superior to IVC with 
reduced toxicities and increased globe salvage62. Yet, reports have arisen regarding 
toxicities dampening the enthusiasm for IAC63-65. 
 
 As both IVC and IAC could potentially be impeded by the BRB focus has shifted 
toward local delivery to the eye to increase cytotoxic concentrations in the vitreous to 
treat seeding. Local delivery could be to the anterior part of the eye, being 
subconjunctival (or subtenon) and intravitreal (IViC) the most common. Subconjunctival 
administration is done into the subconjunctival space whereby high levels of 
chemotherapy readily penetrate into the affected area(s)66. Ongoing clinical trials are 
studying the effectiveness of subconjunctival carboplatin combined with systemic 
topotecan67. The most common agent injected intravitreally is melphalan and, thus far, 
results have shown success in treating vitreous seeding68. However, as with other 
methods of delivery, there are known ocular toxicities associated with intravitreal 
administration of chemotherapeutics69. Taken together, it is clear chemotherapy 
maintains a role in the treatment of Rb.  
 
 
Enucleation 
 
 The practice of enucleation, or removal of the eye(s) for management of Rb dates 
back to the 19th century and is still one of the most frequently used treatments. As the 
first goal of managing Rb is saving the patient’s life, those with advanced intraocular, 
unilateral disease often undergo primary enucleation. For those patients with advanced 
bilateral Rb, the physician will examine both eyes, make a judgement on which eye is 
likely more salvageable, and the worse eye may be enucleated with other treatment (i.e. 
IVC, IAC, cryotherapy, thermotherapy) being administered to the more salvageable eye. 
And, while offering a “cure” for Rb, enucleation is a still a less than desirable treatment 
as it leaves patients permanently scarred, partially (unilateral) or fully (bilateral) blind, 
and may have negative psychological side effects on those undergoing the procedure70-72.   
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Immune ablation and autologous stem cell therapy (ASCT) 
 
 Some small case reports have illustrated the success of high dose chemotherapy 
followed by autologous stem cell transplantation (ASCT)73-77. In these cases, patients 
afflicted with extraocular disease or those with metastatic disease lacking CNS 
involvement are treated with high dose chemotherapy, radiation, and followed by 
autologous stem cell therapy. This therapy permits the use of very high doses of 
chemotherapy, radiation, or both and for the immune system to be reconstituted over time 
using the patients’ own stem cells. ASCT has proven more successful for patients 
presenting with metastatic disease than chemotherapy alone with approximately 73% of 
patients receiving chemotherapy alone developing relapse vs 47% of patients receiving 
chemotherapy and ASCT73,78.  
 
 
Models of Retinoblastoma 
 
 
In vitro models 
 
 Within the field of Rb research, there are three well-characterized human cell 
lines: Y79, Weri-Rb1, and RB355. The first Rb cell line, Y79, was derived from a 2.5 
year old Caucasian female with advanced intraocular and metastatic disease79. Weri-Rb1 
was isolated from a 1 year old Caucasian female with no family history of the disease and 
lack of metastasis80. Similarly, RB355 was isolated from the eye of a child with no family 
history of the disease81. As neither of these cells were clonally expanded, these cells are 
heterogeneous and further work soon has discovered RB355 is genetically related to Y79 
and is considered a subclone82. Y79 is used to study more aggressive, invasive Rb and 
represents the metastatic form of the disease and Weri-Rb1 the less invasive, non-
metastatic model for Rb.   
 
 
In vivo models 
 
 LH-Tag model. One of the earliest in vivo Rb models was created by accident. 
While attempting to induce expression of both SV40 large T and small t antigens in the 
pituitary (using the luteinizing hormone beta subunit) to create a model for pituitary 
tumors, it was found that a mouse (and its direct offspring) formed bilateral disease83. 
Later work elucidated that the large T antigen was capable of disrupting normal pRb 
tumor suppressor function (as well as p53), thus giving rise to tumors84.   
 
 Genetic knock-out and knock-in models. The loss of RB1 was thought to 
underlie the formation of Rb and, although still true in most cases, does not induce 
malignant tumor development in mice. Genetic models with defective RB1 do not form 
Rb, instead form benign tumors called retinomas23. Following this revelation, work 
showed RB1-/-/p107-/- mice formed Rb tumors, demonstrating Rb tumor formation is not 
specific to just RB1 mutations and p107, another member of the pocket protein family, 
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could suppress Rb tumor formation. Yet this model failed to replicate Rb tumorigenesis85. 
Similarly, RB1-/- / p130-/- double knock-out (DKO) mice showed lesions consistent with 
Rb (and similar to RB1/p107 DKO mice)86. The tumors in RB1/p130 DKO mice form 
earlier than those in the RB1/p107 DKO mice. As Rb is known to have intact, normal p53 
expression, the question still remained why p53 could not prevent Rb tumor formation. 
Novel work soon identified MDMX in playing a key role in tumor formation by 
inactivating the p53 tumor suppressor pathway24. Still more complex models have been 
generated encompassing more knockout combinations to further examine the genetics of 
Rb. A table of these models can be seen in Figure 1-187. More work has gone on to show 
these murine models and human Rb samples are molecularly similar88.  
 
 Xenografts. The first Rb xenograft (human Rb cells or tissue surgically grafted 
into mice) used was over 40 years ago, in which the two human Rb cell lines, Y79 and 
Weri-Rb1 were independently injected into the anterior chamber of rabbits to measure 
their abilities to form tumors80. Additional xenografts systems have been made by 
inoculating cells into the flanks of immunocompromised nude mice89. The limitations of 
the flank xenograft model are apparent as the challenge is treating Rb in its native 
environment. Further xenograft models implemented intravitreal inoculation of human 
cells into the eyes of both mice37 and rats90. Subretinal cell inoculations have also been 
utilized to make orthotopic xenografts and more closely mimic the pathophysiology of 
Rb. Orthotopic xenografts have been made using multiple mammals, including mice91 as 
well as rabbits92. Finally, fresh tissue harvested from a patient was transplanted into nude 
mice, however, this was done subcutaneously93. The culmination of these previous 
models ultimately led to the establishment of an orthotopic patient-derived xenograft 
model (PDX)27, a novel system where tissue or cells from a patient’s Rb tumor are 
implanted into an immunodeficient mouse to create a similar environment to the native 
tumor. 
 
 
Challenges in the Retinoblastoma Field 
 
 The greatest challenge in the Rb field is the presence of small pockets of tumors 
floating in the vitreous cavity, called vitreous seeds (or seeding). Regardless of 
classification scheme, ocular salvage is “very unfavorable” in eyes with extensive 
vitreous seeding6. Often times, recurrence of disease is attributed to vitreous seeds. 
Traditionally, EBRT was used to combat and manage the presence of these seeds. 
However, EBRT exposes patients to elevated risks for secondary malignancies and, 
historically, ocular salvage rates rarely exceed 50%94. IVC was then used to target seeds, 
but given their location within the vitreous, cytotoxic concentrations of chemotherapies 
rarely achieved95. Ocular salvage rates are approximately 50% with IVC94. After the 
introduction of IAC, preliminary reports claimed ocular salvage rates around 70%96 
although, there exist conflicting reports (with longer follow up) of ocular salvage rates 
around 50%97. Outcomes are similar to that of systemic therapy (IVC) as selected 
agent(s) did not readily permeate the BRB into the vitreous and thus, were unable to 
achieve cytotoxic concentrations. IViC was utilized and initial ocular survival rates  
  
  
10 
 
 
 
Figure 1-1. Genetic knockout models of retinoblastoma.  
 
There are multiple rodent models of retinoblastoma (Rb). Unlike that seen in the human 
disease, loss of RB1 heterozygosity in mice does not result in tumor formation and RB1 
knockout is embryonically lethal. Therefore, using Cre-Lox technology was used to 
generate retina-specific knockdowns. These models further illustrate how Rb is a very 
heterogenic tumor with few mutations capable of initiating tumorigenesis. Other 
transgenic models include viral-oncogene induced models (LH-Tag) and non-transgenic 
models, including xenografts, orthotopic xenografts, and patient-derived orthotopic 
xenografts. Reprinted with permission from Saudi J Ophthalmol, 27 (3), Nair, RM. et al. 
Animal models in retinoblastoma research, p141-146, Copyright (2013), with permission 
from Elsevier. 
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increased up to 84%98. Despite a number of ocular oncologists’ best efforts, long-term 
ocular salvage rates for those patients treated with IViC have remained at 70%99. 
Subconjunctival administration of carboplatin has also been tested and ocular survival 
rates were 74%67.  
 
 An explanation of why vitreous seeding remains so difficult to treat is the lack of 
preclinical modeling. While there are ample models of Rb to study tumor development 
and drug efficacy, there is an inadequacy of models that develop vitreous seeding. 
Currently, the only in vivo model capable of forming vitreous seeds is the orthotopic 
xenograft rabbit model92. As a result of this, the biology of vitreous seeding remains 
rather elusive. Only recently have studies begun to elucidate more about vitreous seeding 
and how it translates clinically100,101.  
 
 Another reason why ocular salvage rates have not improved is the absence of 
targeted therapies. Most chemotherapies used to treat Rb are broadly targeting cells 
undergoing rapid division; however, these seeds are largely necrotic and show reduced 
proliferation100. To address this, disrupting molecular targets, such as spleen tyrosine 
kinase (SYK), histone deacetylase (HDAC), and MDM2/X/4, have been tested in vitro 
and in vivo using various small molecule inhibitors and are yet to make it into a clinical 
setting24,27,102. Most of these challenges, though, are a direct result of a deficiency in 
understanding the vitreous as a microenvironment. The hope is to develop and utilize new 
therapeutics to assist in clearing these tumors and improve ocular salvage rates beyond 
the current 70% threshold, but this can only be accomplished by growing our 
understanding of vitreous seeds and their unique biology.  
 
 
The Retinoblastoma Tumor Microenvironment  
 
 The idea that tumors are not independent entities and that they interact with other 
systems in the body is not new. Stephen Paget, in 1889, published work examining the 
metastatic patterns of post mortem breast cancer patients and concluded this could not be 
by chance; the cancer and the tissue it metastasized to played a role in development of 
metastatic disease103. Over a century later, it is now well known that tumors are not 
independent entities. Instead, the compartment in which tumors grow and survive is 
called the “tumor microenvironment” (TME). The TME encompasses tumor cells along 
with immune cells, endothelial cells, fibroblasts, cytokines, growth factors, enzymes, and 
other proteins104. And, while the TME is an integral part of tumor biology, very little is 
currently known about the Rb TME.  
 
 
The tumor microenvironment of endophytic and exophoytic Rb 
  
The two main growth patterns of primary Rb tumors are endophytic and 
exophytic (see: Primary Tumor Subtypes). Tumors exhibiting both endophytic and 
exophytic growth are often highly vascularized, illustrating the abundance of endothelial 
cells and pericytes5. Using irradiated, transgenic mice and transplanting them with GFP-
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labeled bone marrow cells, it was discovered that there were a high percentage of tumor-
associated macrophages (TAMs) in advanced intraocular Rb and these TAMs were 
localized largely to the vasculature of the tumor105. How these TAMs interact with the 
tumor is still poorly understood but these TAMs may promote primary tumor vasculature 
and suppress immune function while simultaneously secreting growth factors and 
chemokines that drive processes such as survival and resistance.  
 
 Despite primary tumors having sufficient blood supply, seeds (be they vitreal or 
subretinal) lack this same blood supply and are known to be avascular5. If these cells lack 
vasculature, they are unable to receive normoxic (normal oxygen, O2) levels and grow in 
a low O2, or hypoxic (low O2 concentrations), environment. Rb cells grown in a hypoxic 
environment undergo alterations in their metabolism to survive in this avascular system 
and divided at a much lower rate106. Furthermore, failure of radiotherapy or 
chemotherapy is often attributed to hypoxic status107.  
 
 
The vitreous as a microenvironment 
  
 The vitreous (sometimes referred to as vitreous body or vitreous humor) is a 
translucent medium that encompasses approximately 80% of the eye. Composed of 99% 
water, the remaining 1% is a solid phase composed of sugars, salts, collagen, and 
hyaluronan, as well as chemokines, cytokines, and growth factors108-111. These 
chemokines, cytokines, and growth factors are important in homeostasis but are often 
sequestered in collagen112. These molecules, normally present in the vitreous, are also 
known to be associated with and exacerbate various ocular pathologies, most notably 
diabetic retinopathy (DR) and proliferative vitreoretinopathy (PVR) in rhegmatogenous 
retinal detachments113,114. However, very little is currently known about interactions 
between tumor cells and the vitreous. Furthermore, few studies have attempted to 
characterize the vitreous as a tumor microenvironment and elucidate the role it plays in 
vitreous seeding.  Recent reports began classifying patterns of vitreous seeding as one of 
three types: 1) “dust,” 2) “spheres,” and 3) “clouds”100,101. Briefly, histopathology studies  
revealed “dust” seeds are composed primarily of individual, viable cells while “clouds” 
were primarily composed of necrotic (> 90%) cells with few viable cells; finally, those 
classified as “spheres” are viable cells with necrotic cores and are thought to represent the 
most aggressive seed phenotype101. Interestingly, the presence of macrophages was 
demonstrated in all subtypes of vitreous seeds101. The role(s) of macrophages has yet to 
be elucidated. Furthermore, how seed classification relates to potential treatment options 
and long-term outcomes have yet to be investigated. Therefore, the vitreous may be 
considered a reservoir of untapped potential that may be advantageous for tumor cells to 
gain access to but also to target as potential therapeutic avenues. Rb cells invading the 
vitreous may have access to all of these growth factors, cytokines, and chemokines that 
may aid in tumor survival. 
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The extracellular matrix 
 
 One area that has begun to be studied in Rb is the extracellular matrix (ECM) and 
how tumor cells interact with the ECM. The ECM provides physical support and is 
involved in healthy cell division, migration, differentiation, and survival. Composed 
primarily of proteoglycans and fibrous proteins (e.g. collagen, fibronectin, laminin, etc.), 
the ECM is important not only in homeostasis, but also wound healing and disease115. 
One of the most well characterized interactions is that of matrix metalloproteinases 
(MMPs) and the ECM. MMPs are a family of over 20 proteolytic enzymes with roles in 
tissue remodeling, wound healing, angiogenesis, inflammation, and tumor metastasis 
(Figure 1-2). Their roles in the eye as well as tumor biology will be discussed below. 
 
 Matrix metalloproteinases in the healthy and diseased eye. One of the basic 
functions of MMPs is tissue maintenance and remodeling116. In the normal eye, MMPs 
are expressed by a number of different cell types including fibroblasts, monocytes, 
macrophages, leukocytes, and endothelial cells, all of which are important in 
homeostasis. MMPs are expressed at baseline levels within both anterior and posterior 
segments of the eye and are transcriptionally regulated by specific tissue inhibitors of 
matrix metalloproteinases (TIMPs); it is only under stress (such as wound healing) that 
they may be expressed and activated117-119. One of the classic models for MMP activity is 
corneal wounds where the corneal epithelium is damaged and experiences inflammation 
and regeneration120. Moreover, as MMPs are expressed by endothelial cells (and other 
inflammatory cells), they play a vital role in both healthy neovascularization as well as 
those attributed to disease such as DR121 and AMD122. Studies have begun to elucidate 
the role MMPs secreted by cells within the trabecular meshwork play in the flow of 
aqueous humor and how these molecules may be exploited to reduce intraocular pressure 
for management of glaucoma123. Furthermore, published reports have discovered the 
presence of MMPs within healthy vitreous124. However most of these enzymes were 
found to be pro-MMPs (the inactive form of the enzyme)124. The mechanism and 
necessity of MMPs are well understood yet their role(s) in the eye has yet to be unraveled 
– it is known they play a role in a number of ocular pathologies but their (clinical) 
therapeutic value is uncertain at this time. One role that is clearer is the role MMPs play 
in cancer. 
 
 Matrix metalloproteinases in cancer. As mentioned above, tumors do not act 
alone; alternatively, they interact with a variety of different proteins and cell types, all 
that culminate in a malignant tumor. One such relationship is that of tumor cells and the 
ECM, more specifically that related to the most abundant protein in the body and the 
ECM: collagen. The MMP-collagen interface is well understood under normal, 
physiological conditions to be vital for proper development and maintenance. However, 
some cancers are known to overexpress MMPs, yet most malignancies do not and, 
instead depend on normal, heathy cells to synthesize these enzymes for them through 
interleukins, interferons, and other cytokines and chemokines125. With these overactive 
enzymes, tumors are able to utilize MMP functions and induce a number of the hallmarks 
of cancer including angiogenesis, immune evasion, and survival104,126. With this  
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Figure 1-2. Members of the Matrix Metalloproteinase (MMP) Family. 
 
The matrix metalloproteinase family of protease enzymes includes over 20 members. 
These enzymes are vital for normal development and tissue organization. These 
molecules are also involved in a number of pathological processes including 
angiogenesis, wound healing, and cancer. Most commonly, MMP-1, -2, and -9 are 
associated with cancer progression and metastasis. Reprinted with permission from Nat. 
Rev. Cancer Egeblad M., Werb Z. New functions for the matrix metalloproteinases in 
cancer progression. , 2: 163-176, (2002), with permission from Springer Nature.  
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knowledge, it is quite understandable why patient prognosis (in a number of 
malignancies) is significantly worse when high levels of MMPs are detected 127,128. 
Moreover, patient prognosis is ultimately worse due to higher risk for metastasis, the 
primary cause for cancer-associated mortalities, in which MMPs play a decisive role129.  
The epithelial-to-mesenchymal transition (EMT) is classically understood to be the 
initiation of metastatic disease. Briefly, cells undergoing EMT lose their cellular adhesion 
(i.e. tight junctions), show an increase in motility (via cytoskeletal remodeling), and 
acquire invasive potential through increases in MMPs, most commonly those of MMP-1, 
MMP-2, and MMP-9130. Furthermore, EMT has been demonstrated to confer resistance 
of cancer cells to chemotherapy131.  
 
While there are a number of chemical inhibitors of MMPs, the first “successful” 
inhibitor was BB-94 (aka Batimastat) and was the first broad-spectrum MMP inhibitor 
(MMPI) to reach clinical trials132. Used as an anti-angiogenic and anti-metastatic therapy, 
Batimastat was promptly abandoned due to an inability to be administered orally133. 
Perhaps the most notable MMP inhibitor, BB-2516 (sold by British Biotech under the 
name Marimastat), was a non-specific MMPI marketed as a new antineoplastic and 
oncostatic drug for stomach cancer (and was capable of being administered orally). Both 
preclinical and phase I clinical trials were conducted and showed reduced tumor burden 
(in xenografts) and higher rates of two-year survival rates (in patients)134,135. Ultimately, 
Marimastat failed in phase III clinical trials126. As most of the early MMPIs were non-
specific, side effects such as arthritis and musculoskeletal pain were problematic126. In 
response to toxicities, the next generation of therapeutics are being designed to be MMP-
specific. New technologies such as antibodies and antisense oligonucleotides are 
currently being developed and investigated but clinical trials using these materials are 
lacking126.  
 
 However, when considering the vitreous as a microenvironment, it is the lesser-
known role of MMPs that is perhaps most interesting. With the vitreous containing ECM 
molecules (such as collagen), many of the proteins within the vitreous are sequestered in 
the ECM; it is not until this ECM undergoes proteolysis these growth factors are free to 
bind their receptors and are considered bioactive112. Some of these same protein families 
are strongly linked to the hallmarks of cancer104. One such family, the platelet-derived 
growth factor (PDGF) family is known to play roles in both ocular pathologies and 
cancer. 
 
 
The Platelet-Derived Growth Factor Family 
 
 
Introduction 
 
 There are currently nine genetically-identified members of the platelet-derived 
growth factor (PDGF) family that include: two classic PDGF family members: PDGF-A 
and PDGF-B, two novel family members: PDGF-C and PDGF-D; as well as the vascular 
endothelial growth factor (VEGF) family: VEGF-A, VEGF-B, VEGF-C, VEGF-D, and 
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placental growth factor (PLGF). There are three receptor tyrosine kinases (RTKs) for the 
PDGF family including two homodimers: PDGFR and PDGFR as well as a 
heterodimer: PDGFR. These proteins form homodimers (i.e. PDGF-AA, PDGF-BB, 
etc.) and, to date, only one heterodimer has been found, PDGF-AB. As a part of their 
homology, these signaling molecules have different affinities for their receptors (Figure 
1-3). From early gastrulation and development to hematopoiesis and wound healing, this 
family of proteins is vital to normal health and growth136. Mice lacking copies of either 
PDGFA and PDGFB or either receptor (PDGFRA or PDGFRB) are embryonically 
lethal137-139. While little is currently known about the roles of PDGF-C and PDGF-D in 
physiology, work has shown PDGFC deficiency may be perinatally lethal140 but this 
appears to be background strain- (and sex-) dependent141. Interestingly, PDGFD 
knockouts are quite viable with a slightly abnormal vascularized phenotype142. 
Furthermore, some attempts at identifying tissue-specific expression of PDGFs have 
elicited that PDGF-A and PDGF-C are most commonly affiliated with epithelial cells and 
neuronal progenitor cells, PDGF-B is expressed by endothelial cells and mature neurons, 
and, while less clear, PDGF-D on smooth muscle cells and fibroblasts143. Still, these 
patterns are generalized and fail to capture the complex nature of these signaling 
molecules. However, given their broad, overarching roles in physiology, it is no surprise 
these molecules have been implicated in disease pathologies as well. The roles members 
of the PDGF family play in both ophthalmology and cancer biology are discussed further 
below. 
 
 
Platelet-derived growth factors in ocular health and disease 
 
 While some work has demonstrated PDGFs (specifically PDGF-BB) mediated 
corneal wound healing120, initial investigations of the PDGF family in ocular health 
focused primarily on retina and development due to prior studies identifying the PDGF 
family as requirements for proper development and organization of the central nervous 
system (CNS). PDGF-AA ligand and its primary receptor, PDGFR, were shown to be 
involved in retinal development primarily in the retinal pigment epithelium and 
astrocytes while PDGF-BB ligand and its primary receptor, PDGFR, were detected in 
the hyaloid canal and in vasculature144,145. Other work incidentally discovered that when 
PDGFRB is disrupted in the retina, a lack of pericytes leads to dysregulated vasculature 
and proliferative retinopathy146. Further, expression of PDGFB in photoreceptors of mice 
demonstrated rampant neovascularization and retinal detachments147. These studies 
inadvertently shaped how these signaling molecules would be viewed in the context of 
the eye: PDGF-AA as a molecule involved in the development of the eye and PDGF-BB 
as vasculature-specific molecule148.   
 
 Given their role in neovascularization, more translational and clinical studies 
began examining the PDGF family in patients in diseases that feature neovascularization 
as a primary etiology. High levels of PDGF-AB were detected in patients with 
retinopathies in one of the pioneering studies of PDGFs in ophthalmology 149. These 
levels were increased in patients with both diabetic and non-diabetic retinopathies,  
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Figure 1-3. Members of the PDGF family and their receptors.  
 
Platelet-derived growth factors (and their receptors) play important roles in both health 
and disease. PDGF-AA and PDGF-CC have high affinities for PDGFR; PDGF-BB has 
a high affinity for PDGFR and PDGF-DD is thought to as well. PDGF-AB has the 
highest affinity for its corresponding heterodimer receptor PDGFR. There exist many 
discrepancies between ligand-receptor interactions in vitro (top panel) and in vivo 
(bottom panel). But given their homology, it is thought most ligands are capable of 
binding both homodimeric and heterodimeric receptors. Reprinted with permission from 
Genes Dev, 22 (10), Andrae, J., et al. Role of platelet-derived growth factors in 
physiology and medicine. p1276-1312, Copyright (May 15, 2008), with permission 
through Creative Common CC-BY.  
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illustrating glucose-independent regulation of PDGFs, inverse to what had been 
previously suggested150. More studies added to these data, correlating PDGF levels with 
disease progression and severity151,152.These studies helped identify a new therapeutic 
target and pre-clinical studies examined the potential value of these targets. Targeting 
PDGFs, specifically PDGF-BB, was shown to be successful in preventing 
neovascularization pre-clinically, and clinical trials followed shortly thereafter153,154. 
However, these clinical trials ultimately failed to meet outcomes and the trials were 
terminated155. The future of PDGF's therapeutic value in remedying ocular diseases is 
uncertain but one area where anti-PDGF/PDGFR therapy has shown tremendous value is 
in oncology. 
 
 
Platelet-derived growth factors in cancer 
 
 PDGFs are known to promote tumor angiogenesis; without proper blood supply, 
tumors will fail to grow156. However, the main function of PDGFs is that of a mitogen, or 
a molecule capable of inducing cell division. This signaling also has the potential to be an 
autocrine loop and was seen as potentially useful in tumorigenesis157 Though mutations 
in members of the PDGF family are somewhat rare, this autocrine loop may provide 
selective growth advantages for cells that overexpress a receptor (or receptors) and may 
produce higher levels of the ligand(s)158. One of the most notable examples of tumors 
with overexpression / amplification of PDGFs is glioblastoma, which features an increase 
in PDGFRA with higher expression correlating to worse prognosis159. There have 
multiple attempts of using tyrosine kinase inhibitors (TKIs) to treat glioblastoma, but 
results have been disappointing160. 
 
 There are tumor types that are responsive to TKIs targeting PDGFRs. One such 
tumor is that of gastrointestinal stroma (GISTs). GIST tumors previously carried abysmal 
prognoses with survival rates less than one year; however, work identified these tumors 
frequently possess mutations in either KIT or PDGFRA and may be targeted using TKIs 
161. Patients benefited quite strongly to treatment with imatinib mesylate (IM, a known 
inhibitor of c-kit as well as PDGFRs)161.  
 
 Another tumor, dermatofibrosarcoma protuberans (DP), frequently harbor 
translocations of the PDGFB whereby the gene is fused with that of the gene encoding 
for collagen type 1 alpha 1 (COL1A1) and results in excessive PDGF-B production162. 
This production establishes an autocrine loop, promoting rapid cell proliferation and 
resulting in tumorigenesis. The same TKI, imatinib mesylate, was utilized to block 
PDGF-BB/PDGFR signaling and has been approved for administration in those afflicted 
with DP163. There are ongoing investigations into the PDGF family and their roles in 
other malignancies as well, including leukemias as well as prostate, lung, breast, and liver 
cancers. And though recent work has cast a shadow of doubt on anti-PDGF/PDGFR 
therapy in the field of ophthalmology for neovascularization, oncologists and cancer 
patients have vastly benefited from the therapeutic strategies targeting these key 
molecules.  
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Vascular endothelial growth factor, a sub-family of platelet-derived growth factor 
family 
 
 The other members of the PDGF family, vascular endothelial growth factors 
(VEGF), are more well-understood than the PDGFs. Similar to the PDGF family though, 
VEGFs bind receptor tyrosine kinases (RTKs) and are capable of inducing downstream 
signaling. The VEGF family is most noted for the key role it plays in promoting 
endothelial cell migration and division and therefore, to angiogenesis164. As discussed 
previously, angiogenesis is necessary for tumor growth156. Therefore, by removing access 
to blood supply from tumor cells, these cells may not divide and will die. This idea led to 
the development of the first anti-VEGF monoclonal antibody, bevacizumab, which was 
developed and utilized (alongside chemotherapy) for treatment of metastatic colorectal 
cancers. Today, bevacizumab has been extensively studied in a number of malignancies 
and is even approved for treatment of metastatic colon, renal, and breast cancers, as well 
as use in glioblastomas, lung cancers, and ovarian cancers165. Bevacizumab has even 
been tried preclinically for treatment of Rb in xenografts166,167. Despite modest success, 
anti-VEGF therapy has failed to penetrate a clinical setting for the treatment of Rb. 
Moreover, the focus in Rb that has the largest unmet need is in treating vitreous seeding 
and, as these seeds are avascular, anti-angiogenic therapy is hardly appropriate.  
 
 The area that has heralded the success of anti-VEGF therapy the most is in 
ophthalmology. While studies were being conducted on the role VEGF may play on 
tumor angiogenesis, other studies elucidated that VEGF played a similar role in other 
ocular pathologies, namely AMD and DR168. Just two years after approval of 
bevacizumab for metastatic colon cancer, a more diffusible version of bevacizumab, 
ranibizumab, was approved by the Federal Drug Administration (FDA) for treatment of 
AMD168. While successful, anti-VEGF therapy does not work for all patients and only 
about one-third of patients receive improved visual acuity over time169. To combat this 
problem, anti-VEGF and anti-PDGF therapies were utilized together. These clinical trials 
examined anti-VEGF therapy and compared it to a combined anti-VEGF/-PDGF therapy. 
The combination therapy failed to increase visual acuity when compared to anti-VEGF 
therapy alone and, thus, anti-PDGF therapies were abandoned155.  
 
 
Rationale and Specific Aims 
 
 It is clear that great strides have been made in treating Rb. Survival rates are 
greater than 95% in developed countries. However, vitreous seeding remains a clinical 
challenge in treating a patient with Rb. Numerous studies have shown the importance of 
the tumor microenvironment (TME) in promoting tumorigenesis, survival, metastasis, 
and resistance to therapies, yet little is known about the Rb TME and how the tumor 
interacts with its TME.  
 
 The extracellular matrix (ECM) is of vast importance in the TME, as the tumor 
cells are capable of utilizing the ECM to generate new blood supply, increase pro-tumoral 
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inflammation, and utilize proteolytic processing MMPs to gain access to an increased 
supply of growth factors. One such family of growth factors, the PDGF family, has been 
well studied in both vitreoretinal pathologies as well as multiple malignancies. The 
central hypothesis of this study is that the interactions between the Rb tumor and its 
microenvironment are permissive for the growth and sustain of vitreous seeds. To address 
the central hypothesis I utilized basic Rb cell lines, murine Rb xenografts samples, 
patient-derived xenograft samples, and ex vivo human samples from healthy donors and 
Rb patients. The central hypothesis of this study was tested by pursuing the following 
aims or objectives:  
 
 Aim 1: To test the prediction that MMPs within the ECM play a role in Rb tumor 
migration and angiogenesis by characterization of key pro-tumoral members of the MMP 
family in Rb cell lines. The role of these MMPs in migration and angiogenesis was 
investigated using pharmacological and genetic knock-down approaches. (Chapter 2) 
 
 Aim 2: To test the prediction that the PDGF-PDGFR signaling pathway plays a 
pivotal role in sustainment of Rb. The abundance in the Rb vitreous and signaling activity 
of this pathway in an autocrine and paracrine (from the TME) manner makes it a 
candidate for targeted therapy for the management of vitreous seeds. (Chapter 3) 
 
 Aim 3: To test the pre-clinical safety of targeted anti-PDGFR therapy in other 
cellular components of the TME. The effects of targeted anti-PDGFR therapy in human 
retinal endothelial cells and the inherent properties of Rb in chemotherapy resistance. 
(Chapter 4) 
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CHAPTER 2.    RESULTS I: INHIBITION OF MMP-2 AND MMP-9 DECREASE 
CELLULAR MIGRATION, AND ANGIOGENESIS IN IN VITRO MODELS OF 
RETINOBLASTOMA1 
 
 
Introduction 
 
 Retinoblastoma (Rb) is the most common primary intraocular tumor in children 
with an incidence of approximately 12 cases per million children under 4 years of age in 
the United States 171. Mutation of the tumor suppressor gene, RB1, can lead to the disease 
sporadically or through inheritance. Germline mutations of RB1 account for 
approximately 40% of cases and exhibit an autosomal dominant pattern of inheritance172. 
Germline RB1 often affects both eyes whereas the more common sporadic form of the 
disease is often unilateral and accounts for 60% of all cases172. If diagnosed early, 
intraocular Rb can be effectively treated; however, the more advanced disease can 
metastasize to the central nervous system (CNS) in which case, mortality rates are greatly 
increased173. Tumor invasion from the retina to the sclera and post laminar optic nerve 
are of high risk pathologic features for both hematogenous and CNS metastasis173. 
Clinical risk factors that increase the incidence of metastasis in these patients include 
older age174-176, laterality177, vascularity178,179, and stage present upon diagnosis180. 
 
 The dissemination of malignant neoplasms is assumed to require degradation of 
different components of the matrix and basement membrane. Matrix metalloproteinases 
(MMPs) are responsible for degradation of a number of extracellular matrix (ECM) 
components. There are over 20 recognized MMPs, each with specific substrate 
requirements and structural domains181-183. Among these are two highly associated with 
tumor dissemination and invasiveness184,185: MMP-2 (aka gelatinase A) and MMP-9 
(aka gelatinase B), which degrade type IV collagen and gelatin substrates. Cumulative 
work in different solid tumors has generated great interest in the development of MMP 
inhibitors (MMPI) as potential therapeutic anti-metastatic agents. Some synthetic MMPI 
have been tested in clinical trials in solid tumors other than Rb and show different levels 
of efficacy186,187. Recent clinical trials by Gilead Sciences are evaluating MMP activity in 
different solid tumors, including non-small cell lung carcinoma (NSCLC), pancreatic 
adenocarcinoma, colorectal cancer (CRC) and breast cancer, and their effects in the 
tumor microenvironment by using an anti-MMP-9 therapeutic antibody188. The antibody, 
GS-5745, is a humanized monoclonal antibody against MMP-9, which upon binding 
MMP-9 results in inhibition of ECM degradation and possibly a reduction in tumor 
growth and risk of metastasis189. Immunohistochemical analysis of primary Rb tumors 
show that MMP-2 and MMP-9 protein levels are higher in samples that had invaded the 
optic nerve190,191. To our knowledge, the effects of MMPI on Rb have not been analyzed 
                                                 
 
 
1 Adapted with permission. Webb AH, Gao BT, Goldsmith ZK, et al. Inhibition of MMP-2 and MMP-9 
decreases cellular migration, and angiogenesis in in vitro models of retinoblastoma. BMC Cancer. 
2017;17(1):434. © BioMed Central. 
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comprehensively in vitro. Here, we provide a detailed analysis of two MMPI on cellular 
viability, levels of pro-angiogenic factors, migration and immunomodulatory proteins in 
two well-studied Rb cell lines: Y79 and Weri-1. These two Rb cell lines have somewhat 
different characteristics, with Y79 exhibiting inherent metastatic properties and Weri-1 
exhibiting non-metastatic properties. Our aim was to examine responses of both cell lines 
since it is likely that Rb tumors in vivo may contain mixed populations of tumor cells 
with varying metastatic potential. Our results demonstrate that pharmacological inhibition 
of MMPs reduces Rb cell viability, migration, and secretion of the pro-angiogenic factors 
VEGF and Angiopoietin-2 in either one or both types of Rb cell lines. These promising 
findings provide an impetus for future in vivo studies to evaluate MMPI as a potential 
adjunct therapy for Rb patients. 
 
 
Materials and Methods 
 
 
Cell lines, growth media, and tissue culture conditions 
  
 Y79 (ATCC-HTB-18)79, Weri-1 (ATCC-HTB-169)80, Retinoblastoma (Rb) tumor 
cell lines were purchased from the American Type Culture Collection (ATCC, Manassas, 
VA). Cells were grown in RPMI-1640 (MediaTech, Herndon, VA) supplemented with 
20% Fetal Bovine Serum (Hyclone, Logan, UT), 1% of Penicillin G Sodium 
Salt/Streptomycin Sulfate (100X) (Lonza). Rb cell lines were grown under different 
conditions, including ARP100 (MMP-2 inhibitor, Santa Cruz Biotechnology) at 5μM and 
AG-L-66085 (MMP-9 inhibitor, Santa Cruz Biotechnology) at 5μM concentration, unless 
otherwise specified. Incubation proceeded overnight at 37 °C/5%CO2. The IC50 values 
for ARP100: MMP-2: 12nM; MMP-3: 4.5μM; MMP-7: 50μM. The IC50 values for AG-
L-66085: MMP-9: 5nM; MMP-1: 1.05μM. 
 
 
qPCR analyses 
  
 RNA isolation. RNA from 2.5 × 106 Rb cells was extracted following the 
Qiagen® miRNeasy Mini Kit (Qiagen, Valencia, CA) manufacturer’s recommendations. 
Rb cells were harvested and centrifuged to remove all traces of cell culture medium. Cell 
pellets were lysed and homogenized prior to addition of chloroform. Samples were 
shaken vigorously for 15s prior to centrifugation for 2min at full speed. The upper 
colorless phase was transferred to a clean tube after centrifugation followed by a series of 
alcohol precipitations to provide ideal binding conditions. The lysate was loaded onto an 
RNeasy spin column with a silica membrane to bind the RNA and washed away 
contaminants. Residual DNA was removed by on-column DNase digestion. The 
concentrated RNA was eluted in 15L of RNAse free water. RNA concentration was 
assessed by analysis on Nanodrop 2000 Spectophotometer (ThermoFisher Scientific) and 
purity was assessed by verifying absorbance ratios of 260nm and 280nm (A260/A280). 
Samples with absorbance ratios between 1.8 and 2.0 were considered free of 
contamination.   
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 cDNA synthesis and pre-amplification. Synthesis of cDNA was performed 
using the SuperScript® VILO™ cDNA Synthesis Kit (Life Technologies, Grand Island, 
NY). Following manufacturer’s directions, we used 100ng of isolated RNA (see section 
above) and combined them with 4µL 5X VILO Reaction Buffer and 2µL 10X 
SuperScript Enzyme Mix. Final volume per sample was 20µL using DEPC-treated water 
when necessary. Per manufacturer’s directions, cDNA synthesis reaction was done at 
25ºC for 10min followed by 42ºC incubation for 60min with reaction termination at 85ºC 
for 5min. Material was pre-amplified using 10µL 2X TaqMan® PreAmp Master Mix, 
5µL pooled 0.2X TaqMan® primers, and 5µL cDNA sample for a final volume of 
20µL192. Preamplification reactions were conducted according to manufacturer’s 
guidelines with a 10min enzymatic activation step at 95ºC followed by 14 cycles of 
denaturing (95ºC for 15s) and annealing (60ºC for 4min). Following 14 cycles, enzyme 
was inactivated at 99ºC for 10min and reactions were held at 4ºC until use. 
Preamplification reactions utilized the same primers analyzed to use minimal amounts of 
material while increasing sensitivity of detection. The reaction was kept at −20°C until 
ready to use. 
 
 PCR. We used the following Human TaqMan® Gene Expression 
Assays: HPRT1 (Hs02800695_m1), MMP2 (Hs01548727_m1), MMP7(Hs01042796_m1
), MMP9 (Hs00234579_m1), MMP14(Hs01037003_g1) all from Life Technologies 
(Grand Island, NY). A final volume of 10μL was loaded into each well after combination 
of 5µLTaqMan® Universal Master Mix, 2.5µL cDNA, 0.5µLprimers and 2.0µL 
Nuclease-Free water. White, 96-well PCR plates were run using Roche® LightCycler 480 
using TaqMan® protocol: reaction was initiated at 50ºC for 2min followed by 95ºC for 
10min before 40 PCR cycles were conducted at 95ºC for 15s and 60ºC for 1min. Values 
greater than 35 were excluded due to low confidence. Data was analyzed using the 
Comparative CT (∆∆CT ) Method where ∆CT is the difference between gene-of-interest 
(GOI) and housekeeping gene (HKG) and ∆∆CT is the difference between experimental 
(i.e. MMP2/9I) and untreated. Fold change is determined by 2 raised to the negative 
∆∆CT value [2(-∆∆CT)]192,193. For more information, please see Appendix Table A-1. 
 
 
siRNA experiments 
  
 Y79 Rb cells were plated overnight in 6-well plates at a cell density of 
2.5 × 105 cells per well in 2mL RPMI/10% FBS (no antibiotics) final volume. Two 
solutions were made: solution A contained 0.75μg of siRNA into 100μL of siRNA 
Transfection Medium (sc-36868; Santa Cruz Biotechnology) per well; solution B 
contained 6μL of siRNA Transfection Reagent (sc-29528; Santa Cruz Biotechnology) 
into 100μL siRNA Transfection Medium per reaction. Silencers: MMP2: sc-
29398; MMP9: sc-29400; both from Santa Cruz Biotechnology. Solutions A and B were 
mixed and incubated at RT for 30min. Cells were harvested and washed in siRNA 
Transfection Medium. We proceeded to resuspend harvested cells in 800μL of siRNA 
Transfection Medium per well. We added the mixture of solutions A and B onto the cells, 
mixed gently and incubated for 24h at 37°C/5%CO2. Next, we added 1mL of RPMI/20% 
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FBS without removing the transfection mixture and incubated cells for an additional 24h 
prior to performing functional assays. As a control, we used a scramble sequence (sc-
37007; Santa Cruz Biotechnology) that does not lead to degradation of any known 
cellular mRNA. 
 
 
Protein assessment 
  
 Enzyme-linked immunosorbent assays (ELISA). Human MMP-2 (#KHC3081; 
ThermoFisher Scientific), human MMP-9 (#BMS2016-2; ThermoFisher Scientific), 
human VEGF (#BMS277-2; ThermoFisher Scientific), and universal TGF-β1 
(#BMS249-4; ThermoFisher Scientific) ELISA kits were purchased from Life 
Technologies. Human Angiopoietin-2 was purchased from Sigma-Aldrich (St. Louis, 
MO, RAB0016-1KT). All assays used according to manufacturer’s instructions. 
Biological replicates of cell lysates (25μg for MMP-2 and MMP-9; 40μg for VEGF and 
TGF-β1) were assayed in triplicates. After the addition of the samples, all plates were 
incubated on a shaker at RT for 2h, according to instructions. Plates were washed with 
1X wash buffer and incubated with 100µL of their Biotin Conjugate on a shaker for 1h at 
RT followed by addition of 100µL 1X Streptavidin-HRP at RT for 30min. In the TGF-β1 
Kit, these two steps were combined for a 3h incubation as indicated by the protocol. 
Afterwards, 100μL of stabilized chromogen were added to each well and incubated in the 
dark for 30min at RT followed by addition of 100µL stop solution (0.16M sulfuric acid) 
prior to measuring O.D. at 405nm. 
 
 Western blot assays. Cells were initially washed and pelleted prior to addition of 
ice cold RIPA Buffer (#89900; Life Technologies). Mixtures were placed on ice for 
15min before being vortexed for 10s and placed in a centrifuge at full speed for 5min. 
Supernatant (lysate) was kept and cell debris was discarded194. Protein concentrations 
were calculated using the Pierce™ BCA Protein Assay Kit (Thermo Scientific). A total 
of 50μg of denatured protein (denatured using Bolt® Reducing Agent) was used for each 
sample loaded in a Bolt™ 4–12% Bis-Tris Plus Gel (#NW04125BOX; Invitrogen). 
Membrane was blocked in 20mL of Pierce™ Fast Blocking Buffer (#37575; 
ThermoFisher Scientific) followed by incubation with antibodies. Primary antibodies 
used: MMP-2 (clone D8N9Y) rabbit monoclonal antibody at 1:1000, MMP-9 rabbit 
polyclonal antibody at 1:1000, E2F rabbit polyclonal antibody at 1:1000, and β-Actin 
(clone D6A8) rabbit monoclonal antibody HRP conjugated at 1:1000. Secondary 
antibody was Anti-rabbit IgG, HRP-linked at 1:2000. All antibodies were from Cell 
Signaling Technologies® (Danvers, Massachusetts, USA). We used the Biotinylated 
Protein Ladder Detection Pack (Cell Signaling Technologies®), which includes the 
biotinylated protein ladder and the anti-biotin, HRP-linked antibody. SuperSignal West 
Pico Chemiluminiscent Substrate (Thermo Scientific) was used to develop the signal. 
Densitometry analysis was done using Kodak Molecular Imager comparing mean band 
density195-197. For more information, please see Table A-2. 
 
Bicinchoninic acid (BCA) protein concentration assay. Albumin standards 
were generated ranging from 2000µg/mL to 25µg/mL, 0µg/mL and 20µL of prepared 
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standards were plated on a 96-well microplate. A volume of 2µL of fresh lysate was 
added (in triplicate) followed by addition of 200µL BCA working solution (50:1, Reagent 
A:B). Plates was mixed gently on the benchtop prior to incubation at 37ºC for 30min. 
Plate was then read on a spectrophotometric microplate reader (BioTek µQuant, BioTek 
Instruments, USA) at 562nm. Using linear fit, protein concentrations were generated in 
µg/µL.  
 
 
Cellular proliferation 
  
 Quantitation of cell proliferation and viability was performed through use of 
CellTiter 96® AQueous Non-Radioactive assay (MTS) (G5421; Promega, Madison, 
Wisconsin, USA) following manufacturer’s suggested guidelines. Briefly, 5.0 × 104 Y79 
and Weri-1 Rb cell lines were cultured per well under different culture conditions: 
untreated and both MMP2I and MMP9I from concentrations ranging from 500nM to 
25µM. CellTiter 96® AQueous was added at a concentration of 10μL of reagent per 100μL 
volume per well at specific time points of 0-, 48-, 72-, 96- and 120h after culture. After 
addition of CellTiter reagent, cells were incubated at 37°C/5% CO2 for an additional 2h 
before absorbance was read at 485nm using 630nm as a reference on a 
spectrophotometric microplate reader (BioTek µQuant, BioTek Instruments, USA). 
 
 
Cell cycle analyses 
  
 Y79 cells were plated under different cell culture conditions overnight at 
37°C/5% CO2. Next day cells were then harvested and fixed in 200µL PBS/2% 
paraformaldehyde (PFA) for 15min on ice, then washed and permeabilized using 0.1% 
Triton™ X-100 (Sigma-Aldrich) for 20min. We used far-red fluorescent DNA dye, 
DRAQ5™ (BioLegend, San Diego, CA, USA), at a 1:100 concentration in PBS/1% FBS 
for 15min on ice to assess cell cycle progression. This is a cell-permeant DNA binding 
anthraquinone dye, which intercalates between adenine and thymine (A-T) bases of 
double stranded DNA. DRAQ5™ was excited at 642nm and acquired using a 642 to 
740nm filter on the Amnis FlowSight® imaging cytometer (Amnis Corporation, EMD 
Millipore, Seattle, WA, USA). Sample data acquisition was done using  INSPIRE 
software (Amnis Corporation). Initial acquisition gates were done using dot plots of 
Brightfield Aspect Ratio vs. Area to separate and identify single cell populations from 
doublets and debris. Next, a DRAQ5 Aspect Ratio vs. Intensity dot plot was generated to 
positively identify healthy Y79 cells. Once cell population was identified and acquired, a 
Bright Field Gradient root mean square (RMS) vs. Normalized Frequency histogram was 
generated to identify cell population in focus. From there, a histogram of DRAQ5 
Intensity vs. Normalized Frequency was created to examine phases of cell cycle (G0/G1 
vs. S vs. G2/M). Percentages and statistical report were generated in IDEAS v6.2 
software (Amnis Corporation).    
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Migration and invasion assays 
  
 Migration analysis via the wound healing assay. CytoSelect™ 24-well Would 
Healing Assay kit was purchased from Cell Biolabs Inc. (CBA-120; San Diego, CA). The 
24-well plate was pretreated with 500μL of 0.1mg/mL Poly-L-Lysine hydrobromide 
(Sigma-Aldrich) per manufacturer’s instructions and incubated at 37°C for 1h. Wells 
were washed with distilled, sterile water twice and dried in the biosafety cabinet for 2h. 
We added 500μL of 1X attachment factors (S006100, Life Technologies) containing 
gelatin (substrate of both MMP-2 and MMP-9) per well and incubated at 37°C for 30min. 
Solution was aspirated and replaced by Rb cells at a concentration of 1.0 × 106 cells/mL. 
Cell culture conditions included untreated, MMP2I, and MMP9I, both inhibitors at a final 
concentration of 5µM. We ensured cells were evenly distributed and incubated the plate 
at 37°C to create a 95% confluent monolayer of cells. The inserts were removed; wells 
were washed twice with distilled, sterile water to remove unattached cells and debris. The 
cells were then resuspended in 500μL of respective culture conditions. Pictures were 
taken and 0-, 2-, 6-, 24-, and 48h time points and analyzed for cell migration using an 
Axiovert 40 CFL (Zeiss, Germany) at a 12.5X total magnification (lens 2.5X, objective 
10X, and camera 0.5X). 
 
 Invasion assay. CytoSelect™ Cell Invasion Assay kit was purchased from Cell 
Biolabs Inc (CBA-110, San Diego, CA). We use the provided 8μm pore polycarbonate 
membrane coated with basement membrane matrix solution. Rb cell suspension (in serum 
free media) was placed in the upper chamber to determine the invasion capacity of the 
cells after degradation of the matrix membrane proteins 6h post culture. Invasive cells 
were stained using 400µL of the included Cell Stain Solution and incubated at RT for 
10min before being washed with distilled water.  Invasive cells were then quantified with 
a light microscope under 100X total magnification (lens 2.5X, objective 40X), with 4 
individual fields per insert. Inserts were placed to wells containing 200μL of Extraction 
Solution followed by 10min incubation at RT on an orbital shaker. Quantitation of cells 
measured at OD 560nm using spectrophotometer (BioTek µQuant, BioTek Instruments, 
USA). 
 
 
Statistical analysis 
 
 Data on bar graphs are expressed as means ± SD or ± SEM (as indicated), 
with p < 0.05 considered statistically significant. The data were compared where 
appropriate by paired Student t test or by the Holm-Sidak Method, with alpha = 5.0%, 
using Graph Pad Prism v5. 
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Results 
 
 
Inhibition of MMP-2 and MMP-9 decreases migration in the metastatic Y79 Rb cell 
line, and viability in the non-metastatic Weri-1 model 
 
 Tumor migration and invasion of the optic nerve and the uvea has a significant 
impact in the prognosis of Rb as it denotes metastatic disease often including distant sites 
such as the brain, lungs and/or bones that may be fatal to diseased patients. Ultimately, 
metastatic disease is much more difficult to treat due to lack of effective local therapies 
and often includes much more aggressive and life-threatening treatment options. Previous 
work demonstrated high expression of both MMP-2 and MMP-9 in extra-ocular Rb as 
well as those with optic nerve involvement and worse staging191. To investigate the 
effects of inhibition of MMP-2 and MMP-9 on the migration of Rb cells we used an 
established in vitro system consisting of well characterized Rb cell lines. This system 
represents both a metastatic model, represented by the Y79 cell line, and a non-metastatic 
model, represented by the Weri-1 cell line. The pathogenicity and aggressiveness of these 
cells have been established in an in vivo animal model37. This in vivo study consisted of 
intravitreal injection of 2 x 104 Y79 or Weri-1 cells into mice and found Y79 readily 
invaded the retina, subretinal space, anterior chamber, optic nerve head, choroid, 
contralateral eye, subarachnoid space, and the brain. Meanwhile, Weri-1-injected mice 
displayed little to known invasion and only showed choroidal invasion during late stage 
disease37. The cell lines followed the migration and aggressive patterns from which they 
were derived, Y79 from a patient that ultimately developed brain metastasis and Weri-1 
from a patient without metastatic disease. To test the hypothesis that MMPs would 
control Rb cell migration and invasion, Rb cell lines were added to the upper chamber of 
an 8μm polycarbonate membrane coated with basement membrane proteins in serum free 
RPMI media at a density of 1 x 106. The lower chamber had media in the presence or 
absence of matrix metalloproteinases inhibitors (MMPI). We used ARP100 as an 
inhibitor of MMP-2 at a 5μM concentration; and AG-L-66085 as a MMP-9 inhibitor at a 
5μM concentration, as described in other studies198. If MMP signaling is required for 
migration we would observe a reduction in Rb cell migration through the basement 
membrane after treatment with MMPI. Our results showed a significant reduction of Rb 
cell migration through the basement membrane, or extracellular matrix (ECM), after 
MMPI treatment. These results suggest MMP-2 and MMP-9 activity are necessary to 
degrade ECM and promote cellular invasion in Rb. In Figure 2-1 we show a 
representative field for each insert. Next, we performed quantitation analyses via 
colorimetric change as indicated with Cell Staining Solution and measured on a 
spectrophotometric microplate reader. As shown in Figure 2-1 there is a significant 
difference between untreated Y79 and those treated with the MMPI (Y79 Rb cells, 
Untreated versus MMP2I: 0.397 ± 0.06 versus 0.260 ± 0.010, p = 0.01; versus MMP9I: 
0.225 ± 0.005, p = 0.0009; Weri-1 Rb cells, Untreated versus MMP2I: 0.164 ± 0.028 
versus 0.061 ± 0.014, p = 0.043; versus MMP9I: 0.056 ± 0.018, p = 0.0294). To confirm 
our results, we used a different method, the classic wound healing assay. We adhered Rb 
cells to poly-L-lysine hydrobromide coated surfaces and created artificial wounds of  
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Figure 2-1. Inhibition of MMP-2 and MMP-9 reduced Rb invasion.  
 
Y79 and Weri-1 cells were added to the upper chamber of an 8μm polycarbonate 
membrane coated with basement membrane in serum-free media. The lower chamber 
contained cell culture media with or without MMPI. Six-hours post culture, invasive cells 
degraded the ECM and were collected, stained and counted. Representative figures are 
shown with a 100X total magnification. Cells were extracted, and OD measured for Y79 
and for Weri-1. For each condition n = 3; gap was measured in 5 different points. 
Modified with permission from BMC Cancer. Webb AH, Gao BT, Goldsmith ZK, et al. 
Inhibition of MMP-2 and MMP-9 decreases cellular migration, and angiogenesis in in 
vitro models of retinoblastoma. BMC Cancer. 2017;17(1):434. Copyright (June 20, 
2017), with permission through Creative Common CC-BY. 
 
  
  
29 
 
approximately 900μm. The closure of the gap area was measured at different time 
intervals for up to 48h, as this represents the potential of cells to readily migrate. We 
observed Y79 untreated cells closed the gap area (Figure 2-2) while MMP2I and 
MMP9I-treated Y79 cells showed a significant reduction in migration (Untreated versus 
MMP2I at 24h: 315 ± 45 versus 742.5 ± 22.5, p = 0.0001; versus MMP9I: 
810 ± 36.7, p = 0.0001). Migration potential as measured by the wound-healing assay 
revealed that inhibition of either MMP-2 or MMP-9 caused a significant reduction of 
Y79 cells migration. 
 
Previous reports have demonstrated MMP inhibitors may have cytostatic and 
cytotoxic effects on cancer cells. The exact mechanism(s) behind these observations is 
not well understood. Nonetheless, we hypothesized inhibition of MMP-2 or MMP-9 by 
the pharmacological inhibitors may, in turn, decrease cellular viability. To investigate this 
hypothesis, we treated cells under the same conditions as mentioned above and utilized 
the CellTiter 96® AQueous Non-Radioactive assay (MTS). The cellular viability assays 
showed both MMP2I and MMP9I significantly reduced the viability of Y79 cells (Figure 
2-3) (Untreated versus MMP2I: 116.67% ± 1.40 versus 42.66% ± 1.4, p < 0.005; versus 
MMP9I: 32% ± 0, p < 0.005). We next hypothesized that this reduction in viability would 
be the result of exit from the cell cycle (cytostatic) or cell death (apoptosis). We 
examined cell cycle using a nuclear dye and imaging flow cytometry to determine in 
which phase of the cell cycle these Rb cells were in and expected to see higher 
percentages of cells in G0/G1 phase. In addition to the cytotoxic effect we observed a 
significant increase in the percentage of cells within the G0/G1 cell cycle phase in Y79 
cells treated with MMP9I compared to those untreated (Figure 2-3)[Untreated versus 
MMP9I: G0/G1 phase: 32.44% ± 0.907 versus 49.51 ± 1.059; S phase: 5.23% ± 0.165 
versus 5.28% ± 0.062; G2/M phase: 5.16% ± 0.117 versus 4.252% ± 0.335]. 
 
 Prior studies have demonstrated a lack of invasion and migration of Weri-1 cells 
in vivo, especially when compared to Y79, and found similar patterns of migration / 
invasion to the tumors from which these cells were derived. Mice inoculated with Weri-1 
cells readily form primary tumors, but these tumor cells rarely invade and only migrate 
small distances anteriorly. Furthermore, previous in vitro work has also demonstrated a 
Weri-1-specific lack of binding to choroidal and glioma cells, further demonstrating a 
lack of binding for Wer-1. It is possible Weri-1 lack the necessary cytoskeletal molecular 
machinery to initiate and undergo metastasis. It is for this reason, unfortunately, we were  
not able to carry out the migration assay using Weri-1 cells because these cells detached 
from the surface of the wells after treatment with either of the inhibitors (Figure 2-2), 
which precluded any meaningful measurement. To better understand why they detached 
we did a titration assay using a 500nM to 25μM range of the MMPIs to investigate the 
sensitivity of Weri-1 Rb cells to MMP2I (left) and MMP9I (right) (Figure 2-4) and found 
Weri-1 Rb cells are sensitive to inhibitors even at low concentrations. 
 
 Collectively, these findings support the conclusion that MMP-2 and MMP-9 
activity stimulates Rb cell migration in vitro and that similar pathways could be involved 
in Rb metastasis in vivo. 
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Figure 2-2. Inhibition of MMP-2 and MMP-9 reduced Rb cell migration.  
 
Y79 Rb cells were cultured in the presence or absence of MMP-2 or MMP-9 inhibitors 
for 48h on poly-L-lysine coated wells with gelatin as substrate. Sterile in-well inserts 
created a gap of 900μm. Gap closure was recorded at different time intervals using an 
Axiovert 40 CFL (top left). Total magnification is 12.5X. Plotted results are in shown 
(top right). Weri-1 cells showed increased cell death and detachment from coated 
surface (bottom). For each condition n = 3; gap was measured in 5 different points. 
Modified with permission from BMC Cancer. Webb AH, Gao BT, Goldsmith ZK, et al. 
Inhibition of MMP-2 and MMP-9 decreases cellular migration, and angiogenesis in in 
vitro models of retinoblastoma. BMC Cancer. 2017;17(1):434. Copyright (June 20, 
2017), with permission through Creative Common CC-BY. 
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Figure 2-3. Inhibition of MMP-2 or MMP-9 reduced Rb cell viability and cell cycle 
progression. 
 
Y79 cells were cultured in the presence or absence of the MMPI overnight. Next day, we 
collected cells and assessed viability by Trypan Blue exclusion. (A) Chemical inhibition 
of Y79 with MMPI significantly reduced cell yield when compared to untreated cells. (B) 
RNA interference was used to confirm on-target effects of MMPIs. Y79 were cultured in 
the presence of either MMP2 or MMP9 siRNA. MMP2 and MMP9 knockdown groups 
showed significant reduction in cell yield, illustrating an on-target effect of MMPI. (C) 
Imaging flow cytometry analysis showed inhibition of MMP9 prevents progression of Rb 
cell division using nuclear DRAQ5™ labeling (bottom). Bar graphs indicate results ± 
SEM to control. **p < 0.005. Modified with permission from BMC Cancer. Webb AH, 
Gao BT, Goldsmith ZK, et al. Inhibition of MMP-2 and MMP-9 decreases cellular 
migration, and angiogenesis in in vitro models of retinoblastoma. BMC Cancer. 
2017;17(1):434. Copyright (June 20, 2017), with permission through Creative Common 
CC-BY. 
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Figure 2-4. Weri-1 Rb cells are sensitive to MMPIs.  
 
Weri-1 cells were cultured in the presence or absence of MMPI. The MMPI were used at 
a concentration range of 500nM to 25μM for up to 120h. MTS proliferation solution was 
added to each well at a concentration of 10μL solution per 100μL at specific time points 
(0-, 48-, 72-, 96-, and 120h) and incubated at 37°C/5%CO2 for 2h prior to reading on an 
absorbance reader. Values represent are optical density (O.D.) ± SEM at 482nm with a 
reference wavelength of 630nm. Modified with permission from BMC Cancer. Webb 
AH, Gao BT, Goldsmith ZK, et al. Inhibition of MMP-2 and MMP-9 decreases cellular 
migration, and angiogenesis in in vitro models of retinoblastoma. BMC Cancer. 
2017;17(1):434. Copyright (June 20, 2017), with permission through Creative Common 
CC-BY. 
 
  
  
33 
 
Downregulation of MMP-2 and MMP-9 by pharmacological inhibitors in Y79 cells 
 
 Next, we hypothesized that Y79, considered the more aggressive, metastatic 
model for Rb37, has higher levels of MMP2 and MMP9 at mRNA and protein levels 
compared to the non-metastatic Weri-1. This hypothesis stemmed from a previous ex vivo 
study using tissue of patients with metastatic Rb and both MMP-2 and MMP-9 were 
readily detected in tumors that ultimately metastasized191. To address this hypothesis, we 
investigated the expression of MMPs mRNA by qPCR analysis. Qualitative PCR analysis 
shown in Figure 2-5A revealed Y79 had higher expression of both MMP2 and MMP9 
mRNA transcripts compared to Weri-1, as we hypothesized (Y79, MMP2: 4.116 ± 
0.3, MMP9: 7.186 ± 0.4; Weri-1, MMP2: 2.1 ± 0.4, MMP9: 3.78 ± 0.4). Additional 
analyses were performed to investigate if other MMPs associated with tumor invasion199 
were expressed in these Rb cell lines. We found no detection (ND) of MMP7 mRNA but 
found expression of MMP14 (7.96 ± 0.8) in Y79 cells. Given the recent emphasis in the 
role of MMP-2 and MMP-9 in ECM degradation and cancer invasion we are focusing our 
studies on investigating MMP-2 and MMP-9 activity in Rb. 
 
 MMP regulation occurs primarily at the transcriptional level200. We hypothesized 
that these selective inhibitors would inhibit MMP2 and MMP9 mRNA transcription that 
would ultimately lead to decreased MMP-2 and MMP-9 protein levels. To investigate if 
these inhibitors did block MMP mRNA transcription, we investigated MMP gene 
expression in both Rb cell lines in the cells treated with respective MMPIs relative to 
untreated (baseline) cells. As shown in Figure 2-5B there was a significant reduction in 
the mRNA expression of both MMP2 and MMP9 by their respective inhibitors in Y79 
cells. Similar results were found in Weri-1 cells (Figure 2-5C). These results confirmed 
that MMPs regulate Rb cell migration. Due to our laboratory’s interests in (1) invasion 
and tumor aggressiveness, and (2) vitreous seeds, we concentrated the rest of our 
investigations on Y79, the more aggressive and metastatic Rb tumor model. While we 
demonstrated decreases in MMP mRNA levels, we further hypothesized this 
downregulation would result in decreases of MMP-2 and MMP-9 protein levels, as well. 
To address this we measured both MMP-2 and -9 levels using two conventional 
techniques: MMP secretions were measured using ELISAs and intracellular MMP levels 
were detected using Western blotting. Despite inhibition of MMP2 mRNA, we still 
observed intracellular protein by Western blot (Wb) analysis (Figure 2-5E) but a 
significant reduction by ELISA (Figure 2-5G) [Untreated versus MMP2I: 237 ± 9 versus 
179 ± 10, p < 0.005; versus MMP9I: 260 ± 17, p = 0.266]. The difference could stem 
from the specificity of the assays, as the ELISA measures active enzyme and the Wb 
measured total protein. However, treatment with MMP9I showed a significant reduction 
in MMP-9 intracellular protein by both Wb and ELISA (Figure 2-5E and 5G) 
and Untreated versus MMP2I: 124 ± 3 versus 115 ± 3, p = 0.106; versus MMP9I: 
84 ± 6, p < 0.0005). 
 
 As demonstrated above, regulation of MMPs occurs at the transcriptional level. 
One of the currently-understood interactions involving MMP transcriptional activation is 
through E2F, which is directly involved in MMP gene transcription by binding MMP  
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Figure 2-5. Pharmacological inhibitors of MMP-2 and MMP-9 downregulate MMP2 
and MMP9 mRNA.  
 
A. The following MMPs were examined at the transcriptional level: MMP2, MMP7, 
MMP9, and MMP14. Results show mRNA expression relative to HPRT1. Bar graphs 
indicate results ±SD; n = 3. Y79 Rb cells express MMP2, MMP9, and MMP14; Weri-1 
expressed MMP2and MMP9. B,C Y79 (B) and Weri-1 (C) cells were treated with MMP-
2 and MMP-9 inhibitors overnight. Results show that the inhibitors act at the 
transcriptional level. Bar graphs indicate fold change ±SD; n = 3. D. Knockdown of  
MMP2 and  MMP9 by RNA interference shows on-target effects. E,F Reduction of 
MMP-2 and MMP-9 protein in Rb cells treated with MMPI (E) and siRNA (F); 
*p < 0.05, **p < 0.005. Wb bar graphs indicate results ±SEM ratio of target to β-
actin; n = 3. G,H ELISAs of MMP-2 and MMP-9 protein of whole cell lysates after 
treatment with MMPI (G) or siRNA (H); *p < 0.05, **p < 0.005. I,J, E2F regulates 
MMP expression in Y79 cells. Y79 cells treated with MMPI (I) or with siRNA (J) were 
assessed by Wb analysis for E2F. Western blot bar graphs indicate results ±SEM ratio of 
target protein to β-actin; n = 3; **p < 0.005. Modified with permission from BMC 
Cancer. Webb AH, Gao BT, Goldsmith ZK, et al. Inhibition of MMP-2 and MMP-9 
decreases cellular migration, and angiogenesis in in vitro models of retinoblastoma. BMC 
Cancer. 2017;17(1):434. Copyright (June 20, 2017), with permission through Creative 
Common CC-BY. 
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Figure 2-5.  (continued). 
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promoters and may be activated by MMPs. Classically, E2F belongs to a family of 
transcription factors that regulate cell cycle and DNA replication in mammalian cells201. 
Therefore, we investigated the expression of E2F in Y79 Rb cells and if treatment with 
MMPI could modulate their levels. We hypothesized inhibition of MMP2/9 would result 
in decreased E2F protein. As shown in Figure 2-5I, there is a significant reduction of 
E2F levels in Y79 cells treated with MMP9I, but not MMP2I, suggesting E2F regulates 
MMP-9 expression. Next, we investigated if this was an on-target effect of the MMP9I 
by using siRNA. We targeted MMP2 and MMP9 and confirmed downregulation of their 
gene expression and proteins levels (Figure 2-5D-H) . The results in Figure 
2-5J showed a significant reduction in E2F levels by both MMP2 and MMP9 siRNA 
compared to the non-specific RNA target or scramble group, suggesting this may not be 
an off-target effect of downregulation of the MMP-2 and MMP-9 and that E2F disruption 
is a consequence of MMP inhibition. 
 
 
Pharmacological inhibition of MMPs reduces secretion of angiopoietin-2, but not 
VEGF, in Y79 cells 
 
 Retinoblastoma tumors are highly angiogenic. Aqueous humor from enucleated 
Rb eyes has been shown to trigger significant angiogenic activity202. This angiogenic 
activity has also been targeted preclinically. Vascular endothelial growth factor (VEGF), 
known to underlie angiogenic activity, stimulated MMP-9 production in human retinal 
pigment epithelial cells203. Furthermore, other studies have demonstrated some success in 
decreasing VEGF levels to treat primary tumors in vivo166. To further examine possible 
mechanisms by which MMPs might stimulate migration and other pro-metastatic 
processes in Rb disease, we analyzed the effects of MMP inhibition on production of 
angiogenic factors, including the pro-angiogenic molecules VEGF and Angiopoietin-2. 
These two molecules are known to function synergistically to promote vessel growth and 
maturation. Furthermore, the combination of these two proteins has demonstrated to 
increase MMP-9 levels204. As shown in Figure 2-6A, there was no significant reduction 
in VEGF secretion in Y79 cells after treatment with MMP2I, but there was a significant 
increase after MMP9I treatment (Untreated versus MMP2I: 366 ± 44pg/mL versus 
418 ± 37pg/mL; p = 0.83; versus MMP9I: 440 ± 10pg/mL; p = 0.01). Both VEGF and 
Angiopoietin-2, or perhaps the equilibrium between the two, influence tumor growth and 
vascular regression, prompting us to measure the effects of MMPI on Angiopoietin-2205. 
The protein levels of Angiopoietin-2 in Y79 were reduced, although marginally 
significant, by MMP9I (Figure 2-6B) [Y79 Untreated versus MMP2I: 1120.3 ± 65pg/mL 
versus 1067.6 ± 153pg/mL, p = 0.552; versus MMP9I: 990 ± 90pg/mL, p = 0.05]. In 
contrast, as shown in Figure 2-6A, the non-metastatic Rb cell line Weri-1 showed a 
significant reduction in VEGF after MMP9I treatment (Untreated versus MMP2I: 
371 ± 75pg/mL versus 270 ± 95pg/mL, p = 0.221; versus MMP9I: 
228 ± 60pg/mL; p = 0.005) but a significant increase in Angiopoietin-2 (Untreated versus 
MMP2I: 883 ± 10 versus 1190 ± 13, p < 0.005; versus MMP9I: 1495 ± 147, p < 0.005) 
after treatment (Figure 2-6B). Collectively, these results showed that in the metastatic 
Y79 cell line, we observed a significant increase in VEGF by MMP9I, and a reduction,  
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Figure 2-6. MMP inhibition reduces angiogenic protein levels.  
 
Y79 and Weri-1 cells were cultured in the presence or absence of the MMPI overnight. 
Next day, we collected cell lysates (A-B) and supernatants to investigate protein levels by 
ELISA. A shows VEGF protein levels; B shows Ang-2 protein levels and C, shows levels 
of TGF-β1, an immunomodulator. In all secretion analyses bar graphs indicate results 
±SD; n = 3; *p < 0.05, **p < 0.005, #p = 0.05. Modified with permission from BMC 
Cancer. Webb AH, Gao BT, Goldsmith ZK, et al. Inhibition of MMP-2 and MMP-9 
decreases cellular migration, and angiogenesis in in vitro models of retinoblastoma. BMC 
Cancer. 2017;17(1):434. Copyright (June 20, 2017), with permission through Creative 
Common CC-BY. 
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albeit minimal in Angiopoietin-2 (p = 0.05). The opposite was observed in Weri-1, as 
there was a significant reduction in VEGF by MMP9I and a significant increase in 
Angiopoietin-2 by MMP2I and MMP9I. These results highlight the complexity 
associated with Rb disease and demonstrate how identical molecules play differing roles 
in the physiology and sustainment of Rb. 
 
 While Angiopoietin-2 and VEGF act synergistically to promote angiogenesis, so 
too, do Transforming Growth Factor-beta 1 (TGF-β1) and VEGF. Specifically, these 
molecules are known to promote long-term protection of endothelial cells while 
promoting angiogenesis206. TGF-β1 is a potent immunosuppressor of cytotoxic cells by 
depressing cytolytic ability and thus promoting metastases. Recent work suggests MMPs 
may stimulate TGF-β1 activity201,207. To determine if inhibition of MMP-2 or MMP-9 
could affect the TGF-β1 pathway in Rb, we measured secretion of TGF-β1 by Y79 cells 
after treatment with the inhibitors. As shown in Figure 2-6C TGF-β1 secretion was 
significantly reduced in Y79 cells by either of the inhibitors (Untreated versus MMP2I: 
47.0 ± 11pg/mL versus 20.0 ± 4pg/mL, p = 0.010; versus MMP9I: 
20.7 ± 11pg/mL, p = 0.013). Similarly, we tested TGF-β1 secretion in Weri-1 cells 
(Figure 2-6C) and found it was significantly reduced after MMP-2 inhibition (Untreated 
versus MMP2I: 42.0 ± 4pg/mL versus 13.2 ± 15pg/mL, p = 0.012), but not MMP-9 
inhibition (Untreated versus MMP9I: 32 ± 9pg/mL, p = 0.088). Here, we demonstrated 
the convolution associated with metastatic and non-metastatic Rb cell lines. We found 
MMP-2 and MMP-9 exert direct activity on the angiogenesis through Angiopoietin-2 and 
VEGF and immunomodulation through production of TGF-β1 as well as migration using 
Rb cell lines.  
 
 
Discussion 
 
 Our work focuses on MMP-2 and MMP-9 activity in Rb, the most common 
intraocular malignancy in children. Consistent with previous reports, we show MMP-2 
and MMP-9 are present in Rb. For the first time in retinoblastoma, we provide in vitro 
analysis of two cell lines, Y79 and Weri-1, which represent the metastatic and non-
metastatic model for Rb. Prior studies have failed to examine potential functions of the 
MMPs in Rb. As part of our in-depth analysis we compared both cell lines in their 
response to several properties: invasion, cellular migration, mRNA expression and 
protein levels of MMP-2 and MMP-9, the production of the angiogenic factors VEGF 
and Angiopoietin-2, and the immunomodulatory protein TGF-β1. 
 
 The outcomes of our experiments revealed differences in several intrinsic 
properties associated with tumor progression in Y79 and Weri-1. Tumor cells in patients 
are likely to have diverse cell populations that have varying metastatic potential, thus 
studying both cell lines provides important insight into actual properties of tumor in vivo. 
While these two cell types both respond to MMPI, they do so in different ways using 
different pathways. The MMPI used in this study mediate their effect on Rb cells through 
inhibition of MMP2 and MMP9 mRNA in both Y79 and Weri-1. However, the effects on 
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angiogenic factors differ between cell types and illustrate the complex nature of these 
molecules.  
 
Our results suggest the mechanisms underlying the production of angiogenic 
factors are different among these cells. The production of VEGF in Weri-1 may be more 
dependent on MMP-2 or MMP-9 activity as there was a significant reduction in protein 
production after treatment with MMP2I and MMP9I. Conversely, production of 
Angiopoietin-2 is increased in Weri-1 after MMPI treatment suggesting Angiopoietin-2 
production is independent of MMP-2 or MMP-9 activity. These results suggest these two 
angiogenic pathways are not involved in primary actions on metastasis, as Weri-1 is the 
non-metastatic model. In contrast, Y79 cells showed a significant increase in VEGF 
production after MMPI treatment, although MMP9I reduced Angiopoietin-2. This is of 
interest as the dynamic balance in vessel regression and tumor growth has already been 
examined in a rat glioma model205. Two key players in this model are angiopoietins 
(Ang) and VEGF. Co-expression and increase in both VEGF and Angiopoietin-2 are 
associated with blood vessel proliferation. According to the authors, if there is 
overexpression of one of these players, there is vessel destabilization and regression. 
Other work has already demonstrated that concomitant expression of VEGF and 
Angiopoietin-2 resulted in increased microvessel density in solid tumors and cerebral 
angiogenesis204,208. The co-expression of these angiogenic factors contributes to the 
induction of microvessel sprouting in vascular networks209. Prior studies have examined 
the role of VEGF in Rb xenografts injected with Y79 cells and shown modest reductions 
in tumor burden166. However, this has failed to translate clinically. Collectively, our 
results show destabilization of angiogenic components, VEGF for Weri-1 and 
Angiopoietin-2 for Y79 Rb cells.  
 
TGF-β1 is a pleiotropic cytokine suggested to be the main inducer of tumor 
epithelial-to-mesenchymal (EMT) transition and to facilitate invasion by suppressing the 
host immune system 210-212. In this study we found TGF-β1 to be significantly reduced 
after MMP2I treatment in both Y79 and Weri-1 cells. Work done in the MCF10A breast 
cancer line highlighted the role of this cytokine in the upregulation of MMP-2 and MMP-
9; it is also known that these MMPs participate in growth factor cleavage for further 
cytokine release213. TGF-β is the subject of other ongoing studies as it was demonstrated 
to be localized in proximity to tumor vasculature and to promote drug resistance214 and 
has been implicated in Rb vitreous seeding215. 
 
While this is the first study in Rb to examine MMP function and potential 
therapeutic value, there are limitations to the work presented above. For one, the in vitro 
approach fails to illustrate the complexity of in vivo tumors. The specific assays used in 
this work are classical assays that do not highlight the complex physiological processes 
they are meant to represent. Metastasis is a multi-faceted operation involving key 
molecular and genetic changes that cannot be captured in vitro. We address this 
complexity in future chapters by the development of in vitro assays which mimic the 
physiology of tumors in vivo in a three-dimensional (3D) manner. Another major 
limitation is the inhibitors used in these studies. We used two readily available MMPIs: 
ARP100 (MMP-2 inhibitor) and AG-L-66085 (MMP-9 inhibitor) that have failed to 
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translate clinically, despite their heavy use in the understanding of MMP biology in vitro. 
While MMP inhibitors have yet to achieve widespread use in the clinic, a new generation 
of more targeted, safer inhibitors are emerging that may prove useful in targeting Rb.  
 
Future experiments should utilize an in vivo approach to understand more 
completely the roles MMPs play in Rb tumor metastasis. The work published here 
supports the hypothesis of MMP-2 and MMP-9 promoting two primary hallmarks of the 
metastatic process: invasion and migration. Future experiments to further support this 
hypothesis should be conducted in vivo using orthotopic xenografts of Y79 cells that will 
allow more mechanistic and physiologically-relevant insight in how Rb metastasizes.  
Stable RNA interference of either MMP2 or MMP9 in Y79 cells via shRNA should be 
utilized to determine if disruption of MMP2 or MMP9 mRNA could decrease or prevent 
metastatic disease in an orthotopic xenograft model. After qPCR assessment to determine 
efficacy of the RNA interference  histopathological analyses should examine the extent of 
metastatic disease and progression37. We predict a reduction in the development of 
metastases in shRNA-treated animals. A potential caveat is that we do not understand 
how MMP knockdown may affect the implantation of cells after inoculation to develop 
the xenograft. Therefore, evaluation of the shRNA has to be done after inoculation of Rb 
cells. A more recent alternative to in vivo knockdown is the use of oligonucleotides and 
aptamers. Still, in vivo results would provide valuable insight into the future of MMP 
inhibitors for Rb. These studies also open new avenues of research to develop more 
selective, safer MMP inhibitors based on RNA interference that can address the toxicities 
and lack of specificity associated with the previous generation of MMP-targeted small 
molecule inhibitors.  
 
 
Conclusion 
 
 Our work reveals differences in several intrinsic properties associated with tumor 
progression in two cell lines representing the metastatic and non-metastatic forms of Rb, 
Y79 and Weri-1. Based on our findings we developed a working model shown in Figure 
2-7. In addition to the intrinsic differences in Y79 and Weri-1, MMP-2 and MMP-9 play 
different roles in these cells. MMP-2 and MMP-9 activity stimulate Rb cell migration in 
Y79 and contribute to cell viability in Weri-1 cells. Furthermore, MMP-9 activity plays a 
role in Angiopoietin-2 production in Y79. In contrast, MMP-2 and MMP-9 play 
additional roles in Weri-1 cells. More work is needed to follow up on these promising 
results. Taken together, we provide a comprehensive in vitro analysis of MMP-2 and 
MMP-9 activity in Rb in several checkpoints that are deregulated in cancer, including cell 
cycle, secretion of key immuno- and angiogenic modulators, viability, invasion, and 
migration. Our findings provide initial mechanistic insights into the benefits of potential 
MMP adjunct therapy in Rb patients. 
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Figure 2-7. Working model of the roles of MMP-2 and MMP-9 in retinoblastoma 
cells.  
 
Y79 and Weri-1 cells represent the metastatic and the non-metastatic model for Rb, 
respectively. Our work shows differences in viability, migration and angiogenic-
associated responses in Rb cells after inhibition of MMP-2 and MMP-9. (A) Y79 cells 
showed a profound defect in migration and invasion along with and a significant 
reduction in Angiopoietin-2 and TGF-β1 proteins. These results highlight Y79’s 
migratory and invasive potential, which may be dependent upon MMPs. (B) Analyses of 
Weri-1 cells show MMP-2 and MMP-9 are involved in multiple processes, including 
viability of cells and VEGF, as well as TGF-β1 production. Modified with permission 
from BMC Cancer. Webb AH, Gao BT, Goldsmith ZK, et al. Inhibition of MMP-2 and 
MMP-9 decreases cellular migration, and angiogenesis in in vitro models of 
retinoblastoma. BMC Cancer. 2017;17(1):434. Copyright (June 20, 2017), with 
permission through Creative Common CC-BY.  
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CHAPTER 3.    RESULTS II: TARGETING THE PLATELET-DERIVED 
GROWTH FACTOR-BETA STIMULATORY CIRCUITRY TO CONTROL 
RETINOBLASTOMA SEEDS2 
 
 
Introduction 
 
 While metastatic Rb represents a clinical challenge and carries a dismal 
prognosis, Rb is commonly detected before it can disseminate to the brain or other distant 
organs. However, ocular salvage or preservation of the globe, remains very difficult; 
quite often enucleation is determined to be the best course of treatment. Even if 
enucleation is not initially performed, patients receiving chemotherapy are left partially 
or completely blind and will undergo enucleation in the event of recurrent Rb. The 
greatest impediment to raising ocular salvage rates is the presence of tiny pockets of 
tumors within the vitreous, called vitreous seeds (or seeding). These seeds are also 
thought to be the primary cause of Rb recurrence. Although some vitreous seeds are 
responsive to treatment, the majority of cases are refractory and the mechanisms 
controlling their refractory status are unclear217. Both external beam radiotherapy (EBRT) 
and chemotherapy, regardless of route of delivery (systemic, subconjunctival, intra-
arterial or intravitreal), have failed to provide ocular salvage rates of greater than 70% for 
eyes with vitreous seeds at diagnosis218-221. Overall, patients that present with vitreous 
seeding have a poorer prognosis for ocular salvage180,218,221-223. While the mechanism 
controlling refractory or recurrent vitreous disease is unclear, it is likely related to a 
unique property of Rb cells that allows them to adapt and propagate in semi-solid or 
liquid microenvironments, such as the vitreous and sub-retinal compartments100. Recent 
literature suggests these Rb cells remain in a semi-dormant state as vitreous seeds for 
long periods of time and show reduced proliferative capacity and metabolism224.  
 
Understanding the tumor microenvironment is an important step in achieving 
overall treatment goals for Rb, including patient survival, globe salvage and vision 
preservation217,224. The microenvironment of the vitreous has not been well characterized, 
in particular immunological studies on the interaction of the vitreous microenvironment 
and Rb are lacking. The vitreous body is a translucent medium in the eye composed of a 
liquid (99%) and solid (1%) phase. Recent research has identified the presence of some 
inflammatory, mitogenic, and immunosuppressive mediators in the vitreous109-111. These 
soluble proteins in the vitreous include growth factors, which promote homeostasis as 
well as pathologic processes, most notably diabetic retinopathy and proliferative vitreous 
retinopathy110,149,225,226. These growth factors have been investigated for potential 
therapeutics in a number of diseases including age-related macular degeneration 
(AMD)227, diabetic retinopathy (DR), and proliferative vitreoretinopathy (PVR)154. 
                                                 
 
 
2 Adapted with permission. Goldsmith ZK, Coppess W, Irvine AS, et al. Targeting the Platelet-Derived 
Growth Factor-beta Stimulatory Circuitry to Control Retinoblastoma Seeds. Investigative Ophthalmology 
& Visual Science. 2018;59(11):4486-4495. © Association for Research in Vision and Ophthalmology. 
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Platelet derived growth factor (PDGF) has been identified as one such key regulator149,228 
within the vitreous and has recently been targeted in treatment of DR and PVR155. 
 
PDGF signaling through its receptors has been shown to contribute to different 
pathological processes including tumorigenesis229-231 and angiogenesis229,230,232-234. 
Cellular infiltration, including tumor cells, macrophages, and platelets, may produce and 
secrete PDGF in the vitreous microenvironment that could provide paracrine and 
autocrine stimulation and mitogenic activity to Rb cells via the platelet-derived growth 
factor receptors (PDGFRs). We investigated the PDGFR signaling pathway to better 
understand and potentially target Rb vitreous seed growth. We found that reducing 
PDGFR signaling in Rb tumor cells in vitro reduces tumor cell growth and survival via 
the MDM2 and NFB signaling pathways. 
 
 
Materials and Methods 
 
 
Ethics statement 
  
 The Rb xenografts used in this chapter were developed using human tissue 
derived from Rb patients. Those experiments involving human subjects were approved by 
the Institutional Review Board (IRB) at St. Jude Children’s Research Hospital (SJCRH) 
and The University of Tennessee Health Science Center (UTHSC); informed consent 
obtained when needed. In those experiments using tissue from murine studies, the 
Institutional Animal Care and Use Committee (IACUC) at SJCRH approved the animal 
experiments. All protocols followed the Association for Research in Vision and 
Ophthalmology (ARVO) Statements for the use of animals in vision research, in addition 
to the guidelines for laboratory animal experiments. 
 
 
Cell lines and growth media 
  
 The human Retinoblastoma (Rb) cell lines Y79 (ATCC® HTB-18™)79 and Weri-
Rb-1 80 (ATCC® HTB-169™) were purchased from the American Type Culture 
Collection (Manassas, VA, USA) and cultured in Rb media. This media contains RPMI-
1640 supplemented with L-glutamine (Gibco by Invitrogen, Carlsbad, CA, USA), 20% 
FBS (Gibco by Invitrogen), and 1% penicillin/ streptomycin (Gibco by Invitrogen). Cells 
were kept in a humidified incubator at 37°C/ 5% CO2. Cells were passaged every 3 days 
to keep the cells from reaching over 80% confluency.  
 
 
Orthotopic xenografts 
 
After receiving the appropriate consent tumor samples from enucleated eyes were 
isolated from a diverse population of patients treated at St. Jude Children’s Research 
Hospital (Memphis, TN). These specimens were placed in RPMI media before being 
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processed for engraftment. To prepare for inoculation, tumor samples were first 
dissociated in a solution of trypsin and PBS at 37ºC. Resulting cell suspension was 
washed and counted. Tumor cells were resuspended in RPMI with 10% fetal calf serum 
at approximately 10,000 cells/µL. A volume of 5µL (approximately 50,000 cells) were 
injected into each eye of anesthetized SCID (B6.CB17-Prkdcscid/SzJ; Jackson Labs) mice. 
Tumor progression was then monitored with a digital retinal camera and intraocular 
pressure was regularly measured88.  
 
 
Vitreous samples 
  
 The University of Tennessee Health Science Center and St. Jude Children’s 
Research Hospital Institutional Review Board (IRB) approved the present study. 
Informed consent was obtained in all cases where vitreous was harvested at the time of 
patient enucleation, an optional research objective that is part of an on-going prospective 
clinical trial (NCT01783535) This is in full compliance with and adheres to the tenets of 
the Declaration of Helsinki and the ARVO statement on human subjects. Vitreous from 
eyes with Rb was collected at the time of enucleation. Eyes were trephined immediately 
upon removal without disruption of underlying structures important for diagnostic and 
staging purposes. Tumor was harvested for genetics and biology and vitreous was 
aspirated using an 18-gauge needle and 3mL syringe. Vitreous from healthy controls 
were purchased from BioreclamationIVT (Baltimore, MD, USA). Samples were 
centrifuged to collect supernatants followed by sonication. Samples were aliquoted and 
stored at -20°C. 
 
 
Reagents 
  
 Phosphate-buffered saline (PBS) was purchased from Gibco by Invitrogen 
(Thermo Scientific, Bridgewater, NJ, USA). Gleevec® was purchased in its generic 
chemical form, imatinib mesylate (IM, PubChem ID: 123596), from Sigma-Aldrich 
(Saint Louis, MO, USA). Lyophilized reagent was dissolved in deionized, distilled water 
(ddH2O) to 10mM, aliquoted, and stored at -20°C. Lyophilized recombinant human 
PDGF-BB (10µg) was purchased from Invitrogen (Thermo Scientific), dissolved in acetic 
acid, aliquoted, and stored at -20°C. 
 
 
Immunohistochemistry (IHC) 
  
 Enucleated eyes from Rb patients treated at SJCRH were fixed, embedded in 
paraffin and serially sectioned. Samples were probed with anti-human PDGFR (#16868, 
Abcam, Cambridge, MA, USA), for non-phosphorylated PDGFR, and anti-human p-
PDGFR (#sc-339, Santa Cruz Biotechnology, Inc., Dallas, TX, USA) to label active 
protein for IHC. Enucleated eyes from murine xenografts were fixed, embedded in 
paraffin and serially cut at 4µm thickness using a Leica rotary microtome before sections 
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were mounted on gelatin-coated histologic slides88. For more information, please see 
Table A-2.  
 
 
MTS cell proliferation assay 
  
 Cell proliferation, as a measure of cell viability, was investigated using the 
CellTiter 96® AQueous One Solution Cell Proliferation Assay reagent (Promega, Madison, 
WI, USA). Briefly, Y79 cells were plated in a 96-well plate at a density of 5.0 x 104 cells 
per well. Cells were cultured under different conditions, including Rb media (untreated), 
10ng/mL recombinant human PDGF-BB (rhPDGF-BB), 10µM imatinib mesylate (IM), 
or the combination of rhPDGF-BB and IM. Plates were incubated for 0-, 48-, 72-, 96-, 
and 120h. Proliferation was determined through colorimetric change of absorbance. The 
absorbance values were calculated from a spectrophotometric microplate reader (BioTek 
µQuant, BioTek Instruments, USA) using 490nm as reading wavelength and reference 
wavelength at 630nm. Final values were calculated by subtracting media-only blanks 
from experimental samples. Assays were conducted in quadruplicate. 
 
 
Protein assays 
  
 PDGF-AB / PDGF-BB ELISA. Vitreous samples were diluted 1:10 with Assay 
Buffer from the Invitrogen Human PDGF-BB Platinum ELISA Kit (Invitrogen, Thermo 
Scientific). Diluted samples were placed in either a pre- human PDGF-AB antibody-
coated microwell or a human PDGF-BB antibody-coated microwell plate in triplicate, 
along with reconstituted standards in a serial fold dilution following the manufacturer’s 
instructions. After incubation for 2h at RT, the provided biotin-conjugated anti-human 
PDGF-AB or PDGF-BB antibody was added. After several washes, streptavidin-HRP 
was added followed by incubation with the TMB substrate solution (tetremethyl-
benzidine). Absorbance values were calculated from a spectrophotometric microplate 
reader (BioTek µQuant) using both 450nm and 550nm as reading wavelengths. Averages 
and standard error measurements of the cytokines in both the samples and controls were 
calculated and plotted in Prism Graph Pad.  
 
 Western blot analyses. Y79 cells were treated using the conditions described 
above: Rb media with 10ng/mL recombinant human PDGF-BB (rhPDGF-BB), 10µM 
imatinib mesylate (IM), or the combination of rhPDGF-BB and IM. Cells in complete Rb 
media (untreated) were used as baseline controls. Cells were then lysed using cold RIPA 
buffer containing both Halt™ protease and phosphatase inhibitors (Thermo Scientific). 
Cell lysates were centrifuged at 2500 RPM x 5min to shear DNA. Protein from whole 
cell lysate of 50µg was separated on Bolt® 4-12% Bis-Tris Plus Gels (Thermo Scientific) 
and transferred to an Amersham Hybond polyvinylidene difluoride (PVDF) membrane 
(GE Health Care Life Sciences, Pittsburgh, PA, USA). Membranes were blocked with 
5% BSA in Pierce™ Tris Buffered Saline Tween-20 (TBST, Thermo Scientific) for 1h 
followed by incubation with primary antibodies overnight at 4°C. Thereafter, HRP-linked 
secondary antibodies were added and incubated at RT for 1 hr. All experiments were 
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conducted in triplicate. Primary antibodies used were: polyclonal rabbit anti-PDGFR 
(Santa Cruz Biotechnology, sc-432; 1:100), monoclonal mouse anti-phosphorylated 
PDGFR (Santa Cruz Biotechnology, sc-373805; 1:100), monoclonal mouse anti-VEGF 
(Santa Cruz Biotechnology, sc-53462; 1:200), monoclonal mouse anti-Flk-1 (aka 
VEGFR2, Santa Cruz Biotechnology, sc-6251; 1:200), polyclonal rabbit anti-p-Flk-1 
(aka p-VEGFR2, Santa Cruz Biotechnology, sc-101821; 1:100), monoclonal mouse anti-
MDM2 (Santa Cruz Biotechnology, sc-965; 1:200), monoclonal mouse anti-
phosphorylated MDM2 (Santa Cruz Biotechnology, sc-53368; 1:200), polyclonal rabbit 
anti-AKT (Cell Signaling Technology, #9272; 1:1000), monoclonal rabbit anti-
phosphorylated AKT (Cell Signaling Technology, #4058; 1:1000), monoclonal rabbit 
anti-BCL-2 (Cell Signaling Technology, #2870; 1:1000), monoclonal rabbit anti-GAPDH 
(Cell Signaling Technology, #8884; 1:1000), Secondary antibodies used were: anti-
mouse IgG HRP-linked Antibody (Cell Signaling Technology, #7076; 1:1000) and anti-
rabbit IgG HRP-linked Antibody (Cell Signaling Technology, #7074; 1:1000). 
Endogenous control used was either -actin or GAPDH (both from Cell Signaling 
Technology). Signal was detected using SuperSignal™ West Pico Chemiluminescent 
Substrate (Thermo Scientific). Densitometry analysis was done using Kodak Molecular 
Imager, as described in the previous chapter195-197 For more information, please see Table 
A-2. 
 
 Cleaved caspase-3 ELISA. A commercially available Caspase-3 (active) ELISA 
kit (Invitrogen, Thermo Scientific) was used to assess apoptotic activity. Briefly, 1.0 x 
106 Y79 cells were cultured in complete Rb media or Rb media supplemented with either 
10ng/mL recombinant human PDGF-BB (rhPDGF-BB), 10µM imatinib mesylate (IM), 
or the combination of rhPDGF-BB and IM for 48h. Cells were collected, and protein was 
extracted using Cell Extraction Buffer (Invitrogen) with protease and phosphatase 
inhibitors (Thermo Scientific) before being quantified by Pierce BCA Protein Assay Kit. 
The ELISA was completed according to manufacturer’s instructions: 30µg of total 
extracted protein was incubated in a microplate well in triplicate at room temperature for 
2h. Samples were washed followed by addition of 100µL detection antibody (caspase-3) 
for 1h at RT. This antibody was removed and replaced with anti-rabbit IgG HRP 
antibody for 30min at RT. Antibody was removed and Stabilized Chromogen was added 
to develop blue color for approximately 30min before being stopped by addition of 
100µL stop solution and solution turned yellow. Absorbance values were calculated from 
a spectrophotometric microplate reader (BioTek µQuant) using 450nm as the reading 
wavelength. Averages and standard deviations of the levels of active Caspase-3 in both 
the samples and controls were calculated and plotted in Prism Graph Pad.  
 
Bicinchoninic acid (BCA) protein concentration assay. Albumin standards 
were generated ranging from 2000µg/mL to 25µg/mL, 0µg/mL and 20µL of prepared 
standards were plated on a 96-well microplate. A volume of 2µL of fresh lysate was 
added (in triplicate) followed by addition of 200µL BCA working solution (50:1, Reagent 
A:B). Plates was mixed gently on the benchtop prior to incubation at 37ºC for 30min. 
Plate was then read on a spectrophotometric microplate reader (BioTek µQuant, BioTek 
Instruments, USA) at 562nm. Using linear fit, protein concentrations were generated in 
µg/µL.  
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Flow cytometry studies 
  
 Annexin V and PI labeling. To measure apoptotic activity of Y79 cells, 
Annexin-V (A5) and propidium iodide (PI) were used. After treatment as described 
above, cells were harvested at 0-, 24-, 48-, 72-, and 96h time points and labeled with 
10µL A5-PerCP-Cy5.5 and 5µL PI (BioLegend) and incubated away from light at RT for 
15min. An additional 200µL of Annexin V Binding Buffer were added prior to analysis 
to have a final volume of 400µL. Data was acquired using a BD™ LSR II Cytometer (BD 
Biosciences) using BD FACSDiva™ software and analysis performed using FlowJo 
v.X.0.0.8 (FlowJo, LLC, Tree Star, Ashland, OR, USA). Samples were analyzed in 
triplicate.  
 
 Zombie AquaTM labeling. To assess live versus dead status, we used Zombie 
Aqua™ (BioLegend, #423102), an amine-reactive fluorescent dye permeant to cells with 
compromised membranes. Lyophilized dye was reconstituted in 100µL of DMSO and 
used at a dilution of 1:100 for up to 5x106 cells in PBS. Cells were incubated for 20min at 
RT, covered from light, prior to washing twice with PBS/1% FBS. Data acquired in a 
BD™ LSR II Cytometer (BD Biosciences) using BD FACSDiva™ software. Analysis 
performed using FlowJo v.X.0.0.8 (Tree Star).  
 
 Assessment of expression of PDGFR. Y79 Rb cells cultured in Rb media or Rb 
media including 10ng/mL recombinant human PDGF-BB (rhPDGF-BB), 10µM imatinib 
mesylate (IM), or the combination of rhPDGF-BB and IM were labeled with polyclonal 
rabbit anti-PDGFR (Santa Cruz Biotechnology, sc-432; 1:50) on ice for 30min followed 
by incubation with an anti-rabbit Alexa Fluor® 647 (Thermo Scientific, 1:50) secondary 
antibody for 30min. Cells were fixed with 2% paraformaldehyde for 20min prior to 
analysis. Data acquisition was done in a ZE5 Cell Analyzer (aka YETI), from Propel 
Labs (Fort Collins, CO, USA). Analysis was done using FlowJo software v.X.0.0.8 (Tree 
Star). For more information, please see Table A-2. 
 
 p65 NFB Nuclear Translocation by imaging flow cytometry. Y79 Rb cells 
cultured Rb media or Rb media including 10ng/mL recombinant human PDGF-BB 
(rhPDGF-BB), 10µM imatinib mesylate (IM), or the combination of rhPDGF-BB and 
IM. Collected cells were transferred into low binding micro-centrifuge tubes, washed in 
PBS and fixed in 2% paraformaldehyde prior to permeabilization in 0.01% Triton X-100. 
Samples were blocked with PBS/1% FBS before addition of a monoclonal rabbit anti-p65 
(Cell Signaling Technology, #8242, 1:100) antibody for 1h in ice. Following primary 
antibody labeling, cells were washed with PBS and an anti-rabbit Alexa Fluor® 488 
(Thermo Scientific, 1:100) secondary antibody was added for 1h. Nuclei were labeled 
with DRAQ5™ (BioLegend, San Diego, CA, USA, 1:100). Cells were analyzed using the 
Amnis FlowSight® Imaging Cytometer (EMD Millipore, Amnis Corporation, Seattle, 
WA, USA). Data was analyzed using the “Nuclear Translocation” feature in IDEAS® 
software (EMD Millipore, Amnis Corporation). Mean fluorescent intensity (MFI) was 
measured to investigate levels of p65 as well as percentage of cells with p65 translocation 
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to the nucleus. We used the 488nm, 642nm, and 785nm excitation lasers. The 
fluorescence controls were single labeled cells acquired with both 488nm and 642nm 
lasers while ensuring the Side Scatter (SSC, 785nm) and Bright Field (BF) channels were 
OFF. We collected a minimum of 10,000 events (cells) from each sample; experiments 
done in triplicate. For more information, please see Table A-2. 
 
 
Invasion assay 
 
CytoSelect™ Cell Invasion Assay kit was purchased from Cell BioLabs, Inc (San 
Diego, CA). We used the 8μm pore polycarbonate membrane coated with basement 
membrane matrix solution. Rb cell suspension (serum free media) was placed in the 
upper chamber to determine the invasion capacity of the cells after degradation of the 
matrix membrane proteins 6h post culture. Invasive cells were stained using 400µL of the 
included Cell Stain Solution and incubated at RT for 10min before being washed with 
distilled water and quantified with a light microscope under 100X total magnification 
(lens 2.5X, objective 40X), with 4 individual fields per insert. Inserts were placed into 
wells containing 200μL of Extraction Solution followed by 10min incubation at RT on an 
orbital shaker. Quantitation of cells measured at OD 560nm using spectrophotometer.  
 
 
Three-dimensional cell culture system 
 
Y79 cells were harvested and labeled with the carboxyfluorescein succinimidyl 
ester (CFSE) Cell Division Tracker Kit (BioLegend). Briefly, cells were washed in PBS 
prior to addition of 1µM CFSE per mL of cell suspension. Cells were incubated for 5min 
at 37°C prior to quenching on ice for 5min with 20mL cold complete media. After 
quenching, cells were washed twice in cold media. CFSE-labeled cells were mixed with 
nanoshuttles using 1µL of nanoshuttles (n3D Biosciences, Houston, TX, USA) per 
10,000 cells. These cells were incubated overnight at 37ºC / 5% CO2. The next day, cells 
with nanoshuttles were magnetized for 30min using the 6-well concentrating drive (n3D 
Biosciences, Houston, TX, USA) and plated at 2.5 x 105 cells per well of a 6-well plate 
with a 2mL final volume. Cells were re-magnetized for 30min using the 6-well levitating 
drive (n3D Biosciences, Houston, TX, USA) before the magnet was removed. The plate 
was placed in a NanoDock Station for 48h in the incubator. Data images were recorded 
every hour using an iPod (Apple) and a magnifying glass on top of the plate. Data 
analysis was performed using the NIH ImageJ Software (imagej.nih.gov/ij/). The images 
were converted to black and white using the Image J Software Color Thresholding tool. 
Measurements were taken of the growth in each well for 48h. Color threshold and 
brightness were kept constant across all images.  Following 48h, spheroids were fixed 
with 4% paraformaldehyde for 4h at RT and then washed with PBS (magnet was placed 
under plate during washes to maintain spheroid). Labeling was done by adding 2mL of 
Antigen Retrieval Solution and incubated at 8ºC for 20min before being washed 
accordingly. We added 500µL of 0.01% Triton X-100 permeabilization buffer for 15min 
at RT. To prevent non-specific binding, 1mL of PBS/10% FBS was added and incubated 
for 1h at RT. Blocking solution was aspirated off and primary antibody was added for 
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overnight incubation at 4ºC. Primary antibodies included: monoclonal rabbit anti-
phosphorylated VEGFR2 (Cell Signaling Technology, #3770; 1:100) and polyclonal 
rabbit anti-PDGFR (Santa Cruz Biotechnology, sc-432; 1:100). Alexa Fluor® 647 
donkey anti-rabbit IgG (Invitrogen, A31573; 1:100) secondary antibody was added and 
incubated for 2h at RT followed by adequate washing. Samples were allowed to air dry 
for 1h before being imaged on a Nikon C1 confocal microscope. All microscope settings, 
including laser levels, were held constant and images were collected in identical 
methodology to allow for relative comparisons of signal intensity within and between 
experiments. 
 
 
qPCR analyses 
  
 RNA isolation. RNA from 2.5 × 106 Rb cells was extracted following the 
Qiagen® miRNeasy Mini Kit (Qiagen, Valencia, CA) manufacturer’s recommendations. 
Rb cells were harvested and centrifuged to remove all traces of cell culture medium. Cell 
pellets were lysed and homogenized prior to addition of chloroform. Samples were 
shaken vigorously for 15s prior to centrifugation for 2min at full speed. The upper 
colorless phase was transferred to a clean tube after centrifugation followed by a series of 
alcohol precipitations to provide ideal binding conditions. The lysate was loaded onto an 
RNeasy spin column with a silica membrane to bind the RNA and washed away 
contaminants. Residual DNA was removed by on-column DNase digestion. The 
concentrated RNA was eluted in 15µL of RNAse free water. RNA concentration was 
assessed by analysis on Nanodrop 2000 Spectophotometer (ThermoFisher Scientific) and 
purity was assessed by verifying absorbance ratios of 260nm and 280nm (A260/A280). 
Samples with absorbance ratios between 1.8 and 2.0 were considered free of 
contamination.  
 
 cDNA synthesis. Synthesis of cDNA was performed using the SuperScript® 
VILO™ cDNA Synthesis Kit (Life Technologies, Grand Island, NY). Following 
manufacturer’s directions, we used 100ng of isolated RNA (see section above) and 
combined them with 4µL 5X VILO Reaction Buffer and 2µL 10X SuperScript Enzyme 
Mix. Final volume per sample was 20µL using DEPC-treated water when necessary. Per 
manufacturer’s directions, cDNA synthesis reaction was done at 25ºC for 10min followed 
by 42ºC incubation for 60min with reaction termination at 85ºC for 5min.  
 
 Pre-amplification and PCR. The synthesized cDNA was preamplified with 
TaqMan® PreAmp Master Mix to improve detection sensitivity and optimize the use of 
limited material. The following gene expression assays were used (Thermo Scientific): 
PDGFRA (Hs009998018_m1), PDGFRB (Hs01019589_m1), PDGFA 
(Hs00234994_m1), PDGFB (Hs_00966522_m1), MDM2 (Hs00540450_m1), MDM4 
(Hs00910358_m1), VEGFA (Hs00900055_m1), FLT1 (aka VEGFR2, Hs01052961_m1) 
HPRT1 (Hs02800695_m1) all from Life Technologies (Grand Island, NY). Material was 
preamplified using 10µL 2X TaqMan® PreAmp Master Mix, 5µL pooled 0.2X TaqMan® 
primers, and 5µL cDNA sample for a final volume of 20µL192. Preamplification reactions 
were conducted according to manufacturer’s guidelines with a 10min enzymatic 
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activation step at 95ºC followed by 14 cycles of denaturing (95ºC for 15s) and annealing 
(60ºC for 4min). Following 14 cycles, enzyme was inactivated at 99ºC for 10min and 
reactions were held at 4ºC until use. Preamplification utilized the same primers analyzed 
to use minimal amounts of material while increasing sensitivity of detection. The reaction 
was kept at −20°C until ready to use. A final volume of 10μL was loaded into each well 
after combination of 5µLTaqMan® Universal Master Mix, 2.5µL cDNA, 0.5µLprimers 
and 2.0µL Nuclease-Free water. White, 96-well PCR plates were run using Roche® 
LightCycler 480 using TaqMan® protocol: reaction was initiated at 50ºC for 2min 
followed by 95ºC for 10min before 40 PCR cycles were conducted at 95ºC for 15s and 
60ºC for 1min. Values greater than 35 were excluded due to low confidence. Data was 
analyzed using the Comparative CT (∆∆CT ) Method where ∆CT is the difference between 
gene-of-interest (GOI) and housekeeping gene (HKG) and ∆∆CT is the difference 
between experimental and untreated. Fold change is determined by 2 raised to the 
negative ∆∆CT value [2(-∆∆CT)]192,193. For more information, please see Table A-1.  
 
 siRNA transfections. Y79 cells were plated overnight in 6-well plates at a final 
density of 3.0 x 105 cells per well in 2mL Rb media (without antibiotics). Lyophilized 
PDGFRB siRNA duplex (sc-29942, Santa Cruz Biotechnology) was diluted in nuclease-
free water to a final concentration of 10µM following manufacturer’s instructions.  A 
total of 0.6µg of PDGFRB siRNA was diluted in 100µL of siRNA Transfection Medium 
(Santa Cruz Biotechnology) per well (Solution A). In parallel, 6µL of siRNA 
Transfection Reagent were added into 100µL siRNA Transfection Medium (Solution B) 
per well. Solution A and solution B were combined and incubated at RT for 30min. 
Meanwhile, Y79 cells were harvested, washed in Transfection Medium and were 
resuspended in 800µL of siRNA Transfection Medium per well following addition of 
Solution A + B. Cells were incubated for 6h at 37ºC / 5% CO2. At this point, 1mL of 
RPMI / 20% FBS was added and cells were incubated for 18h prior to performing 
functional assays. As a control, we used a scramble sequence that is known to not target 
any specific oligonucleotides. 
 
 Statistical analyses. Data were analyzed using Prism 6 for Mac OS X (GraphPad 
Software, Inc., La Jolla, CA). Statistical significance determined using the Holm-Sidak 
method, with alpha=5.000%. Values where p<0.05 were considered significant. 
 
 
Results 
 
 
Expression of the Platelet-Derived Growth Factor Receptor signaling network in 
retinoblastoma tumor and tumor-derived cell lines 
 
 Proteomic analyses have identified over 600 proteins within the vitreous235. Some 
of these proteins are known to play significant roles in pathological conditions that 
including vitreal components, most notably: VEGF and PDGF in diabetic retinopathy 
(DR) and age-related macular degeneration (AMD). A common denominator of these 
ocular pathologies is the presence of PDGF. Additionally, a previous study reported 
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limited success in targeting VEGF in Rb, another abundant growth factor within the 
vitreous. We hypothesized PDGF within the vitreous, not VEGF, could sustain vitreous 
seeds via activation of the Platelet-Derived Growth Factor Receptor-beta (PDGFR) To 
first test this hypothesis, we investigated the expression of PDGFR in primary human 
Rb samples from enucleated eyes by immunohistochemistry (IHC). Our results in Figure 
3-1A-D measured low expression of the non-phosphorylated form of the PDGFR 
protein and high expression of the active or phosphorylated form of PDGFR (p-
PDGFR) in ex vivo primary tumor tissue. Next, we analyzed samples by IHC from eyes 
of Rb patients with advanced intraocular diffuse disease vitreous seeds that were 
primarily enucleated. We measured high expression of the p-PDGFR (Figure 3-1E,F) 
compared to the non-phosphorylated PDGFR. The human orthotopic xenograft for Rb 
has been already established as a comparable model to Rb disease with the molecular 
signatures of the primary tumors. This xenograft model is generated by engraftment of 
Rb cells derived from tissue of patients afflicted with Rb that are treated at St. Jude 
Children’s Research Hospital. Harvested Rb cells are injected intravitreally into SCID 
mice to generate tumors that may be monitored both by retinal camera as well as 
tonometry to measure intraocular pressure for several weeks. Mice may then be sacrificed 
before enucleation, paraffin-embedding of tissue, cryo-sectioning, and immunolabeling. 
Details on the xenograft have been already published88. Using this system, we 
investigated the expression of PDGFR in samples from human patient-derived 
orthotopic xenografts (PDX). As shown in Figure 3-1G,H the IHC displayed low 
expression of the non-phosphorylated PDGFR compared to the p-PDGFR. Taken 
together, we observed activity of the PDGFR signaling network in vivo.  
 
 Gene expression of the PDGFR network was evaluated by qPCR analyses to 
quantify mRNA expression of the most common members of the PDGF family. 
Examination of mRNA levels would also allow us to confirm our IHC results above 
(Figure 3-1G,H). To differentiate between human Rb cells and the murine 
microenvironment (host) by the species-specificity of the gene expression assays. We 
analyzed a cohort of paraffin embedded tissue samples from PDX in and measured higher 
PDGFRB mRNA expression compared to PDGFRA ((Figure 3-2, left) 23.0±10.0 
compared to 8.1±0.01, mean ± SEM). PDGFB mRNA was also measured at higher levels 
that PDGFA in the PDX samples (3.2±2.0 compared to 1.8±2.0). 
 
 The Y79 and Weri-1 Rb cells are the most characterized Rb tumor-derived cell 
lines. Y79 is considered a metastatic and aggressive cell line while Weri-1 is considered 
the non-metastatic Rb model37. Y79 measured higher expression of PDGFRB compared 
to the PDGFRA mRNA ((Figure 3-2, right) 17.5±0.05 compared to 1.0±0.2). In contrast, 
Weri-1 Rb cells measured similar PDGFRA and PDGFRB mRNA expression (Figure 3-
2, right); 4.5±0.5 compared to 3.0±0.05). Because vitreous seeds are considered an 
aggressive phenotype, we focus the rest of the in vitro work on Y79 Rb cells. 
 
 There are multiple ligands within the PDGF family; there are four known 
homodimers (PDGF-AA, -BB, -CC, and -DD) and one heterodimer (PDGF-AB). 
Classically, PDGF-AA and -CC were known to bind and activate PDGFR; PDGF-BB  
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Figure 3-1. Immunohistochemistry of the active and non-active forms of PDGFR 
in Rb.  
 
(A-D) Representative images of immunohistochemical staining for expression of 
PDGFR and phosphorylated PDGFR (p-PDGFR) from enucleated eyes of Rb 
patients. (E-F) Representative image of immunohistochemical results of PDGFR in 
vitreous seeds. (G-H) Images from patient-derived orthotopic xenograft. Reprinted with 
permission. Goldsmith ZK, Coppess W, Irvine AS, et al. Targeting the Platelet-Derived 
Growth Factor-beta Stimulatory Circuitry to Control Retinoblastoma Seeds. Invest 
Ophthalmol Vis Sci. 2018;59(11):4486-4495. Copyright (2018), with permission through 
Creative Common CC-BY. 
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Figure 3-2. Expression of the key PDGF family members and the PDGFR in Rb.  
 
qPCR analysis of mRNA isolated from both (left) PDX and (right) both Rb cell lines 
Y79 and Weri-Rb-1 for key members of PDGF signaling pathway. N=9 in PDX mRNA 
analyses with 4 replicates per sample; N=4 for Y79 and Weri-1 mRNA analyses with 4 
replicates per sample; Reprinted with permission. Goldsmith ZK, Coppess W, Irvine AS, 
et al. Targeting the Platelet-Derived Growth Factor-beta Stimulatory Circuitry to Control 
Retinoblastoma Seeds. Invest Ophthalmol Vis Sci. 2018;59(11):4486-4495. Copyright 
(2018), with permission through Creative Common CC-BY. 
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and -DD activated PDGFR, and PDGF-AB was capable inducing activation of both 
homodimeric receptors (PDGFR and PDGFR) as well as the heterodimeric receptor 
PDGFR). As we had previously demonstrated activation of PDGFR, we 
hypothesized this activation would be attributable to an abundance of either PDGF-AB or 
PDGF-BB within the vitreous. To investigate the abundance of these ligands within the 
vitreous, we collected samples of vitreous from eyes of Rb patients that were primarily 
enucleated as a part of an ongoing clinical trial (NCT01783535) and compared the 
protein levels to those of healthy controls (purchased, BioreclamationIVT, Baltimore, 
MD) by Enzyme-linked Immunosorbent Assay (ELISA). We discovered PDGF-BB 
(Figure 3-3, left) to be more abundant in the Rb samples compared to those of healthy 
controls (Rb samples: 360.22±80.261pg/mL, healthy controls: below the level of 
detection; **p<0.005). Similarly, the levels of PDGF-BB were higher in the Rb samples 
compared to healthy controls (1728.73±297.73 compared to 332.70±76.220pg/mL; 
***p<0.0005). The levels of PDGF-BB in the Rb samples were 5.19-fold higher than the 
healthy controls (Figure 3-3, right). Together, this work illustrates high levels of the p-
PDGFR that may be attributable to the abundance of its primary stimulatory ligand, 
PDGF-BB. 
 
 
Pharmacological disruption of PDGFR signaling reduced Rb proliferation, 
invasion, and increased cell death 
 
 The PDGFR signaling pathway has been implicated in a number of cancers and 
ophthalmic diseases. As Rb is considered an orphan disease and has a relatively low 
incidence, studies aimed at identifying novel targets of therapeutic value are limited; 
therefore, the ideal candidate to disrupt PDGFR signaling would be a therapy that is 
currently utilized within the pediatric population and is already FDA-approved for 
treatment of tumors and, ideally, pediatric malignancies236,237. Therefore, to conduct our 
studies, we chose to utilize imatinib mesylate (IM) (marketed by Novartis as Gleevec®) to 
disrupt the PDGFR pathway and investigate the role(s) it may play in Rb. IM was an 
ideal candidate as it is already clinically approved to treat both chronic myeloid leukemia 
(CML) and acute lymphocytic leukemia (ALL) within the pediatric population, as well as 
gastrointestinal stromal tumors (GISTs).  We generated a dose-response curve and 
determined the most efficacious dose at controlling cellular proliferation was 10µM. The 
disruption of the PDGFR signaling pathway was confirmed by Western blotting shown 
(Figure 3-4, left). We measured increased levels of PDGFR activity when recombinant 
human PDGF (rhPDGF) is added to Y79 cells (0.415±0.05; *p<0.05). In contrast, there is 
a striking reduction of the receptor signaling activity when cells were treated with IM 
(0.223±0.05; **p<0.005) or rhPDGF + IM (0.151±0.05; **p<0.005), which mimics the 
physiology of the disease and treatment in the vitreous microenvironment, compared to 
rhPDGF. Next, we quantified the percentage of Y79 PDGFR+ cells by flow cytometry 
analysis and found a significant reduction of Y79 cells expressing the PDGFR after IM 
treatment compared to untreated and rhPDGF-treated cells (rhPDGF: 86.10%±4.0, IM: 
58.36%±2.8, rhPDGF + IM: 61.33%±6.7; **p<0.005), as shown in Figure 3-4, right. We 
measured cell viability by the MTS cellular proliferation assay. The results showed a  
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Figure 3-3. Abundance of PDGF ligands in the vitreous of Rb patients.  
 
PDGF-AB and PDGF-BB ELISAs were used to quantify levels of protein within the 
vitreous microenvironment. Levels of PDGF-AB (left) and PDGF-BB (right) in vitreous 
samples from healthy controls vitreous compared to those of Rb patients. N=6 in ELISA 
analyses done in triplicates. All results represent mean ±SEM; **p<0.005; ***p<0.0005. 
Reprinted with permission. Goldsmith ZK, Coppess W, Irvine AS, et al. Targeting the 
Platelet-Derived Growth Factor-beta Stimulatory Circuitry to Control Retinoblastoma 
Seeds. Invest Ophthalmol Vis Sci. 2018;59(11):4486-4495. Copyright (2018), with 
permission through Creative Common CC-BY. 
 
 
 
 
 
 
Figure 3-4. Imatinib mesylate disrupts PDGF-PDGFR signaling.  
 
Y79 cells were cultured in the presence or absence of either PDGF-BB (10ng/mL) or the 
PDGFR inhibitor imatinib mesylate (IM, 10µM). Western blot analyses of the activity 
of the PDGFR by measurement of the ratio of phosphorylated-PDGFR to total 
PDGFR (left) Flow cytometry analyses showing the percentage of Y79 cells that 
express PDGFR (right). N=3 and 3 replicates per sample. All results represent mean 
±SEM; **p<0.005. Reprinted with permission. Goldsmith ZK, Coppess W, Irvine AS, et 
al. Targeting the Platelet-Derived Growth Factor-beta Stimulatory Circuitry to Control 
Retinoblastoma Seeds. Invest Ophthalmol Vis Sci. 2018;59(11):4486-4495. Copyright 
(2018), with permission through Creative Common CC-BY.  
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significant increase in proliferation over 120h in the presence of rhPDGF illustrating a 
potential mitogenic role. This mitogenic effect was inhibited by IM and rhPDGF + IM 
treatment (Figure 3-5, left; *p<0.05, **p<0.005, ***p<0.0005). We then investigated if 
inhibition of PDGFR could increase cell death (Figure 3-5, right) by flow cytometry 
analysis of apoptotic (Annexin V+PI+) cells. At the time of setting up the cell cultures we 
measured cell death of Y79 cells to obtain the baseline levels. We measured cell death by 
using Annexin V and PI and found about 3% cell death. To confirm these results, we 
used Zombie Aqua™, which is a sensitive amine-reactive dye that is non-permeant to live 
cells and found 5.8% of cell death. There was a significant increase in cell death in IM 
(19.51%±5.3; *p<0.05) and rhPDGF + IM (27.77%±2.7; ***p<0.0005) compared to 
untreated (11.55%±0.6) and rhPDGF (13.16%±0.8).  These results illustrated the role of 
the PDGFR signaling in Rb cell growth and death. 
 
 As Y79 cells represent the aggressive and metastatic model of disease, we 
measured the invasive potential of these cells to test if the PDGF-PDGFR signaling 
pathway controls invasion by culturing them in well inserts coated with basement 
membrane170. We measured the ability of cells to invade basement membrane via 
quantitation of cells per field (Figure 3-6). This data demonstrated IM (139.66±10.3; 
*p<0.05) and rhPDGF + IM (163.33±6.0; *p<0.05) treated cells showed less invasion 
compared to untreated (171.0±7.7) and rhPDGF (240.0±20.7) treated cells. We quantified 
the cells that crossed the membrane by removal of the non-invasive cells followed by 
labeling of the invasive cells. Representative images of cells in each condition are shown 
(Figure 3-6, right).  
 
 
Disruption of PDGFR targets the MDM2 and NFB signaling cascades 
 
 The primary goal of this research is to understand more about how interactions 
with the TME may promote Rb cell survival. One such mechanism by which cells are 
capable of surviving is through inhibition of apoptosis by key cell signaling molecules, 
such as MDM2 and NFB signaling. These two molecules are linked to anti-apoptotic 
mechanisms that have yet to be studied within the context of the PDGFR pathway in 
Rb. We hypothesized that disruption of the PDGFR pathway by IM, could result in 
decreases in activity of both MDM2 and NFB that could account for the increases in 
apoptotic cells we demonstrated earlier. Hence, we investigated the in-depth mechanisms 
by which PDGFR controls Rb cell survival and death. Quantitative PCR analysis 
demonstrated downregulation of MDM2 mRNA after disruption of the PDGFR pathway 
(IM: 1.565±0.41, rhPDGF + IM: 1.905±0.48) compared to rhPDGF-treated (4.306±0.44) 
cells (Figure 3-7A). A similar effect was measured when MDM4 mRNA, another 
regulator of tumor suppression, was tested (Figure 3-7B). We then examined MDM2 
signaling activity by Western blot analysis and discovered MDM2 signaling is impaired 
in IM (0.5±0.2; *p<0.05) and rhPDGF + IM-treated (0.4±0.001; **p<0.005) cells 
compared to the levels of untreated (1.0±0.0) and rhPDGF (1.1±0.1) (Figure 3-7C). We 
further hypothesized this key signaling event could be at least partially regulated by the  
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Figure 3-5. PDGF-PDGFR signaling induces Rb cell proliferation and regulates 
survival.  
 
Y79 cells were cultured in the presence or absence of either PDGF-BB (10ng/mL) or the 
PDGFR inhibitor imatinib mesylate (IM, 10µM). Left, Assessment of Y79 cellular 
proliferation over time in the presence of either PDGF-BB or IM using the concentrations 
described above. Middle, The percentage cells undergoing apoptosis was measured by 
Annexin V and PI labeling using flow cytometry. Dead cells displayed an Annexin V+PI+ 
phenotype. Right, Evaluation of cell viability by Zombie Aqua labeling (top) or Annexin 
V+PI+ (bottom) of Y79 Rb cells at 0 hr. N=3 and 3 replicates per sample. All results 
represent mean ±SEM; *p<0.05, **p<0.005, ***p<0.0005. Reprinted with permission. 
Goldsmith ZK, Coppess W, Irvine AS, et al. Targeting the Platelet-Derived Growth 
Factor-beta Stimulatory Circuitry to Control Retinoblastoma Seeds. Invest Ophthalmol 
Vis Sci. 2018;59(11):4486-4495. Copyright (2018), with permission through Creative 
Common CC-BY. 
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Figure 3-6. Reduction in invasive capacity of Y79 cells after IM treatment on 
basement membrane-coated inserts.  
 
Y79 cells were cultured in the presence or absence of either PDGF-BB (10ng/mL) or the 
PDGFR inhibitor imatinib mesylate (IM, 10µM). (left) total counts per field, and (right) 
representative images of fields counted. N=3 and 3 replicates per sample. All results 
represent mean ±SEM; *p<0.05. Reprinted with permission. Goldsmith ZK, Coppess W, 
Irvine AS, et al. Targeting the Platelet-Derived Growth Factor-beta Stimulatory Circuitry 
to Control Retinoblastoma Seeds. Invest Ophthalmol Vis Sci. 2018;59(11):4486-4495.  
Copyright (2018), with permission through Creative Common CC-BY. 
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Figure 3-7. PDGF-PDGFR signaling regulates cell survival signaling.  
 
Y79 cells were cultured in the presence or absence of either PDGF-BB (10ng/mL) or the 
PDGFR inhibitor imatinib mesylate (IM, 10µM). (A-B) qPCR analyses on mRNA 
levels of (A) MDM2 and (B) MDM4 relative to untreated Y79 cells under the cell culture 
conditions described above. (C-D) Western blot analyses (C) of MDM2 activity and (D) 
AKT activity after disruption of the PDGFR signaling cascade. (E-F) Evaluation of the 
anti-apoptotic mediator (E) BCL-2 by Western blot and the pro-apoptotic cleaved 
(active) capsase-3 by ELISA (F). N=3 and 3 replicates per sample. All results represent 
mean ±SEM; *p<0.05, **p<0.005, ***p<0.0005. Reprinted with permission. Goldsmith 
ZK, Coppess W, Irvine AS, et al. Targeting the Platelet-Derived Growth Factor-beta 
Stimulatory Circuitry to Control Retinoblastoma Seeds. Invest Ophthalmol Vis Sci. 
2018;59(11):4486-4495. Copyright (2018), with permission through Creative Common 
CC-BY. 
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upstream activator of MDM2, AKT and, therefore, investigated if the reduction in cell 
proliferation is AKT-dependent. A small, albeit significant (*p<0.05), modulation of  
AKT signaling activity in rhPDGF + IM-treated cells (Figure 3-7D). 
 
 After examination of MDM2 and AKT, both involved in cell survival pathways, 
we investigated the mechanisms by which PDGFR controls cell death in Rb. We 
postulated this disruption of AKT could also affect other downstream targets involved in 
apoptotic signaling, most notably the anti-apoptotic molecular BCL-2, and an executioner 
caspase, Caspase-3. We first assessed the levels of the anti-apoptotic BCL-2 protein after 
PDGFR disruption. Y79 cells treated with IM and rhPDGF + IM have a significant 
reduction in BCL-2 levels (Figure 3-7E). We also investigated the role of cleaved 
Caspase-3, the final effector in inducing programmed cell death. We measured the 
abundance of cleaved Caspase-3 by ELISA to investigate if the BCL-2 reduction was 
concomitant to an increase in cleaved Caspase-3 (Figure 3-7F). IM-treated cells showed 
a significant increase in cleaved Caspase-3 (0.336±0.01; *p<0.05) compared to the rest of 
the cell culture conditions (untreated: 0.293±0.002, rhPDGF: 0.286±0.007).  
 
Our next investigation aimed to evaluate if inhibition of PDGFR signaling could 
result in a potential compensatory effect in VEGF-VEGFR2 signaling, which is 
expressed in Rb170,238,239. Previous work from our lab (see Chapter 2 above; Figure 2-6A) 
demonstrated how targeting and inhibiting the MMPs, VEGF levels would increase or 
decrease in a cell-dependent manner and this could alter the TME to become more (or 
less) angiogenic, for example. Therefore, in a similar manner, we hypothesized inhibition 
of PDGFR would result in a similar decrease in VEGF levels that could decrease 
VEGF-VEGFR signaling. We confirmed the expression of VEGFA mRNA in Y79 cells 
and in the PDX model of Rb (Figure 3-8A-B). Protein analysis through VEGF ELISA 
revealed elevated levels of VEGF in the vitreous of Rb patients compared to those of 
health vitreous (Figure 3-8C). Additional qPCR analyses on Y79 cells revealed no 
difference in VEGFA and VEGFR2 mRNA expression after disruption of the PDGFR 
signaling (Figure 3-8D-E). Despite no changes at the transcriptional level there was a 
reduction in VEGFR2 signaling after treatment with IM (Figure 3-8F) (IM: 0.93±0.06, 
rhPDGF + IM: 0.77±0.04; *p<0.05) compared to the controls (untreated: 1.00±0.04, 
rhPDGF: 1.00±0.007). These results demonstrate targeting PDGF-PDGFR signaling 
does not result in a compensatory mechanism through VEGF-VEGFR2.  
 
 The disruption of PDGFR signaling via IM showed this pathway plays a role in 
Rb tumor cell survival. We hypothesized the suppression of Y79 survival may occur via a 
crosstalk between MDM2 and NFB. To address this, we utilized imaging flow 
cytometry to measure the nuclear translocation of the NFB p65 subunit. Quantitative 
analysis showed a distinct reduction in the percentage of cells showing p65 nuclear 
translocation (Figure 3-9A) after IM treatment (IM: 17.8%±0.7, rhPDGF + IM: 
22.8%±0.8; ***p<0.0005) compared to the untreated (33.0%±0.0) and rhPDGF 
(45.0%±0.0) controls. Along with a reduction on the percentage of cells showing p65 
nuclear translocation, we measured an overall reduction in the p65 protein by 
measurement of the mean fluorescent intensity (Figure 3-9B) in the presence of IM (IM:  
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Figure 3-8. Lack of VEGF-VEGFR2 compensatory mechanism when PDGF-
PDGFR signaling is disrupted.  
 
(A-B) VEGFA mRNA levels were measured by qPCR analysis in both Y79 (A) cells and 
PDX (B). (C) Measurement of VEGFA levels in a cohort of vitreous samples from 
healthy controls compared to vitreous of Rb patients. Y79 cells were cultured in the 
presence or absence of either PDGF-BB (10ng/mL) or the PDGFR inhibitor imatinib 
mesylate (IM, 10µM). (D-E) Both VEGFA (D) and VEGFR2  (E) mRNA levels were 
measured across respective treatments as well as (F) Western blot analyses of VEGFR2. 
Experiments from (A,C-F), done with N=3 and each sample done in triplicates. 
Experiment from (B) N=9 and each sample done in replicates of 4. N=6 in ELISA 
analyses done in triplicates. All results represent mean ±SEM; *p<0.05. Reprinted with 
permission. Goldsmith ZK, Coppess W, Irvine AS, et al. Targeting the Platelet-Derived 
Growth Factor-beta Stimulatory Circuitry to Control Retinoblastoma Seeds. Invest 
Ophthalmol Vis Sci. 2018;59(11):4486-4495. Copyright (2018), with permission through 
Creative Common CC-BY. 
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Figure 3-9. Disrupting PDGF-PDGFR signaling decreases NFB nuclear  
translocation.  
 
Y79 cells were cultured in the presence or absence of either PDGF-BB (10ng/mL) or the 
PDGFR inhibitor imatinib mesylate (IM, 10µM). (A-C) Assessment of the NFB 
signaling, (top left) the percentage of treated Y79 cells with nuclear localization of the 
p65 subunit and (top right) the expression (or mean fluorescent intensity) of the p65 
subunit using an Amnis FlowSight® Imaging Cytometer. Representative images of Y79 
cells (bottom) labeled and analyzed for nuclear (labeled with DRAQ5™) translocation of 
the p65 subunit of NFB (AlexaFluor 488 conjugated). Experiments from A-C tested 
10,000 cells. All results represent mean ±SEM; *p<0.05, ***p<0.0005. Reprinted with 
permission. Goldsmith ZK, Coppess W, Irvine AS, et al. Targeting the Platelet-Derived 
Growth Factor-beta Stimulatory Circuitry to Control Retinoblastoma Seeds. Invest 
Ophthalmol Vis Sci. 2018;59(11):4486-4495. Copyright (2018), with permission through 
Creative Common CC-BY. 
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1.627x103±3.0x104, rhPDGF + IM: 7.5x104±2.3x104; *p<0.05) compared to the controls 
(untreated: 1.25x105±2.0x104, rhPDGF: 1.35x105±5.6x104). Representative images of the 
p65 nuclear localization analyses are shown in Figure 3-9C. Co-localization of p65 
(green) to the nucleus (red) is depicted in yellow. Collectively, our work supports our 
hypothesis that the PDGFR promotes Rb cell survival and death via modulation of 
MDM2 and nuclear translocation of the pro-survival NFB molecule. 
 
 
Reduction of Rb spheroids by IM in a 3D cell culture model of Retinoblastoma 
vitreous seeds 
 
 There have been no in vitro models for Rb vitreous seeds. As a result of a lack of 
proper in vitro models, studies on vitreous seeds are quite limited. To investigate vitreous 
seeds, studies would need to be done either using ex vivo human tissue or in vivo using 
the rabbit xenograft model92. To understand more about their in vivo development and 
behavior, an in vitro model could prove quite valuable. Furthermore, an in vitro model of 
vitreous seeds would provide a novel tool to develop drug screens while preclinically 
testing efficacy of potential future therapeutics. We adapted our in vitro 3D cell culture 
system to recreate Rb seeds in a vitreous-like microenvironment for in-depth study. 
Schematics of the procedure are shown in Figure 3-10A. These “seeds” were generated 
by magnetic levitation and the resulting spheroids were visible to the naked eye (Figure 
3-10B). Multiple aggregates or clusters of cells are found within the cell cultures. Using 
the 3D system, we are able to generate a spheroid that forms one large mass by addition 
of magnetic nanoshuttles to our cell culture that is further magnetized. The viability of 
Y79 cells in a standard cell culture system was compared to that of the 3D system. 
Quantitative analysis of live cells by trypan blue exclusion (Figure 3-10C) revealed no 
difference in the viability of cells after overnight culture. We compared images of our 
magnetically-generated Rb spheroids to ex vivo Rb seeds found similar morphology 
(Figure 3-10D).  
 
We then measured the area of the spheroids using ImageJ (NIH) over time after 
treatment with IM. We discovered a reduction in the area of Rb spheroids 48hrs after 
rhPDGF + IM treatment (*p<0.05) compared to the control groups (Figure 3-11A). Y79 
cells were labeled with carboxyfluorescein succinimidyl ester (CFSE) to trace and 
visualize the cells fluorescently. We observed the center of the spheroid to have fewer 
cells than the rest of the spheroid (Figure 3-11B, shown at 48h) when CFSE+ Rb 
spheroids were cultured over time. The size of the translucent center is larger in those 
spheroids treated with IM (both IM and rhPDGF + IM) compared to the control groups, 
suggesting death. We confirmed our flow cytometry findings (Figure 3-4) of a 
qualitative reduction in the expression of PDGFR and VEGFR2 in IM treated-cells 
(Figure 3-11C) by using immunofluorescence microscopy in the 3D system. Through the 
use of a 3D cell culture model we generated Rb spheroids that showed a reduction in the 
spheroid area after disruption of the PDGFR signaling as well as a lack of VEGFR2 
activity. 
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Figure 3-10. Three-dimensional magnetic tumor spheroids as an in vitro model for 
vitreous seeds.  
 
Using commercially available magnetic nanoshuttles, (top) Y79 cells were magnetized to 
form three-dimensional tumor spheroids (see: red arrow). (bottom left) Trypan blue 
exclusion was used to measure cell viability in samples with spheroid formation versus 
non-spheroid. (Bottom right, top) Comparison of an ex vivo vitreous seed to (Bottom 
right, bottom) a representative three-dimensional tumor spheroid. All results in (C) 
represent mean ±SEM. Reprinted with permission. Goldsmith ZK, Coppess W, Irvine 
AS, et al. Targeting the Platelet-Derived Growth Factor-beta Stimulatory Circuitry to 
Control Retinoblastoma Seeds. Invest Ophthalmol Vis Sci. 2018;59(11):4486-4495. 
Copyright (2018), with permission through Creative Common CC-BY. 
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Figure 3-11. Quantitative and qualitative assessment of first in vitro model of 
vitreous seeds.  
 
Using commercially available magnetic nanoshuttles, (top) Measurements of magnetized 
Rb spheroid area over time. CFSE-labeled Rb spheroids were assessed (middle) 
morphologically and for PDGFR (bottom) expression 48hrs after culture. All results in 
top represent mean ±SEM; *p<0.05. In imaging experiments, a minimum of 3 wells of 
spheroids were generated per culture condition. Reprinted with permission. Goldsmith 
ZK, Coppess W, Irvine AS, et al. Targeting the Platelet-Derived Growth Factor-beta 
Stimulatory Circuitry to Control Retinoblastoma Seeds. Invest Ophthalmol Vis Sci. 
2018;59(11):4486-4495. Copyright (2018), with permission through Creative Common 
CC-B 
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Reduction in cell viability, MDM2 signaling and p65 nuclear translocation are 
PDGFR-specific 
 
 To confirm if the reduction of cell viability was PDGFR-specific or an off-target 
effect of the IM drug we knocked down PDGFRB by siRNA technology. We confirmed 
PDGFRB mRNA knockdown after PDGFRB siRNA transfection (0.339±0.060) 
compared to samples transduced with random nucleotides (Scramble, 0.8±0.002) and 
untreated (1.0±0.00) controls (Figure 3-12A). We then evaluated the effect of PDGFRB 
gene knockdown on Rb cell survival and death. To address this, we labeled cells with 
Annexin V and PI labeling as before (Figure 3-5B) and analyzed by flow cytometry. The 
analysis showed a reduction in the percentage of live (AnnexinVnegPIneg) cells in 
PDGFRB siRNA transfected cells compared to the Scramble and untreated controls 
(Figure 3-12B). The percentage of early apoptotic cells with a phenotype of Annexin 
V+PIneg increased in PDGFRB siRNA transfected samples compared to untreated and 
Scramble-treated cells (Figure 3-12C). Similarly, the percentage of late apoptotic cells, 
defined as Annexin V+PI+, increased in PDGFRB siRNA transfected cells compared to 
untreated and Scramble-transfected cells (Figure 3-12D). The percentage of Annexin 
V+PI+ cells was higher in Scramble-transfected cells compared to untreated cells. 
However, the magnitude of the increase in the percentage of late apoptotic cells in 
PDGFRB siRNA-transfected cells is larger in the Scramble-treated group. As part of our 
investigation on the role of PDGFR in Rb cell survival and death we measured MDM2 
signaling in the siRNA transfections. Western blot demonstrated a reduction, not 
significant (p=0.06), in MDM2 signaling in PDGFRB siRNA-transfected cells compared 
to the control group (Figure 3-12E). 
 
 Activation of NFB may occur from multiple upstream cell-surface receptors. As 
some of these cell-service receptors are tyrosine kinases and IM is a TKI, we wished to 
confirm that disruption of p65 nuclear translocation was PDGFR-specific and not the 
result of a non-specific effect of IM. We demonstrated a reduction in the p65 subunit of 
NFB and in the nuclear translocation after pharmacological disruption of PDGFR with 
IM (Figure 3-9). We hypothesized that, just as interference of PDGFRB by siRNA 
resulted in increases in percentage of apoptotic cells, we would also detect reductions in 
nuclear translocation of p65. To confirm this was a PDGFR-dependent effect, we 
compared these parameters in PDGFRB siRNA-transfected cells to Scramble and 
untreated controls (Figure 3-12F).The results revealed a marked reduction of the 
percentage of cells showing p65 nuclear translocation in the PDGFRB siRNA-transfected 
(9.10%±0.45, ***p<0.0005) cells (Figure 3-12E, untreated: 45.04%±2.25, Scramble: 
38.33%±2.9) in addition to a reduction in the amount of p65 protein Figure 3-12G, 
1.17x105±5.8x103) compared to the control groups (untreated: 1.82x105±8.1x103, 
Scramble: 2.03x105±1.1x103). Co-localization of p65 (green) to the nucleus (red) is 
shown in yellow in Figure 3-12H. Our PDGFRB siRNA transfection findings confirmed 
our results using the pharmacological inhibitor of PDGFR IM and support our 
hypothesis that the PDGFR plays an essential role in Rb cell survival and death, MDM2 
signaling and NFB. 
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Figure 3-12. Confirmation of PDGFR-specific effects in Rb cells by PDGFRB 
siRNA.  
 
PDGFRB gene expression in Y79 was targeted using commercially available siRNA. (A) 
qPCR analyses confirmed effective knockdown of PDGFRB mRNA in siRNA 
transfected samples compared to non-specific oligonucleotides and untreated cells. The 
percentages of viable and apoptotic cells were determined by flow cytometry analysis 
using (B) the Annexin VnegPIneg phenotype for live cells, (C) the percentage of early 
apoptotic (Annexin V+) and (D) late apoptotic (Annexin V+PI+) cells. (E).  Western blot 
analyses were done to measure activity levels of MDM2 after transfection of PDGFRB 
siRNA. (F-H) Using the Amnis FlowSight® Imaging Cytometer, untreated, scramble, or 
PDGFRB siRNA- transfected Y79 cells were labeled and analyzed for (F) the percentage 
of p65 nuclear translocation and (G) the expression (mean fluorescent intensity) of the 
p65 subunit. (H) Representative images in each condition. Experiments from F-H 
evaluated 10,000 cells. All results represent mean ±SEM; *p<0.05, **p<0.005, 
***p<0.0005. Reprinted with permission. Goldsmith ZK, Coppess W, Irvine AS, et al. 
Targeting the Platelet-Derived Growth Factor-beta Stimulatory Circuitry to Control 
Retinoblastoma Seeds. Invest Ophthalmol Vis Sci. 2018;59(11):4486-4495. Copyright 
(2018), with permission through Creative Common CC-BY. 
 
  
  
69 
 
Discussion 
 
 Our findings demonstrate that PDGFR signaling promotes the growth of Rb 
seeds, reduces Rb tumor apoptotic activity, and controls their invasive potential. These 
results suggest the PDGFR signaling network may be a novel target to control Rb, 
especially in settings with recurrent or recalcitrant vitreous disease. Rb is the most 
common primary intraocular malignancy in children. Although Rb is highly treatable in 
developed countries, treating eyes with vitreous seeds remains challenging. About a third 
of the patients who undergo eye-sparing therapies still require enucleation due to 
recalcitrant disease. This in part due to vitreous seeding, which is difficult to treat due to 
the anatomical location of the seeds and the refractory nature of them to the most 
commonly used chemotherapeutics. Therefore, understanding more about vitreous seeds 
and their microenvironment may prove advantageous in developing novel therapies 
against Rb seeds and lead to improved ocular salvage and visual preservation. 
Only recently has PDGFR signaling pathway in Rb come under scrutiny and been 
demonstrated in Rb samples by immunohistochemistry240 and showed in vitro the 
potential use of imatinib in reducing the growth of Rb prior to radiation using cell 
lines241. Our work confirmed the immunohistochemical studies by Burnier and 
demonstrated the PDGF-PDGFR signaling sustains Rb growth in both autocrine, growth 
factors stemming from the tumor cells, and paracrine, stemming from other, non-tumoral 
cellular infiltration, stimulatory loops. We demonstrated this stimulatory circuitry by the 
high expression of PDGFB mRNA in Rb tumor cells, the levels of active PDGFR 
signaling, and the abundance of the PDGFR ligands, PDGF-AB and PDGF-BB, in the 
vitreous microenvironment of Rb patients.  
 
Imatinib mesylate, aka as STI571, is marketed as Gleevec® by Novartis 
Pharmaceuticals Corporation. This compound belongs to the 2-phenylaminopyrimidine 
class drugs, which selectively inhibits the tyrosine kinase activity of the PDGFR, KIT, 
and BCR-ABL protein tyrosine kinases242,243. Considered one of the major breakthroughs 
in cancer treatments, IM lifted the death sentence associated with Chronic Myelogenous 
Leukemia (CML) after its first clinical study237, and is now indicated for multiple 
malignancies236,244-249. IM has shown antitumor activity as a neo-adjuvant in glioblastoma 
multiforme (GBM)250. Similar to Rb, GBM shows high expression of PDGFRs. More 
importantly, these studies suggest a clinically safer application in the pediatric population 
and some penetration of IM to the Blood-Brain Barrier (BBB). The Blood-Retinal Barrier 
(BRB) is considered the counterpart of the BBB in the retina. Emerging evidence shows 
the use of IM in reducing neuroinflammation in autoimmune disorders that target the 
central nervous system, such as multiple sclerosis (MS)251,252. In addition to the 
amelioration in neuroinflammation, IM restores the integrity of the BBB in a rat model of 
MS251. Together, these investigations became part of our rationale to investigate the 
PDGFR signaling pathway in Rb by using IM.  
 
Vascular endothelial growth factor (VEGF) is abundant under pathological 
conditions. VEGF plays a role in tumor angiogenesis and the neutralization of this protein 
can reduce tumor vascularization in vivo. Prior work has demonstrated the use of 
bevacizumab, a monoclonal antibody against VEGF, in the suppression of angiogenesis 
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and Rb growth in vitro using Y79 cells166. The use of bevacizumab in vivo also reduced 
tumor burden166. To achieve a reduction in tumor burden, the authors injected 
intraperitoneally 50-100µg of bevacizumab twice a week for 4 weeks to xenografted 
mice. This and other studies suggested anti-angiogenic therapy by inhibition of VEGF 
might be a suitable therapy against Rb166,253. However, recent work demonstrated that 
anti-VEGF therapy does not affect Rb cell viability and is not Rb specific254. We 
postulate PDGF-PDGFR signaling may contribute to VEGF production in the tumor 
microenvironment, as evidenced by the reduction in VEGFR2 signaling in Rb cell lines 
after disruption of the PDGFR signaling pathway. 
 
 That we know very little regarding vitreous seeds (and even less about the 
microenvironment) has precluded the advancement in the development of novel therapies 
against Rb vitreous seeds. We generated a novel 3D cell culture system based on the 
magnetic levitation studies to develop Rb tumor seeds in vitro255. When these spheroids 
were examined morphologically, they were similar to in vivo Rb vitreous seeds. The three 
main subtypes of vitreous seeding were recently outlined patterns: dust, spheres, and 
clouds100. Each of the subtypes results in different characteristics and potentially 
treatment responses. Furthermore, the histopathology associated with each subtype and 
concluded spheres to be the most aggressive subtype101. We compared our in vitro 
spheroids to the morphological characteristics previously described101 and discovered 
similarities to the spheres subtype. A translucent center was observed in the spheroids 
and some spheroids exhibited Rb cell detachment from the outer area. These studies 
validated our in vitro 3D system for the further study of Rb spheroids.  
 
 In this investigation we focused on the downstream signaling components of the 
PDGFR in Rb biology. We discovered the PDGFR signaling is active in ocular tissues, 
including the vitreous, from Rb patients compared to healthy controls. These results were 
confirmed using a PDX model, which have comparable molecular features to primary 
tumors. We also demonstrated the PDGFR signaling cascade is pivotal for Rb cell 
growth, survival and invasion. In an important step toward the successful evolution from 
translational research into future clinical applications, we generated a 3D cell culture 
system to study Rb spheroids. These spheroids have similar morphological features to the 
Rb sphere subtype of vitreous seeds. This cell culture system provides a unique 
opportunity to study the interactions between Rb and the microenvironment in vitro as it 
mimics the natural physiology by production of components of the extracellular matrix 
and growth factors. This study demonstrated pre-clinically that PDGF from both 
autocrine and exogenous sources signals through the PDGFR to sustain Rb growth in an 
avascular system, such as the vitreous. Targeting the PDGFR could increase the 
sensitivity of these tumor cells to current treatments as current therapies have failed to 
address the reduced proliferative capacity and metabolisms of these unique tumor seeds. 
 
 Following these studies, further work must be conducted in vivo to properly 
assess the therapeutic value of targeting the PDGF-PDGFR signaling pathway as a 
novel target to treat vitreous seeding. As this work is aimed at vitreous seeds, it only 
seems appropriate to conduct this future work using the rabbit xenograft model; this 
model has multiple features that make it an ideal modeling system: 1) the rabbit xenograft 
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is the only model that readily forms vitreous seeds, 2) the size and volume of the eye are 
approximate to that of a small child, and 3) this model can withstand multiple injections, 
similarly to what is used within the clinic now. Preclinical assessment of anti-
PDGFR therapy should be done following injection and vitreous seed formation 
(approximately 6-8 weeks) primarily using fundus imaging to check for presence (or 
absence of vitreous seeds) as well as histopathology to examine vitreous seed phenotype 
and activation status of PDGFR Depending on the success of this study, future 
experiments can test other therapeutic avenues to disrupt PDGF-PDGFR signaling 
including neutralizing antibodies against PDGF-BB, aptamers, RNA interference, etc. As 
an alternative, additional studies should be aimed at examining the role of anti- 
PDGFR therapy as an adjuvant therapy to sensitize vitreous seeds. 
 
 
Conclusion 
 
 The work presented herein demonstrates the abundance of key PDGF ligands and 
the activation status of PDGFR as they relate specifically to vitreous seeds. We 
demonstrated PDGF-PDGFR signaling regulates key tumor cell behaviors including 
proliferation, invasion, and, most notably, survival. Moreover, we provide mechanistic 
insight that this survival is driven by the downstream targets of PDGFR signaling, most 
notably the anti-apoptotic molecules MDM2 and BCL-2 as well as the pro-survival 
molecule NFB. We also developed the first in vitro model of vitreous seeds based on 
magnetic levitation. This model can further our understanding of vitreous seeds and 
supplies a much-needed preclinical model to test therapeutic efficacy. Nonetheless, 
further in vivo experiments are needed to evaluate the therapeutic value of 
PDGFR therapies. Taken together, the work presented here demonstrates a highly 
translational approach to successfully identify and inhibit a new potential target in 
PDGFR for vitreous seeding. These results point to the possibility of 
PDGFR inhibition as an adjuvant therapy for Rb.  
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CHAPTER 4.    RESULTS III: ANTI-PLATELET-DERIVED GROWTH 
THERAPY AS A POTENTIAL TARGET TO DECREASE RESISTANCE  
 
 
Introduction 
 
 Within the field of oncology, there has been a recent shift from the understanding 
of tumors as independent actors to that of a complex web of interactions featuring 
multiple cytokines and cell types, called the tumor microenvironment (TME). 
Interactions between the tumor and the TME are capable of altering fundamental 
processes of tumors including growth, survival, metastasis, and resistance. Interest in the 
TME has grown exponentially due to the possibility of new, more targeted therapies. As 
our lab is primarily interested in developing new therapies to target and clear vitreous 
seeds to increase ocular salvage rates, understanding more about the Rb TME is essential 
in meeting the treatment goals of Rb. Unfortunately, vitreous seeding remains the most 
challenging aspect of treating and managing Rb. Quite often these seeds are refractory to 
chemotherapy and thus lead to disease recurrence. How? and why? these seeds are 
refractory is not understood as very little is currently known about the Rb TME. Previous 
attempts have demonstrated a number of cytokines and growth factors within the vitreous 
that play a role in ocular pathologies225,226 however these studies are not directly related 
to Rb or vitreous seeding. Studies aimed at demonstrating other cell types within the 
TME of retinoblastoma (Rb) have detected the presence of two non-tumor cell types: 1) 
macrophages105,256 and retinal vascular endothelial cells257. This gap in knowledge has 
resulted in a failure to raise ocular salvage rates over the past 20 years218-221.   
 
Previous Rb studies aiming at vascular endothelial growth factor (VEGF) have 
failed to achieve clinical success166,258. Furthermore, the vitreous lacks vasculature so 
anti-angiogenic therapy should not aid in the clearance of vitreous seeds. To potentially 
target vitreous seeds, we recently identified the Platelet-Derived Growth Factor Receptor-
beta (PDGFR) as being highly active in Rb disease and vitreous216. We targeted the 
PDGF-PDGFR signaling pathway using imatinib mesylate (IM, aka Gleevec® from 
Novartis) and showed in vitro reduction of Rb growth, invasion, and survival in an 
MDM2- and NF-B-dependent manner. While we demonstrated early, preclinical 
success of anti-PDGF-PDGFR therapy, we were also interested in how PDGF-PDGFR 
signaling may represent a potential mechanism by which vitreous seeds can evade cell 
death in response to chemotherapy.  
 
Drug resistance is a major problem in cancer biology, whereby tumor cells no 
longer to respond to certain treatments (most commonly chemotherapy). There are 
multiple mechanisms that confer resistance to tumor cells including: 1) drug efflux, or the 
removal of intracellular drugs from the cell; 2) genetic responses promoting expression of 
resistance genes; 3) enhanced DNA repair to prevent programmed cell death; 4) 
alterations in tumor molecules that promote alternative activation of similar pathways; 
and 5) changes in metabolic pathways that result in decreased drug concentrations259. 
Cooperation between stromal cells and tumor cells have also been found to decrease drug 
efficacy through secretion of growth factors such as VEGF and PDGF260,261. Ultimately, 
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cells that are drug resistant are not only more difficult to treat but are often more 
aggressive, more likely to metastasize, and give rise to disease recurrence. Perhaps the 
most well studied area in drug resistance is that of drug efflux where cells efflux, or 
pump, intracellular agents (i.e. chemotherapy) out of the cell resulting in less cytotoxic 
concentrations of chemotherapy. The ATP-binding cassette (ABC) transporter family is a 
group of efflux pumps that have been implicated in cancer drug resistance262-264.  
 
The objectives of this study are two-fold: first, to investigate in vitro if other 
components of the TME would be affected by the PDGF-PDGFR pathway and IM 
toxicity, and second, to investigate if this signaling pathway would exert an effect in 
known mechanisms of chemoresistance.  
 
 
Materials and Methods 
 
 
Ethics statement 
  
 As stated in previous chapters, all experiments involving human subjects were 
approved by the Institutional Review Board (IRB) at St. Jude Children’s Research 
Hospital (SJCRH) and The University of Tennessee Health Science Center (UTHSC); 
informed consent obtained when needed. In those experiments using tissue from murine 
xenografts, the Institutional Animal Care and Use Committee (IACUC) at SJCRH 
approved the animal experiments. All protocols followed the ARVO Statements for the 
use of animals in vision research, in addition to the guidelines for laboratory animal 
experiments. 
 
 
Cell lines and cell culture conditions 
  
Retinoblastoma cell lines.  The human Retinoblastoma (Rb) cell lines Y79 
(ATCC® HTB-18™)79 was purchased from the American Type Culture Collection 
(Manassas, VA, USA) and cultured in Rb media. This media contains RPMI-1640 
supplemented with L-glutamine (Gibco by Invitrogen, Carlsbad, CA, USA), 20% FBS 
(Gibco by Invitrogen), and 1% penicillin/ streptomycin (Gibco by Invitrogen).  
 
Breast cancer cell line.  Metastatic breast cancer cells MDA-MB-231 (ATCC® 
HTB-26)265 were a gift from Dr. T.J. Hollingsworth (UTHSC) and maintained in DMEM 
supplemented with 10% FBS (Gibco by Invitrogen) and 1% Amphotericin B / 
Gentamicin. Cells were kept in a humidified incubator at 37°C/ 5% CO2. 
 
Primary human retinal microvascular endothelial cells (hRECs, ACBRI 
181).  These cells were purchased from Applied Cell Biology Research Institute. hRECs 
were cultured using Complete Classic Medium was used, consisting of Complete Serum-
Free Medium with 10% HI-FBS (Gibco by Invitrogen), and 1% penicillin/ streptomycin 
(Gibco by Invitrogen). ACBRI181 were used for experiments before passage 8. 
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Cell culture conditions.  Cells were cultured using four different conditions: 
untreated, recombinant human Platelet-Derived Growth Factor (rhPDGF, 10ng/mL), 
Imatinib Mesylate (IM, 10µM), and the combination of rhPDGF + IM.  
 
 
Vitreous samples 
  
 The University of Tennessee Health Science Center and St. Jude Children’s 
Research Hospital Institutional Review Board (IRB) approved the present study. 
Informed consent was obtained in all cases where vitreous was harvested at the time of 
patient enucleation, an optional research objective that is part of an on-going prospective 
clinical trial (NCT01783535) This is in full compliance with and adheres to the tenets of 
the Declaration of Helsinki and the ARVO statement on human subjects. Vitreous from 
eyes with Rb was collected at the time of enucleation. Eyes were trephined immediately 
upon removal without disruption of underlying structures important for diagnostic and 
staging purposes. Tumor was harvested for genetics and biology and vitreous was 
aspirated using an 18-gauge needle and 3mL syringe. Vitreous from healthy controls 
were purchased from BioreclamationIVT (Baltimore, MD, USA). Samples were 
centrifuged, aliquoted and stored at -20°C. 
 
 
Reagents 
  
 Phosphate-buffered saline (PBS) was purchased from Gibco by Invitrogen 
(Thermo Scientific, Bridgewater, NJ, USA). Gleevec® was purchased in its generic 
chemical form, imatinib mesylate (IM, PubChem ID: 123596), from Sigma-Aldrich 
(Saint Louis, MO, USA). Lyophilized reagent was dissolved in deionized, distilled water 
(ddH2O) to 10mM, aliquoted, and stored at -20°C. Lyophilized recombinant human 
PDGF-BB (10µg) was purchased from Invitrogen (Thermo Scientific), dissolved in acetic 
acid, aliquoted, and stored at -20°C. 
 
 
MTS cell proliferation assay 
  
 Cell proliferation studies were performed using the CellTiter 96® AQueous One 
Solution Cell Proliferation Assay (Promega, Madison, Wisconsin, USA) as before170. 
Briefly, 1.0 x 104 hREC cells per well were cultured in the conditions described above. 
CellTiter reagent was added at a concentration of 20µL per 100µL volume per well at 
specific time points of 0-, 48-, 72-, and 96h after culture. Cells were incubated at 37°C 
for 2h before absorbance was read at 490nm using a 96-well plate reader. Values 
expressed as mean ± SEM, n=3 with 4 replicates. Statistical analysis done using Prism 
Graph Pad. 
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qPCR analysis 
  
 RNA isolation. RNA from Y79 Rb cells, hRECs, and each vitreous sample were 
extracted following the Qiagen® miRNeasy Mini Kit (Qiagen, Valencia, CA) 
manufacturer’s recommendations. Rb cells were harvested and centrifuged to remove all 
traces of cell culture medium. Cell pellets were lysed and homogenized prior to addition 
of chloroform. Samples were shaken vigorously for 15s prior to centrifugation for 2min 
at full speed. The upper colorless phase was transferred to a clean tube after 
centrifugation followed by a series of alcohol precipitations to provide ideal binding 
conditions. The lysate was loaded onto an RNeasy spin column with a silica membrane to 
bind the RNA and washed away contaminants. Residual DNA was removed by on-
column DNase digestion. The concentrated RNA was eluted in 15µL of RNAse free 
water. RNA concentration was assessed by analysis on Nanodrop 2000 Spectophotometer 
(ThermoFisher Scientific) and purity was assessed by verifying absorbance ratios of 
260nm and 280nm (A260/A280). Samples with absorbance ratios between 1.8 and 2.0 
were considered free of contamination. For more information, please see Table A-1. 
 
 cDNA synthesis and pre-amplification. Synthesis of cDNA was performed 
using the SuperScript® VILO™ cDNA Synthesis Kit (Life Technologies, Grand Island, 
NY). Following manufacturer’s directions, we used 100ng of isolated RNA (see section 
above) and combined them with 4µL 5X VILO Reaction Buffer and 2µL 10X 
SuperScript Enzyme Mix. Final volume per sample was 20µL using DEPC-treated water 
when necessary. Per manufacturer’s directions, cDNA synthesis reaction was done at 
25ºC for 10min followed by 42ºC incubation for 60min with reaction termination at 85ºC 
for 5min. Material was pre-amplified using 10µL 2X TaqMan® PreAmp Master Mix, 
5µL pooled 0.2X TaqMan® primers, and 5µL cDNA sample for a final volume of 
20µL192. Preamplification reactions were conducted according to manufacturer’s 
guidelines with a 10min enzymatic activation step at 95ºC followed by 14 cycles of 
denaturing (95ºC for 15s) and annealing (60ºC for 4min). Following 14 cycles, enzyme 
was inactivated at 99ºC for 10min and reactions were held at 4ºC until use. 
Preamplification utilized the same primers analyzed to use minimal amounts of material 
while increasing sensitivity of detection. The reaction was kept at −20°C until ready to 
use. 
 
PCR. We used the following Human TaqMan® Gene Expression 
Assays: HPRT1 (Hs02800695_m1), PDGFRB (Hs01019589_m1), FLT1 
(Hs01052961_m1), ABCB1 (Hs00184500_m1), ABCC1 (Hs01561483_m1), 
ABCC2 (Hs00960489_m1), ABCG2 (Hs01053790_m1), CD44 (Hs01075864_m1) all 
from Life Technologies (Grand Island, NY). A final volume of 10μL was loaded into 
each well after combination of 5µLTaqMan® Universal Master Mix, 2.5µL cDNA, 
0.5µLprimers and 2.0µL Nuclease-Free water. White, 96-well PCR plates were run using 
Roche® LightCycler 480 using TaqMan® protocol: reaction was initiated at 50ºC for 
2min followed by 95ºC for 10min before 40 PCR cycles were conducted at 95ºC for 15s 
and 60ºC for 1min. Values greater than 35 were excluded due to low confidence. Data 
was analyzed using the Comparative CT (∆∆CT ) Method where ∆CT is the difference 
between gene-of-interest (GOI) and housekeeping gene (HKG) and ∆∆CT is the 
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difference between experimental (i.e. PDGF, IM, or PDGF+IM) and untreated. Fold 
change is determined by 2 raised to the negative ∆∆CT value [2(-∆∆CT)]192,193. For more 
information, please see Table A-1. 
 
 
Tube formation assay 
  
 hRECs were cultured on Reduced Growth-Factor Matrigel (BD Biosciences, 
Bedford, MA) in complete media (10% FBS, Cell BioSystems) or low serum (0.2% 
FBS). Additional culture conditions included rhPDGF and IM. Images were taken at both 
6- and 18h using a Nikon C1 confocal microscope using 4X objective. Results are 
representative of two independent experiments; three fields were taken per group at both 
10X (data not shown) and 4X.  
 
 
Flow cytometry analyses 
  
 Rb cell:hREC co-cultures. Monocultures of Y79 Rb, hRECs and co-cultures of 
Y79 Rb and hRECs (Rb:hREC) were treated using recombinant human Platelet-Derived 
Growth Factor (rhPDGF, 10ng/mL), Imatinib Mesylate (IM, 10µM), and the combination 
of rhPDGF + IM. Cell cultures were harvested at 24h, fixed in PBS / 2% 
paraformaldehyde, and labeled with anti-human PDGFR APC or with anti-VEGF-A 
AF700 (BioLegend). Data acquisition was performed using a Bio-Rad ZE5 Cell Analyzer 
(aka YETI, Propel Labs, Fort Collins, CO); analysis done using FlowJo vX.0.5 (Tree 
Star). For more information, please see Table A-2. 
 
 Assessment of efflux activity. The activity of multidrug resistance proteins was 
analyzed by eFLUXX-ID® Green multidrug resistance assay kit (ENZ-51029-K100, 
ENZO Lifesciences, New York, NY, USA) by manufacturer’s suggested instructions. 
Briefly, 4.0 x 106 Y79 cells were plated and treated with either rhPDGF or IM for 24h. 
After 24h, cells were harvested, washed, and resuspended in full media containing 
respective MDRP inhibitors at 37ºC for 10min. eFLUXX-ID® Green dye was then added 
and cells were incubated for an additional 30min at 37ºC. Data acquisition was done in a 
ZE5 Cell Analyzer (aka YETI), from Propel Labs (Fort Collins, CO, USA). Analysis was 
done using FlowJo software v.X.0.0.8 (Tree Star). 
 
 Assessment of co-expression of the pPDGFR and CD44 proteins. Y79 Rb 
cells cultured in the conditions described above were permeabilized with Intracellular 
Staining Perm and Wash Buffer (BioLegend, San Diego, CA, USA) and labeled with 
polyclonal rabbit anti-p-PDGFR (Cell Signaling Technology, #4549; 1:50) as well as 
anti-human CD44 PerCP/Cy5.5 (BioLegend, San Diego, CA, USA) antibodies on ice for 
30min followed by incubation with an anti-rabbit Alexa Fluor® 488 (Thermo Scientific, 
1:50) secondary antibody for 30m. Cells were then fixed with 2% paraformaldehyde 
(ThermoFisher) for 20min prior to analysis. Data acquisition was done in a ZE5 Cell 
Analyzer (aka YETI), from Propel Labs (Fort Collins, CO, USA). Analysis was done  
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using FlowJo software v.X.0.0.8 (Tree Star). For more information, please see Table  
A-2. 
 
 
Results 
 
 
Proliferation of primary human retinal endothelial cells is independent of PDGF-
PDGFR signaling 
 
Prior work from members of our collaborative team have demonstrated how 
chemotherapy can potentially induce ocular toxicities via inflammation and leukostasis 
resulting in hREC death. Therefore, we tested whether disruption of PDGF-PDGFR 
signaling or an off-target effect of IM can induce similar effects in vitro. As we 
previously demonstrated an abundance of active PDGFR (p- PDGFR) in Rb (Figure 
3-1), we hypothesized targeting PDGF-PDGFR would be tumor specific and, therefore, 
less toxic to hRECs. To explore this hypothesis, we first measured Y79 proliferation 
using the tyrosine kinase inhibitor (TKI) imatinib mesylate (IM), a known inhibitor of 
cKit, Bcr-abl, and PDGFRs. We had previously identified 10M as the most efficacious 
concentration216. Inhibiting the PDGFR signaling with IM significantly reducing 
proliferation of Y79 Rb cells at 72h (Figure 4-1A). As a physiological control, we 
stimulated Y79 Rb cells with recombinant human PDGF-BB (rhPDGF), which we 
discovered to be highly abundant in the tumor microenvironment of Rb by examination 
of Rb patient vitreous samples. To investigate what role PDGF-BB may have on hRECs 
and to test if IM may be toxic to hRECs, we cultured hRECs in the same conditions as 
Y79 Rb cells. We tested proliferation over 96h using MTS cellular proliferation assay 
and measured no changes in cellular proliferation (Figure 4-1B). These results illustrate 
how hREC proliferation occurs independent of PDGF-PDGFR signaling. Next, we 
investigated the expression levels of PDGFR in hRECs as a means to measure PDGFR 
activity. We harvested mRNA from hRECs and Y79 cells to measure the expression of 
FLT1 (VEGFR1) and PDGFRB relative to HPRT1, a housekeeping gene. The mRNA 
expression of FLT1 was higher in hRECs compared to Y79 Rb cells. However, PDGFRB 
mRNA expression was not detected (Figure 4-1C) in hRECs, while high expression was 
uncovered in Y79 Rb controls. Taken together, these results demonstrate how targeting of 
PDGF-PDGFR signaling should not have anti-proliferative effects in hRECs, as they do 
not express PDGFRB. 
 
 
Disruption of the PDGF-PDGFR signaling pathway does not affect angiogenic 
activity in hRECs 
 
 As we did not determine any changes in proliferation and noted a lack of 
PDGFR mRNA expression in hRECs, we hypothesized stimulation with rhPDGF would 
not promote hREC organization or tube formation. Furthermore, we hypothesized 
inhibition of PDGF-PDGFR by IM would similarly fail to have an effect on tube  
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Figure 4-1. hREC proliferation occurs independent of PDGF-PDGFR signaling.  
 
Y79 cells or hRECs were cultured in the presence or absence of either PDGF-BB 
(10ng/mL) or the PDGFR inhibitor imatinib mesylate (IM, 10µM). (A) Assessment of 
Y79 cellular proliferation at 72h the presence of either PDGF-BB or IM using the 
concentrations described above. (B) Assessment of hREC proliferation over 96h in the 
presence of either PDGF-BB or IM using the concentrations described above. (C) qPCR 
analysis was done on both cell types to measure mRNA levels of both FLT1 and 
PDGFRB. All experiments done with N=3 and each sample done in triplicates. All results 
in represent mean ±SEM; **p<0.005.  
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formation. To test this hypothesis that anti-PDGFR treatment will not affect angiogenic 
activity of hRECs, we cultured hRECs on reduced-growth factor extracellular matrices 
under the following conditions: complete media (with 10% FBS), low serum (0.2% FBS), 
and low serum + rhPDGF (10ng/mL). Non-pathogenic organization of hRECs display 
complex tubular structures similar to blood vessels (Figure 4-2, right). Under stressful 
conditions, simulated through serum starvation, hRECs do not readily organize into these 
branched structures, as shown in Figure 4-2, left. Next, we tested if the PDGF-PDGFR 
signaling could restore hRECs ability of tube formation through addition of exogenous 
rhPDGF. Results in Figure 4-2, middle demonstrate this signaling pathway cannot rescue 
hRECs angiogenic activity in vitro, defined by the tube formation assay. 
 
As a next step, we tested if the PDGF-PDGFR signaling pathway is capable of 
promoting or stimulating tube formation. hRECs were all cultured in complete media and 
under the following conditions: untreated, stimulated with rhPDGF (10ng/mL) or IM 
(10µM). We found no morphological changes in hREC vascular organization (Figure  
4-3). Furthermore, to test if Rb cell secretions (i.e. PDGFs, VEGFs) could promote 
angiogenesis, hRECs were cultured in the presence of Y79 conditioned-media (CM). 
When cultured in the presence of CM, we found, similarly, tube formation of hRECs did 
not change (data not shown). Ultimately, these results indicate hRECs angiogenic 
function is independent of PDGF-PDGFR signaling. 
 
 
Reduction in hREC VEGF production is PDGFR-independent 
 
 To evaluate cellular interactions and potential role(s) PDGF-PDGFR signaling 
may play in the Rb tumor microenvironment, we set up a co-culture system composed of 
Y79 Rb cells and hRECs using the same conditions described before. Y79 Rb cells were 
labeled with the non-toxic dye carboxyfluorescein succinimidyl ester (CFSE) to trace the 
cells during single cell analyses, while leaving the hRECs unlabeled (Figure 4-4A). Co-
cultures of Rb:hRECs were done using two different ratios, 1:1 and 1:10, to examine 
potential cell number-dependent roles. Labeling for PDGFR, we found that IM reduced 
the number of PDGFR+ cells in Y79 monocultures (Figure 4-4B, top left) while we 
further confirmed our previous mRNA analysis as hRECs did not express PDGFR 
(Figure 4-4B). In our co-cultures, we measured reductions in the percentage of cells 
expressing PDGFR after IM treatment (Figure 4-4B, top left).  
 
Next, we examined the percentage of vascular endothelial growth factor-A 
(VEGF-A)-producing cells in both mono- and co-cultures after disruption of the PDGF-
PDGFR signaling pathway. In contrast to PDGFR expression, we measured reductions 
in the percentage of VEGF-A-producing cells in Y79 Rb and hRECs after treatment with 
IM (Figure 4-4C, bottom left). The reduction in the percentage of VEGF-A-producing 
cells was also demonstrated in the co-cultures (Figure 4-4C, bottom left). Collectively, 
our results show a reduction in Y79 Rb cells expressing PDGFR+ and a reduction in 
VEGF-A-producing cells in both Rb tumor cells and hRECs. 
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Figure 4-2. PDGF-PDGFR signaling is unable to initiate tube formation.  
 
hRECs were serum starved overnight before plating on reduced growth factor Matrigel 
and treated with rhPDGF (10ng/mL). Images were taken at 6h and 18h using a Nikon C1 
microscope and 10X (above) and 4X (data not shown) objectives. All experiments done 
in quadruplicate. Images above are representative of field of view. 
 
 
 
 
 
 
Figure 4-3. PDGF-PDGFR signaling is not required for hREC tube formation.  
 
hRECs were serum starved overnight before plating on reduced growth factor Matrigel 
and treated with rhPDGF (10ng/mL) or imatinib mesylate (10µM). Images were taken at 
6h and 18h using a Nikon C1 microscope and 10X (above) and 4X (data not shown) 
objectives. All experiments done in quadruplicate. Images above are representative of 
field of view. 
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Figure 4-4. Treatment with IM reduces hREC VEGF production.  
 
Y79 and hREC co-cultures were generated. (A) Schematic representation of experimental 
design. Y79 cells were labeled with CFSE to distinguish them from hRECs. Cells were 
plated alone or in specific ratios (Rb:hREC) to measure cellular interactions. All cultures 
were treated with rhPDGF (10ng/mL) or imatinib mesylate (10µM). (B) Assessment of 
PDGFR+ by flow cytometry. (C) Identifying the percentage of VEGF-A producing cells 
(VEGF-A+) using flow cytometry. N=2 due to lack of hREC viability. 
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Expression of ATP-binding cassette (ABC) transporter family in the Rb vitreous 
and a tumor-derived cell line 
 
 Members of the ABC transporters play essential roles in the development of 
chemoresistance. We followed up on previous studies266,267 examining ABC transporters 
in Rb by immunohistochemistry and hypothesized ABC transporters would be expressed 
in the vitreous of Rb patients. Moreover, if these previous studies were true, we would 
see heterogeneic expression of ABC transporters. To address this hypothesis, we first 
investigated the expression of four major ATP-binding cassette (ABC) transporters in the 
vitreous microenvironment of Rb samples from patients that were underwent primary 
enucleation (NCT01783535). The mRNA expression was compared to those of vitreous 
from healthy (purchased, BioreclamationIVT, Baltimore, MD). Rb vitreous samples 
measured detectable expression of ABCC1 (MRP1; 0.8051.876), ABCC2 (MRP2; 
2.4071.021), and ABCG2 (BCRP; 3.3590.728) compared to the controls (Figure 4-5). 
The expression of ABCB1 was quite variable (0.8051.876). These results help illustrate 
the heterogeneity of Rb tumors and, more specifically, the heterogeneity in expression of 
the ABC family in Rb. To have an in vitro system we could use to study in more detail in 
lab, we assessed the mRNA expression of these genes in vitro using Y79 Rb cells. We 
detected expression of ABCC1 and ABCC2 while ABCB1 and ABCG2 were below 
detection threshold (Figure 4-6). Next, we evaluated the expression of these genes under 
stimulatory conditions and demonstrated that rhPDGF did not alter mRNA expression of 
these ABC transporters (Figure 4-6).  
 
 
Disruption of PDGF-PDGFR signaling reduces ABC transporter efflux 
 
 The lack of retention of chemotherapy drugs inside tumor cells, or efflux, is one 
of the major obstacles to successful chemotherapy treatments. Prior preclinical studies 
demonstrated PDGF provided a tumor-specific efflux of chemotherapy and, when PDGF- 
PDGFR signaling was inhibited, drug uptake was significantly improved268. Based on 
this study, we hypothesized PDGF-PDGFR signaling may promote drug efflux by 
MDRPs resulting in decreased intracellular chemotherapy concentrations that are below 
cytotoxicity threshold. To investigate this hypothesis, we quantified the ABC transporters 
efflux by chemical inhibition of the efflux pumps and measurement of an intracellular 
dye using the eFLUXX-ID® green multidrug resistance assay kit. This kit utilizes a cell 
permeant dye that, upon entrance intracellularly is cleaved by cellular esterases, and may 
only be effluxed by ABC transporters. Therefore, if drug efflux levels of Rb cells are 
high, this dye is pumped extracellularly, and fluorescence levels are low; on the other 
hand, if Rb cells have low efflux levels, this dye remains intracellularly, and cells 
maintain high amounts of fluorescence. Given the heterogeneic expression of MDRPs in 
Rb samples, we expect high levels of efflux (and therefore, low levels of fluorescence). 
Furthermore, we expect stimulation with rhPDGF to increase efflux activity (decreasing 
fluorescence further). We also expect treatment with IM to inhibit efflux, thereby 
increasing intracellular fluorescence. Surprisingly, we detected high amounts of 
intracellular fluorescence regardless of treatment condition (Figure 4-7). The results  
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Figure 4-5. Expression of the ABC transporters in naïve human Rb vitreous.  
 
qPCR analysis of mRNA isolated from ex vivo naïve Rb vitreous for key members of 
ABC transporter chemoresistance pathway. N=8 with 4 replicates per sample. Bar graphs 
indicate results ± SEM to control. 
 
 
 
 
 
 
Figure 4-6. Expression of the ABC transporters in Y79 cell lines is not altered by 
PDGF-PDGFR signaling.  
 
Y79 cells were stimulated for 24h with rhPDGF (10ng/mL). After, RNA was isolated, 
cDNA was synthesized, and PCR was conducted. qPCR analysis of mRNA isolated from 
Y79 Rb cells for key members of ABC transporter chemoresistance pathway. N=4 with 4 
replicates per sample. Bar graphs indicate results ± SEM to control. 
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Figure 4-7, ABC transporter efflux activity is low in Y79 Rb cells.  
 
Y79 cells were treated for 24h with rhPDGF (10ng/mL) or IM (10µM). After 24h, cells 
were collected and assayed using the eFFLUXX-ID® multidrug resistance assay kit. Flow 
cytometry histogram is shown. MDA-MB-231 cells were used a negative control. 
Samples were immediately  run on a BioRad ZE5. N=3 with 3 replicates per sample.  
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changes in efflux activity in Rb cells. The results for Y79 were similarly to demonstrated 
the well-characterized and negative control metastatic breast cancer cell line, MDA-MB-
231 (Figure 4-7, right). This data illustrates that Rb does express ABC transporters at 
both mRNA and protein levels266,267; however, there may be a lack of functionality.  
 
 
CD44 is overexpressed in the naïve Rb vitreous and is by PDGF-PDGFR signaling 
 
 The hyaluronan receptor, or CD44, has been heavily implicated in modulating of 
the resistance to chemotherapy by regulation of the interactions between tumor cells and 
the ECM. Therefore, CD44 mRNA expression was investigated. We utilized ex vivo 
human Rb samples and measured a 40-fold increase in CD44 mRNA relative to HPRT1 
in naïve Rb patients (Figure 4-8) that have not received any treatment. The results above 
further suggest drug resistance is an innate feature of vitreous seeds.  
 
 The overexpression of CD44 may be dependent on the TME. Next, we tested if 
the PDGF-PDGFR signaling pathway may play a role in the overexpression of CD44. 
Y79 Rb cells were treated with rhPDGF or IM and analyzed for the active form of the 
PDGFR (p-PDGFR) and CD44. IM reduced the percentage of cells showing double 
positivity for p-PDGFR+ and CD44+ compared to rhPDGF stimulated cells (rhPDGF: 
53.1% vs rhPDGF + IM: 35.4%) (Figure 4-9). Also, the decrease in p-PDGFR+CD44+ 
cells is enhanced by the combination of rhPDGF and IM conditions that mimic the TME 
(rhPDGF: 56.3% vs. rhPDGF + IM: 79.1%). These results illustrate a potential role 
PDGF-PDGFR signaling may play in resistance by promoting a more resistant 
phenotype (CD44+).  
 
 
Discussion 
 
 Retinoblastoma (Rb) remains the most common intraocular malignancy afflicting 
children. While survival rates are above 90% in developed countries, ocular salvage rates 
have not readily exceeded 70% in over 2 decades primarily due to the presence of 
vitreous seeds. These seeds and their location within the vitreous make them exceedingly 
difficult to treat via systemic chemotherapy. To achieve higher, more tumoricidal doses, 
new mechanisms for drug delivery have been developed in recent decades, specifically 
those of super-selective intra-ophthalmic artery chemotherapy (IAC) and intravitreal 
chemotherapy (IVT)68,269. These new treatment mechanisms have garnered much 
attention due to their ability to increase ocular salvage by preliminary results. To achieve 
tumoricidal concentrations, current treatments such as melphalan and carboplatin are 
often administered in high doses that have severe side effects for the pediatric population 
including ischemia, neutropenia, a higher risk for development of a secondary 
malignancy, and blindness50,270,271. Previous work from our team identified how 
melphalan and carboplatin, two commonly administered chemotherapies to treat Rb, 
increase retinal endothelial cell death and inflammation63,257. Even if high doses are  
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Figure 4-8. Expression of CD44 in naive human Rb vitreous. 
 
qPCR analysis of mRNA isolated from ex vivo naïve Rb vitreous for CD44. N=5 with 4 
replicates per sample of human healthy vitreous. N=8 with 4 replicates per sample of Rb 
vitreous. Bar graphs indicate results ± SEM to control. 
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Figure 4-9. CD44 is mediated by PDGFR activity.  
 
Assessment of CD44 positivity after disruption of PDGFR signaling. Y79 cells were treated for 24h with rhPDGF (10ng/mL) or IM 
(10µM). After 24h, cells were collected and labelled with anti-human PerCP/Cy5.5 CD44 and p-PDGFR antibody with AlexaFluor® 
488 secondary. Samples were run on a BioRad ZE5. Flow cytometry histogram is shown. N=3 with 3 replicates per sample.  
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achieved, vitreous seeds are typically resistant to chemotherapy, further demonstrating 
the challenges in treating these seeds.  
 
 In this study, we first chose to focus on assessing potential cytotoxicity of anti-
PDGF-PDGFR therapy to endothelial cells. As endothelial cells are necessary to supply 
the healthy neural retina with nutrients via blood supply, significant loss of these 
endothelial cells can result in neurodegeneration and, ultimately, vision loss. These 
endothelial cells are also the primary component of the blood-retinal barrier (BRB) that 
prevents cellular infiltration into the healthy retina and use of an anti-PDGFR therapy 
could help maintain this essential structure272,273. Our study demonstrates the pro-
apoptotic effects of IM are Rb cell specific, as hRECs proliferation and angiogenic 
activity are not affected. In contrast to human umbilical vein endothelial cells (hUVEC), 
which are widely used in in vitro studies of endothelial cells, hRECs do not signal 
through the PDGFR. This was demonstrated in our studies by genomic and flow 
cytometry analyses. This work suggests anti-PDGFR therapy could be an Rb tumor-
specific therapy. 
 
 This work suggests that disruption of this signaling pathway is a targeted and safe 
therapy. Next, we chose to also explore drug resistance. As mentioned above, vitreous 
seeds are challenging to treat not only due to their unique location but also because they 
are resistant to chemotherapy. Members of our collaborative team had previously 
identified members of the ATP-binding cassette (ABC) transporter family in Rb 
samples266. Immunohistochemical analyses on naive ex vivo samples demonstrated the 
expression of MDR1, MRP1, and MRP2. BCRP was not detected in any of the cohort 
samples. In addition to this pioneering study, further work comparing naïve samples and 
samples obtained patients who had undergone systemic chemotherapy demonstrated this 
expression was not induced (or altered) by chemotherapy267. Instead, this resistance is an 
innate feature of Rb tumors. Using freshly isolated  ex vivo vitreous samples from 
patients with vitreous seeds, we analyzed mRNA levels and measured heterogeneic 
expression of ABCB1 (MDR1), ABCC1 (MRP1), ABCC2 (MRP2), and, surprisingly, 
ABCG2 (BCRP), further demonstrating multiple levels of complexity of these tumors. 
 
 The defining-role of these MDRPs in chemoresistance is their ability to efflux 
intracellular chemotherapy drugs extracellularly. To test the ability of Rb cells to efflux, 
we utilized a novel efflux assay kit. A cell-permeant, fluorescent dye is used to measure 
this efflux. There is an inverse relationship between efflux and fluorescence. As a control, 
we used the MDA-MB-231 cell line of metastatic breast cancer cells that have been 
shown to lack efflux activity274. We postulated a small number of Rb cells may be 
promoting chemoresistance. This could explain the non-statistical significance in our 
results. Future studies could evaluate efflux using ex vivo samples and not cell lines. 
While we were performing these studies recent work from Nair et al. illustrated a low 
percentage (< 5%) of Y79 cells express MDRPs263. With such a small percentage of cells, 
quantitation of efflux activity will be drowned out by the large cohort of cells collected. 
Nonetheless, we do observe small differences among treatment groups and future studies 
must be conducted to elucidate how PDGF-PDGFR signaling may promote ABC 
transporter activity and be a potential target to decrease chemoresistance. Additional 
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unidentified proteins might contribute to Rb chemoresistance. A previous study 
demonstrated an unidentified member of the ABC transporter family mediates Y79 ABC 
transporter efflux275. 
 
 To further evaluate mechanisms involved in chemoresistance, we investigated the 
expression of the hyaluronan receptor, or CD44, in ex vivo Rb naive vitreous samples. 
CD44 has been implicated in chemoresistance in a number of tumors and is known to 
assist in the regulation of MDRPs and ABC transporters276. When we compared them to 
healthy vitreous, we found a surprisingly high amount of CD44 mRNA in our Rb 
vitreous samples. These results support our hypothesis on the importance of the TME in 
Rb and how this TME may promote vitreous seed survival and resistance through CD44 
while providing further evidence that chemoresistance is also an inherent tumor property 
of Rb.  
 
In contrast to the efflux studies of the ABC transporters, we saw major differences 
in the percentage of CD44-positivity based on treatment. First, we measured a higher 
percentage of p-PDGFR+CD44+ cells upon rhPDGF stimulation compared to baseline 
levels. Therefore, we hypothesized disruption of the PDGF-PDGFR signaling pathway 
by IM would reduce this phenotype. In fact, IM reduced the percentage of p-
PDGFR+CD44+ cells while increasing the percentage of double-negative cells (p-
PDGFRnegCD44neg). Ultimately, these results demonstrate that interactions between Rb 
cells and the microenvironment contribute to chemoresistance and warrants further 
investigations. 
 
 The present study investigated the role of the PDGF-PDGFR signaling pathway 
in hRECs as well as potential mechanisms for drug resistance. As a functional readout of 
disruption of the PDGF-PDGFR signaling pathway in hRECs, we used genomic 
(PDGFRB mRNA expression), flow cytometry (percentage of PDGFR+ cells and 
VEGFA-producing cells), and angiogenic (tube formation assay) approaches to verify 
targeting PDGF-PDGFR signaling is not cytotoxic to hRECs. Follow up studies are 
needed to investigate endothelial cell leukostasis and toxicity in vivo. We hypothesize 
that anti-PDGF-PDGFR therapy will be an Rb-specific therapy without the toxicities 
associated with chemotherapy. 
 
We also investigated the expression of ABC transporters in ex vivo naïve vitreous 
samples from Rb patients and in vitro by using a cell line to understand chemoresistance 
mechanisms. Moreover, we performed a comprehensive analysis on the percentage of 
PDGFR+ cells showing positivity to CD44, a protein associated with drug resistance 
mechanisms. This work, for the first time, provides a potential mechanism by which 
vitreous seeds may utilize their microenvironment for their own survival and 
chemotherapy resistance.   
 
Drug resistance in cancer is a complex and multifactorial process involving 
multiple pathways and mediators and merits more, in-depth studies.  Resistant Rb cell 
lines should be developed and mRNA analysis should compare members of the ABC 
transporter family to chemo-sensitive cells. Similar to this study, functionality should 
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also be tested using the same (or equivalent) dye-based assay. As the major limitations of 
this work are the in vitro approach and lack of in vivo studies as well as the results that 
are correlative, not specifically causative, future studies must use the in vivo approach 
using the same orthotopic xenograft rabbit model previously mentioned. These cells may 
also be engrafted in to the rabbit model to form vitreous seeds and will allow for a more 
comprehensive, in vivo study to elucidate mechanistically, how vitreous seeds are able to 
resist chemotherapy.  
 
  
  
91 
 
CHAPTER 5.    DISCUSSION 
 
 
In their groundbreaking reviews, Doug Hanahan and Robert Weinberg established 
six primary mechanisms for tumor development and survival104. Yet, it is now understood 
that tumor cells do not act alone and that these hallmarks are not inherently tumor cell-
dependent. Tumors are not one-dimensional, independent entities, instead they are 
composed of multiple cell types such as fibroblasts, endothelial cells, macrophages and 
monocytes, leukocytes, and pericytes that communicate within cells and their 
microenvironment through multiple proteins, receptors, and chemokines and cytokines. 
The crucial role of these interactions between tumors and stromal cells has broad 
implications for the hallmarks of cancer including metastasis, resistance, treatment 
options, and ultimately patient survival. These decisive communications have been vastly 
studied in malignancies such as breast277 and pancreactic278 cancers. However, there is a 
lack of such knowledge in Rb and, specifically, vitreous seeding. While very little is 
currently known regarding presence (or absence) of stromal cell types and composition of 
the Rb TME, it has been established that Rb cells exhibit unique properties allowing them 
to survive in the semi-solid, semi-liquid vitreous microenvironment (Rb seeds). 
Furthermore, these seeds have reduced rates of proliferation and they are resistant to 
conventional chemotherapeutics100,266. Therefore, to target vitreous seeds, we need 
therapeutics aimed specifically at reducing vitreous seed survival signaling and reducing 
resistance. The focus of the work described herein is 1) to establish Rb-TME interactions 
that promote tumor survival and 2) demonstrate how investigating the TME can provide 
essential knowledge and emphasize the need to study not only the tumor, but the 
microenvironment that surrounds it.  
 
 The origins of vitreous seeding remain unknown. However, one key step in 
vitreous seed formation is the disruption (or invasion) of the vitreoretinal interface, 
namely the inner limiting membrane (ILM) which is primarily composed of type IV and 
VI collagens279. We identified members of the matrix metalloproteinase (MMP) family 
were expressed in both metastatic (Y79) and non-metastatic (Weri-1) Rb cell lines. These 
two MMPs are gelatinases that are responsible for degrading type IV collagen. We 
further identified pharmacological inhibition of these MMPs resulted in decreased Rb cell 
migration and invasion via transcriptional regulation of MMP-2 and -9. Surprisingly, we 
did see significant decreases in cell survival, as well. MMPs regulation primarily occurs 
through mRNA transcription, perhaps most notably by the E2F transcription factor 
family280. We demonstrated targeting MMPs decreased E2F levels that resulted in 
reduced MMP mRNA. Most notably was the discovery of different intrinsic properties of 
these cells. Despite their clear involvement in angiogenesis, MMPs do not appear to play 
a major role in angiogenesis for Y79 as illustrated by the lack of changes in two key 
angiogenic molecules (VEGF and Ang-2) and may be more involved in metastasis (TGF-
); meanwhile, we demonstrated Weri-1 angiogenic activity as well as metastasis may be 
partially regulated through MMP activity.  
 
As previous clinical trials targeting MMPs failed due to lack of specificity for 
MMPs, we feel MMPIs are not strong candidates for clinical administration. One area 
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that may be beneficial to investigate is the targeting of tissue inhibitors of 
metalloproteinases (TIMPs) that regulate the activities of MMPs. Prior studies have 
demonstrated the expression and function of TIMPs in metastatic Rb, but their 
therapeutic potential has yet to be tested190. By targeting these TIMPs, toxicities 
associated with the prior therapies could potentially be circumvented.  
 
 As the vitreous contains growth factors, cytokines, and chemokines, access to this 
supply of signaling molecules may assist in tumor survival. However, often times growth 
factors are sequestered in ECM and may only be considered bioavailable after ECM 
remodeling (via molecules such as the MMPs)112. One such family of molecules, the 
PDGF family, have already been implicated and targeted in vitreoretinal pathologies113,114 
as well as oncogenesis157. We describe here the expression of active PDGFR and 
abundance of its primary ligand, PDGF-BB using ex vivo samples. Disruption of PDGF- 
PDGFR signaling resulted in decreases in proliferation and invasion as well as increases 
in apoptotic activity. We provide mechanistic insight in how this signaling cascade drives 
survival through MDM2 and NFB signaling.  
 
 Resistance is one of the major challenges in cancer treatments. The use of targeted 
therapies and immunotherapy were thought to undermine this problem. While initially 
responsible to targeted therapies, cancer cells are able to adapt and utilize similar effector 
pathways to confer survival281. As members of the same family of PDGFs, we postulate 
VEGF-VEGFR signaling may represent a potential compensatory mechanism for 
resistance in Rb. We found inhibition of PDGF-PDGFR signaling did not result in 
increases in VEGF-A or VEGFR activity by demonstrating no change in VEGFA (or 
VEGFR2) mRNA as well as a significant decrease in VEGFR2 protein activity. These 
results do not rule out development of another compensatory mechanism and future in 
vivo studies should incorporate these potential shortcomings Xenografts should be 
generated using tumor samples from patients with recurrent disease and inhibition of 
PDGF-PDGFR signaling should be tested therapeutically against these resistant tumors. 
Regular measurement of other major receptor tyrosine kinases may prove beneficial in 
identifying other potential therapeutic targets that underlie survival.  
 
The PDGFR inhibitor chosen in these studies, imatinib, was developed and first 
used as an inhibitor for the Bcr-Abl fusion protein associated with chronic myelogenous 
leukemia (CML) as well as acute lymphoblastic leukemia (ALL)236. Other targets of 
imatinib include stem cell factor receptor (c-Kit) and PDGFRs (both PDGFR and 
PDGFR). To investigate if these cytotoxic effects were PDGFR-specific as we 
hypothesized, we utilized siRNA technology and targeted the PDGFRB gene. The 
disruption of PDGFR dysregulated the downstream targets and pro-survival factors 
MDM2 and NFB resulting in increased Rb cell apoptosis and decreasing cell survival. 
This confirmed the role of PDGFR in Rb cell survival. Our pre-clinical studies 
evaluated the safety of IM as a potential therapy on primary human retinal endothelial 
cells (hRECs). Results from our collaborators previously demonstrated both carboplatin 
and melphalan induced hREC toxicity as well inflammation63,257,282,283. We did not 
observe any IM-associated toxicities in hRECs indicating a potential Rb-specific effect. 
These results are quite promising preclinically and demonstrate that targeting the PDGF-
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PDGFR signaling pathway may prevent toxicities associated with therapies currently in 
use. In addition to finding inhibition of PDGF-PDGFR signaling may be Rb-specific, 
we demonstrated the necessity of using site-specific cells is vital for preclinical testing. 
Prior studies have also examined endothelial cells within the context of Rb but have 
utilized hUVECs. We observed hRECs do not express PDGFRB mRNA whereas other 
studies have demonstrated hUVECs do express PDGFR. Therefore, future preclinical 
studies examining endothelial-Rb cell interactions should utilize physiologically-
consistent cells that would normally inhabit the Rb TME, such as hRECs. 
 
The lack of in vitro and in vivo preclinical models has exacerbated the gap in 
knowledge of vitreous seeds. To date, the one in vivo animal model capable of 
developing vitreous seeds is the rabbit orthotopic xenograft92. This is an expensive model 
to generate and maintain. To circumvent this caveat, we utilized magnetic nanoparticles 
to generate three-dimensional spheroids that closely resemble vitreous seeds. This 
technology provides an in vitro platform that is quick and reproducible while providing a 
more physiologically relevant, three-dimensional model that better recapitulates in vivo 
and ex vivo pathology. This 3D system will allow researchers to test pre-clinically 
potential therapies in addition to provide a “small scale” high-throughput screening for 
drug discovery. This model can be extended further and utilized for co-culture systems 
that utilize tumor cells along other cell types in the TME to generate spheroids as we 
demonstrated by establishing co-cultures with hRECs. Furthermore, pre-labeling cell 
populations (such as with CFSE) allows for the examination of individual cell types by 
immunofluorescence and flow cytometry. This methodology will allow in-depth analysis 
of cellular interactions within the microenvironment. This technique will provide 
valuable insight into how current and future therapies alter tumor properties and how 
multiple cell types may respond to these drugs. 
 
 Vitreous seeds are understood to be resistant to chemotherapy. While this is in 
part due to the anatomical location of seeds and the reduced proliferation rates of seeds -- 
as most chemotherapies target rapidly dividing cells, current research has failed to 
elucidate mechanistic insights into why or how these seeds are capable of surviving. The 
vitreous is a unique microenvironment and these seeds reside in an avascular system. As 
most chemotherapeutic routes of delivery depend on diffusion through the bloodstream, 
cells in an avascular system are exposed to much lower concentrations of these drugs and 
this concentration is less likely to be cytotoxic. Moreover, cells that are sensitive are 
killed while those resistant cells persist and give rise to recurrence. However, when 
concentrations are much higher (e.g. through IViC administration), higher rates of ocular 
salvage are still not achieved, demonstrating this effect may be related specifically to 
these cells (and thereby, their microenvironment). To attempt to explain chemoresistance,  
previous work from members of our team demonstrated heterogenous expression of 
proteins involved in drug resistance (MDRPs)266. Follow up work using naïve eyes as 
well as those that had undergone treatment found no differences in expression of MDRPs 
indicating that treatment does not induce drug resistance, resistant cells are selected267. 
We confirmed these results using ex vivo naïve Rb vitreous samples and found 
heterogenous mRNA expression of these MDRPs. We also characterized these MDRPs in 
vitro using the Y79 Rb cell line and could not detect either ABCB1 and ABCG2 mRNA, 
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emphasizing the heterogeneity of the tumors and the importance of the interactions 
between the tumors and their microenvironment. To further measure these MDRP efflux 
capacity, we deployed a commercially-available assay kit and demonstrated low Y79 
efflux activity. It is worth noting small changes were seen between treatment groups, 
though the physiological relevance of these small changes is unknown. We hypothesized 
this may be attributable to a small percentage of cells with active ABC transporters, as 
had been previously demonstrated263. Instead, we focused our attention on another 
protein associated with chemotherapy resistance: CD44. 
  
 Recent reports demonstrated Y79 cells that were more chemoresistant to 
carboplatin expressed two biomarkers -- CD133 and CD44263. These resistant cells’ 
phenotype was CD44hi and, surprisingly, CD133lo 263. In order to further examine how 
TME may alter properties of the tumor and elaborate on others’ previous studies, we 
examined the expression of CD44 and how PDGF from the microenvironment may 
induce a more resistant phenotype. We measured CD44 mRNA at higher levels (~ 40-
fold) in naïve vitreous from Rb patients versus the healthy vitreous controls.  
 
 Resistant Y79 cells measured increased expression of CD44 mRNA. We have 
previously demonstrated PDGF-PDGFR signaling regulates NFB signaling. Therefore, 
we investigated how PDGF-PDGFR signaling may contribute to CD44 mRNA 
expression as CD44 is a target gene of the transcription factor NFB. Ultimately, we 
revealed a high percentage of p-PDGFR positive (PDGFR+) cells were simultaneously 
positive for CD44 (CD44+); in turn, when PDGF-PDGFR signaling is inhibited by IM, 
there is a decrease in percentage of double-positive (PDGFR+/CD44+) cells and an 
increase in double-negative (PDGFRneg/CD44neg) cells. Taken together, these results 
implicate how PDGF-PDGFR signaling may promote a more resistant phenotype 
through CD44. More work needs to be conducted on the potential importance of CD44 
within resistant and recurrent disease. Cell lines overexpressing CD44 should be 
generated to determine the role(s) CD44 plays in recurrence and resistant in addition to in 
vitro and in vivo testing of anti-CD44 targeted therapies (such as previously conducted in 
ovarian cancer284) to examine potential therapeutic value.  
 
 This work has provided compelling evidence of the importance of the 
microenvironment in Rb growth, survival, response to treatment (or lack thereof), and 
metastasis. However, there is a still a lack of understanding about the vitreous as a tumor 
microenvironment in Rb. As future advancements in genomic and proteomics continue, 
the vitreous microenvironment needs to be characterized. Future pre-clinical animal 
model studies will be essential to determine the therapeutic and clinical value anti-
PDGFR as a targeted therapy or sensitizing agent for Rb. We foresee these studies 
should be conducted in vivo using the rabbit orthotopic xenograft as it is the only model 
capable of forming vitreous seeds. This model is also capable of withstanding multiple 
injections and more closely resembles the volume of a pediatric eye. Using this model, 
the role the ABC transporter family and CD44 may play in chemoresistance can also be 
determined. Preclinical examination targeting the PDGF-PDGFR signaling cascade 
could further demonstrate a link between microenvironment and promoting 
chemoresistance. In depth studies could further examine tumor features through use of 
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human-specific antibodies and primers while comparing results to the host by employing 
rabbit-specific reagents. Our studies are groundwork for future studies to identify novel 
targets for therapy to clear vitreous seeds and raise ocular salvage rates much higher than 
the 70% that has been the norm for so long.  
 
  In conclusion, this work reveals, for the first time, how the TME may alter 
properties of Rb cells. We demonstrated how interactions with the ECM by the MMPs 
promotes invasion and migration and that, when these interactions are inhibited, Rb cell 
secretions are altered and survival decreases. We identified highly active PDGFR within 
the vitreous of ex vivo human Rb tissue and discovered the roles the PDGF-PDGFR 
signaling pathway plays in Rb cell proliferation, invasion, and survival. Disruption of the 
PDGF-PDGFR signaling pathway resulted in reduced proliferation and invasion, as well 
as increase in percentage of apoptotic cells. We provided mechanistic insight that 
illustrated this survival signaling may be mediated by MDM2 and NFB. Furthermore, as 
demonstrated targeting PDGFR does not induce toxicities in hRECs and this therapeutic 
target may be Rb-cell specific. We examined the role the PDGFR signaling cascade 
may play in promoting resistance to chemotherapy. We indicated this drug resistance is 
an inherent property of these Rb cells and denoted heterogeneity of the ABC transporters. 
We found CD44 highly expressed in the vitreous of naïve human Rb vitreous and 
demonstrated how cells with active PDGFR are also positive for CD44 and, when this 
signaling is disrupted, CD44 concomitantly decreases. Ultimately, targeting the PDGF-
PDGFR signaling pathway may be useful in targeting chemoresistant cells. Based on 
our findings, we developed a working model (Figure 5-1).  
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Figure 5-1. Working model of vitreous seed microenvironment.  
 
Rb cells express MMPs. Upon entrance in to the vitreous, these cells secrete these 
gelatinases (orange) that induce ECM degradation and remodeling (blue). This 
remodeling frees sequestered growth factors (i.e. PDGF, red) that are, in turn, free to bind 
receptors. Ligand-receptor interactions induce a downstream signaling cascade that 
results in anti-apoptotic activity via MDM2 as well as pro-survival (and pro-resistance) 
signaling through NFB. Ultimately, access to the vitreous confers on these cells as 
growth and survival advantage that is difficult to overcome. .  
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APPENDIX.  TABLES OF PRIMERS AND ANTIBODIES USED 
 
 
Table A-1. List of all MRNA primers used. 
 
Gene Manufacturer Identifier 
MMP2 Applied Biosystems, Thermo Scientific Hs01548727_m1 
MMP7 Applied Biosystems, Thermo Scientific Hs01042796_m1 
MMP9 Applied Biosystems, Thermo Scientific Hs00234579_m1 
MMP14 Applied Biosystems, Thermo Scientific Hs01037003_g1 
PDGFRA Applied Biosystems, Thermo Scientific Hs_00998018_m1 
PDGFRB Applied Biosystems, Thermo Scientific Hs01019589_m1 
PDGFA Applied Biosystems, Thermo Scientific Hs00234994_m1 
PDGFB Applied Biosystems, Thermo Scientific Hs_00966522_m1 
MDM2 Applied Biosystems, Thermo Scientific Hs00540450_m1 
MDM4 Applied Biosystems, Thermo Scientific Hs00910358_m1 
VEGFA Applied Biosystems, Thermo Scientific Hs00900055_m1 
FLT1 Applied Biosystems, Thermo Scientific Hs01052961_m1 
HPRT1 Applied Biosystems, Thermo Scientific Hs02800695_m1 
ABCB1 Applied Biosystems, Thermo Scientific Hs00184500_m1 
ABCC1 Applied Biosystems, Thermo Scientific Hs01561483_m1 
ABCC2 Applied Biosystems, Thermo Scientific Hs00960489_m1 
ABCG2 Applied Biosystems, Thermo Scientific Hs01053790_m1 
CD44 Applied Biosystems, Thermo Scientific Hs01075864_m1 
TaqMan® PreAmp Master Mix Applied Biosystems, Thermo Scientific Cat# 4391128 
TaqMan® Universal Master Mix Applied Biosystems, Thermo Scientific Cat# 4440040 
SuperScript® VILO cDNA 
Synthesis Kit 
Invitrogen, Thermo Scientific Cat# 11754250 
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Table A-1. List of all antibodies used. 
 
Antibody Manufacturer Identifier 
Anti-human PDGFR Abcam Cat# 16868 
CFSE Cell Division Tracker Kit BioLegend Cat# 423801 
DRAQ5™ BioLegend Cat# 424101 
Monoclonal mouse anti-VEGF-A  BioLegend Cat# 16701 
Monoclonal mouse anti-CD140b APC BioLegend Cat# 323608 
anti-human CD44 PerCP/Cy5.5 BioLegend Cat# 103032 
eFFLUX-ID® Green multidrug resistance dye ENZO Lifesciences ENZ-51029-K100 
Monoclonal rabbit anti-MMP2 Cell Signaling Technology Cat# 13132 
Polyclonal rabbit anti-MMP9 Cell Signaling Technology Cat# 3852 
Polyclonal rabbit anti-E2F Cell Signaling Technology Cat# 3742 
Monoclonal -actin HRP-conjugated Cell Signaling Technology Cat# 12620 
Polyclonal rabbit anti-AKT Cell Signaling Technology Cat# 9272 
Monoclonal rabbit anti-pAKT Cell Signaling Technology Cat# 4058 
Monoclonal rabbit anti-BCL2 Cell Signaling Technology Cat# 2870 
Monoclonal rabbit anti-GAPDH Cell Signaling Technology Cat# 8884 
Anti-mouse IgG HRP-linked Antibody Cell Signaling Technology Cat# 7076 
Anti-rabbit IgG HRP-linked Antibody Cell Signaling Technology Cat# 7074 
Monoclonal rabbit anti-p65 Cell Signaling Technology Cat# 8242 
Anti-human phosphorylated PDGFR Santa Cruz Cat# sc-339 
Polyclonal rabbit anti-PDGFR Santa Cruz Cat# sc-432 
Monoclonal mouse anti-pPDGFR Santa Cruz Cat# sc-373805 
Monoclonal mouse anti-VEGF Santa Cruz Cat# sc-53462 
Monoclonal mouse anti-Flk-1 Santa Cruz Cat# sc-6251 
Monoclonal mouse anti-p-Flk-1 Santa Cruz Cat# sc-101821 
Monoclonal mouse anti-MDM2 Santa Cruz Cat# sc-965 
Monoclonal mouse anti-pMDM2 Santa Cruz Cat# sc-53368 
Donkey anti-rabbit Alexa Fluor 647 Thermo Scientific Cat# A31573 
Goat anti-mouse Alexa Fluor 700 Thermo Scientific Cat# A21036 
Donkey anti-rabbit Alexa Fluor 488 Thermo Scientific Cat# A21206 
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